References

Writing Process:

1. Clinical Practice Guidelines We Can Trust. 2011. https://www.ncbi.nlm.nih.gov/pubmed/24983061

Executive Summary:

2. Lazarus E, Ortiz-Pujols S. Increasing clinical awareness of obesity as a serious, chronic, relapsing, and treatable disease. Am J Manag Care. 2022;28(15 Suppl):S271-S278. doi:10.37765/ajmc.2022.89290
3. Bray GA, Kim KK, Wilding JPH, et al.: Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017 18:715-723. https://www.ncbi.nlm.nih.gov/pubmed/28489290
4. Sharma AM, Kushner RF: A proposed clinical staging system for obesity. Int J Obes (Lond) 2009 33:289-295. https://www.ncbi.nlm.nih.gov/pubmed/19188927

The Disease of Obesity:

5. Fitch AK, Bays HE: Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022 1:100004.
6. Kyle TK, Dhurandhar EJ, Allison DB: Regarding Obesity as a Disease: Evolving Policies and Their Implications. Endocrinol Metab Clin North Am 2016 45:511-520. https://www.ncbi.nlm.nih.gov/pubmed/27519127
7. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024 Mar 16;403(10431):1027-1050. doi: 10.1016/S0140-6736(23)02750-2. Epub 2024 Feb 29. PMID: 38432237; PMCID: PMC7615769
8. Kilov D, Kilov G: Philosophical determinants of obesity as a disease. Obes Rev 2018 19:41-48. https://www.ncbi.nlm.nih.gov/pubmed/28960759
9. Bray GA, Kim KK, Wilding JPH, et al.: Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017 18:715-723. https://www.ncbi.nlm.nih.gov/pubmed/28489290
10. Krishnaswami A, Ashok R, Sidney S, et al.: Real-World Effectiveness of a Medically Supervised Weight Management Program in a Large Integrated Health Care Delivery System: Five-Year Outcomes. Perm J 2018 22:17-082. https://www.ncbi.nlm.nih.gov/pubmed/29401050
11. Edwards BA, Bristow C, O'Driscoll DM, et al.: Assessing the impact of diet, exercise and the combination of the two as a treatment for OSA: A systematic review and meta-analysis. Respirology 2019 24:740-751. https://www.ncbi.nlm.nih.gov/pubmed/31116901
12. Danielsen KK, Svendsen M, Maehlum S, et al.: Changes in body composition, cardiovascular disease risk factors, and eating behavior after an intensive lifestyle intervention with high volume of physical activity in severely obese subjects: a prospective clinical controlled trial. J Obes 2013 2013:325464. https://www.ncbi.nlm.nih.gov/pubmed/23710347
13. Ussery EN, Fulton JE, Galuska DA, et al.: Joint Prevalence of Sitting Time and Leisure-Time Physical Activity Among US Adults, 2015-2016. JAMA 2018 320:2036-2038. https://www.ncbi.nlm.nih.gov/pubmed/30458482
14. Dansinger ML, Williams PT, Superko HR, et al.: Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors. Lipids Health Dis 2019 18:154. https://www.ncbi.nlm.nih.gov/pubmed/31311555
15. Ma C, Avenell A, Bolland M, et al.: Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ 2017 359:j4849. https://www.ncbi.nlm.nih.gov/pubmed/29138133

16. Fuller NR, Burns J, Sainsbury A, et al.: Examining the association between depression and obesity during a weight management programme. Clin Obes 2017 7:354-359. https://www.ncbi.nlm.nih.gov/pubmed/28801940

17. Reddy YNV, Anantha-Narayanan M, Obokata M, et al.: Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. JACC Heart Fail 2019 7:678-687. https://www.ncbi.nlm.nih.gov/pubmed/31302042

18. Colditz GA, Peterson LL: Obesity and Cancer: Evidence, Impact, and Future Directions. Clin Chem 2018 64:154-162. https://www.ncbi.nlm.nih.gov/pubmed/29038151

19. Fabricatore AN, Wadden TA, Higginbotham AJ, et al.: Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. Int J Obes (Lond) 2011 35:1363-1376. https://www.ncbi.nlm.nih.gov/pubmed/21343903

20. Dawes AJ, Maggard-Gibbons M, Maher AR, et al.: Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery: A Meta-analysis. JAMA 2016 315:150-163. https://www.ncbi.nlm.nih.gov/pubmed/26757464

21. Ma C, Avenell A, Bolland M, et al.: Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ 2017 359:j4849. https://www.ncbi.nlm.nih.gov/pubmed/29138133

22. Fuller NR, Burns J, Sainsbury A, et al.: Examining the association between depression and obesity during a weight management programme. Clin Obes 2017 7:354-359. https://www.ncbi.nlm.nih.gov/pubmed/28801940

23. Reddy YNV, Anantha-Narayanan M, Obokata M, et al.: Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. JACC Heart Fail 2019 7:678-687. https://www.ncbi.nlm.nih.gov/pubmed/31302042

24. Colditz GA, Peterson LL: Obesity and Cancer: Evidence, Impact, and Future Directions. Clin Chem 2018 64:154-162. https://www.ncbi.nlm.nih.gov/pubmed/29038151

25. Fabricatore AN, Wadden TA, Higginbotham AJ, et al.: Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. Int J Obes (Lond) 2011 35:1363-1376. https://www.ncbi.nlm.nih.gov/pubmed/21343903

26. Dawes AJ, Maggard-Gibbons M, Maher AR, et al.: Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery: A Meta-analysis. JAMA 2016 315:150-163. https://www.ncbi.nlm.nih.gov/pubmed/26757464

27. Moran LJ, Brinkworth GD, Martin S, et al.: Long-Term Effects of a Randomised Controlled Trial Comparing High Protein or High Carbohydrate Weight Loss Diets on Testosterone, SHBG, Erectile and Urinary Function in Overweight and Obese Men. PLoS One 2016 11:e0161297. https://www.ncbi.nlm.nih.gov/pubmed/27584019

28. Green DD, Engel SG, Mitchell JE: Psychological aspects of bariatric surgery. Curr Opin Psychiatry 2014 27:448-452. https://www.ncbi.nlm.nih.gov/pubmed/25247457

29. Cardoso L, Rodrigues D, Gomes L, et al.: Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis. Diabetes Obes Metab 2017 19:1223-1232. https://www.ncbi.nlm.nih.gov/pubmed/28244626

30. Song Z, Baicker K: Effect of a Workplace Wellness Program on Employee Health and Economic Outcomes: A Randomized Clinical Trial. JAMA 2019 321:1491-1501. https://www.ncbi.nlm.nih.gov/pubmed/30990549

31. Jakicic JM, Davis KK, Rogers RJ, et al.: Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss: The IDEA Randomized Clinical Trial. JAMA 2016 316:1161-1171. https://www.ncbi.nlm.nih.gov/pubmed/27654602

32. Sniehotta FF, Evans EH, Sainsbury K, et al.: Behavioural intervention for weight loss maintenance versus standard weight advice in adults with obesity: A randomised controlled trial in the UK (NULevel Trial). PLoS Med 2019 16:e1002793. https://www.ncbi.nlm.nih.gov/pubmed/31063507

33. Brickwood KJ, Watson G, O'Brien J, et al.: Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth 2019 7:e11819. https://www.ncbi.nlm.nih.gov/pubmed/30977740

34. Chan R, Nguyen M, Smith R, et al.: Effect of Serial Anthropometric Measurements and Motivational Text Messages on Weight Reduction Among Workers: Pilot Randomized Controlled Trial. JMIR Mhealth Uhealth 2019 7:e11832. https://www.ncbi.nlm.nih.gov/pubmed/31017585

35. Kononova A, Li L, Kamp K, et al.: The Use of Wearable Activity Trackers Among Older Adults: Focus Group Study of Tracker Perceptions, Motivators, and Barriers in the Maintenance Stage of Behavior Change. JMIR Mhealth Uhealth 2019 7:e9832. https://www.ncbi.nlm.nih.gov/pubmed/30950807

36. Cheatham SW, Stull KR, Fantigrassi M, et al.: The efficacy of wearable activity tracking technology as part of a weight loss program: a systematic review. J Sports Med Phys Fitness 2018 58:534-548. https://www.ncbi.nlm.nih.gov/pubmed/28488834

37. Nakata Y, Sasai H, Tsujimoto T, et al.: Web-based intervention to promote weight-loss maintenance using an activity monitor: A randomized controlled trial. Prev Med Rep 2019 14:100839. https://www.ncbi.nlm.nih.gov/pubmed/3090668

38. Jastreboff AM, Kotz CM, Kahan S, et al.: Obesity as a Disease: The Obesity Society 2018 Position Statement. Obesity (Silver Spring) 2019 27:7-9. https://www.ncbi.nlm.nih.gov/pubmed/30569641

39. Bays H: Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox. Curr Atheroscler Rep 2014 16:409. https://www.ncbi.nlm.nih.gov/pubmed/24659222

40. Hales CM, Carroll MD, Fryar CD, et al.: Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS Data Brief 2017 1-8. https://www.ncbi.nlm.nih.gov/pubmed/29155689

41. Fryar CD, Kruszon-Moran D, Gu Q, et al.: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999–2000 Through 2015–2016. National Health Statistics Reports 2018 Number 122:1 - 16.

42. Araujo J, Cai J, Stevens J: Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. Metab Syndr Relat Disord 2019 17:46-52. https://www.ncbi.nlm.nih.gov/pubmed/30484738

43. Hirode G, Wong RJ: Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA 2020 323(24):2526-2528 https://pubmed.ncbi.nlm.nih.gov/32573660/

44. Gurka MJ, Filipp SL, DeBoer MD: Geographical variation in the prevalence of obesity, metabolic syndrome, and diabetes among US adults. Nutr Diabetes 2018 8:14. https://www.ncbi.nlm.nih.gov/pubmed/29549249

45. Ward ZJ, Bleich SN, Cradock AL, et al.: Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med 2019 381:2440-2450. https://www.ncbi.nlm.nih.gov/pubmed/31851800

46. Puhl R, Peterson JL, Luedicke J: Motivating or stigmatizing? Public perceptions of weight-related language used by health providers. Int J Obes (Lond) 2013 37:612-619. https://www.ncbi.nlm.nih.gov/pubmed/22777543

47. Ravussin E, Ryan D: Response to "The need for people-first language in our Obesity journal". Obesity (Silver Spring) 2015 23:918. https://www.ncbi.nlm.nih.gov/pubmed/25919920

48. National Institute of Diabetes and Digestive and Kidney Diseases. Health Information: Talking with patients about weight loss. https://www.niddk.nih.gov/health-information/health-topics/weight-control/medical/Pages/medical-care-for-patients-with-obesity.aspx (Accessed August 20, 2016).

49. Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. https://www.cdc.gov/obesity/data/prevalence-maps.html (Accessed January 15, 2023).

50. Stierman J, Afful B, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. National Health Statistics Reports Number 158: 1 – 21.

51. Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis. 2017 Mar 16;14:E24. doi: 10.5888/pcd14.160287. PMID: 28301314; PMCID: PMC5364735.

52. American Society of Metabolic and Bariatric Surgeons Standards Manual version 2.0. Resources for Optimal Care of the Metabolic and Bariatric Surgery Patient 2016 https://www.facs.org/~/media/files/quality%20programs/bariatric/mbsaqip%20standardsmanual.ashx (Accessed September 10, 2016).

53. Kushner RF, Kahan S: Introduction: The State of Obesity in 2017. Med Clin North Am 2018 102:1-11. https://www.ncbi.nlm.nih.gov/pubmed/29156178

54. Bays H, Scinta W: Adiposopathy and epigenetics: an introduction to obesity as a transgenerational disease. Curr Med Res Opin 2015 31:2059-2069. https://www.ncbi.nlm.nih.gov/pubmed/26331354

55. Dalamaga M, Kounatidis D, Tsilingiris D, et al. The Role of Endocrine Disruptors Bisphenols and Phthalates in Obesity: Current Evidence, Perspectives and Controversies. Int J Mol Sci. 2024;25(1):675. Pub-

lished 2024 Jan 4. doi:10.3390/ijms25010675

56. Heindel JJ, Alvarez JA, Atlas E, et al. Obesogens and Obesity: State-of-the-Science and Future Directions Summary from a Healthy Environment and Endocrine Disruptors Strategies Workshop. Am J Clin Nutr. 2023;118(1):329-337. doi:10.1016/j.ajcnut.2023.05.024

57. Gupta R, Kumar P, Fahmi N, et al. Endocrine disruption and obesity: A current review on environmental obesogens. Current Research in Green and Sustainable Chemistry. 2020;3:100009. doi:10.1016/j.crgsc.2020.06.002

58. Heindel JJ, Vom Saal FS, Blumberg B, et al. Parma consensus statement on metabolic disruptors [published correction appears in Environ Health. 2017 Dec 6;16(1):130. doi: 10.1186/s12940-017-0343-0]. Environ Health. 2015;14:54. Published 2015 Jun 20. doi:10.1186/s12940-015-0042-7

Genetic Etiology:

59. Chung WK: An overview of mongenic and syndromic obesities in humans. Pediatr Blood Cancer 2012 58:122-128. https://www.ncbi.nlm.nih.gov/pubmed/21994130

60. Herbst KL: Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin 2012 33:155-172. https://www.ncbi.nlm.nih.gov/pubmed/22301856

61. National Organization for Rare Disorders (NORD). Familial Partial Lipodystrophy https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/ Accessed December 3, 2017.

62. Melvin A, Adams C, Flanagan C, et al.: Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1. J Clin Endocrinol Metab 2017 102:3616-3620. https://www.ncbi.nlm.nih.gov/pubmed/28973478

63. Youngson NA, Morris MJ: What obesity research tells us about epigenetic mechanisms. Philos Trans R Soc Lond B Biol Sci 2013 368:20110337. https://www.ncbi.nlm.nih.gov/pubmed/23166398

64. Curley JP, Mashoodh R, Champagne FA: Epigenetics and the origins of paternal effects. Horm Behav 2011 59:306-314. https://www.ncbi.nlm.nih.gov/pubmed/20620140

65. Heslehurst N, Vieira R, Akhter Z, et al.: The association between maternal body mass index and child obesity: A systematic review and meta-analysis. PLoS Med 2019 16:e1002817. https://www.ncbi.nlm.nih.gov/pubmed/31185012

66. Ling C, Ronn T: Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab 2019 29:1028-1044. https://www.ncbi.nlm.nih.gov/pubmed/30982733

67. Soubry A, Schildkraut JM, Murtha A, et al.: Paternal obesity is associated with IGF2 hypomethylation in newborns: results from a Newborn Epigenetics Study (NEST) cohort. BMC Med 2013 11:29. https://www.ncbi.nlm.nih.gov/pubmed/23388414

68. Fruhbeck G, Busetto L, Dicker D, et al.: The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts 2019 12:131-136. https://www.ncbi.nlm.nih.gov/pubmed/30844811

69. Bays HE: Adiposopathy is “sick fat” a cardiovascular disease? J Am Coll Cardiol 2011 57:2461-2473. https://www.ncbi.nlm.nih.gov/pubmed/21679848

70. Bays HE: “Sick fat,” metabolic disease, and atherosclerosis. Am J Med 2009 122:S26-37. https://www.ncbi.nlm.nih.gov/pubmed/19110085

71. Bays HE: Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating “sick fat” through improving fat function with antidiabetes therapies. Am J Cardiol 2012 110:4B-12B. https://www.ncbi.nlm.nih.gov/pubmed/23062567

72. Salvestrini V, Sell C, Lorenzini A: Obesity May Accelerate the Aging Process. Front Endocrinol (Lausanne) 2019 10:266. https://www.ncbi.nlm.nih.gov/pubmed/31130916

73. Pettersen-Dahl A, Murzakanova G, Sandvik L, Laine K. Maternal body mass index as a predictor for de-

livery method. Acta Obstet Gynecol Scand. 2018 Feb;97(2):212-218. doi: 10.1111/aogs.13265. Epub 2017 Dec 14. PMID: 29164597.

74. Archer E. The childhood obesity epidemic as a result of nongenetic evolution: the maternal resources hypothesis. Mayo Clin Proc. 2015 Jan;90(1):77-92. doi: 10.1016/j.mayocp.2014.08.006. Epub 2014 Nov 17. PMID: 25440888; PMCID: PMC4289440.

75. Dugas C. et al. Is A Healthy Diet Associated with Lower Anthropometric and Glycemic Alterations in Predisposed Children Born from Mothers with Gestational Diabetes Mellitus? Obes Facts. 2017;10:396-406 2022

76. Pettersen-Dahl A, Murzakanova G, Sandvik L, Laine K. Maternal body mass index as a predictor for delivery method. Acta Obstet Gynecol Scand. 2018 Feb;97(2):212-218. doi: 10.1111/aogs.13265. Epub 2017 Dec 14. PMID: 29164597.

77. Keith, L., Seo, C., Wahi, M. M., Huggins, S., Carmody, M., Faerber, G., ... & Rockson, S. G. (2024). Proposed Framework for Research Case Definitions of Lipedema. Lymphatic Research and Biology, 22(2), 93-105.

Obesity Classification:

78. De Lorenzo A, Soldati L, Sarlo F, et al.: New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol 2016 22:681-703. https://www.ncbi.nlm.nih.gov/pubmed/26811617

79. Rahman M, Berenson AB: Accuracy of current body mass index obesity classification for white, black, and Hispanic reproductive- age women. Obstet Gynecol 2010 115:982-988. https://www.ncbi.nlm.nih.gov/pubmed/20410772

80. Misra A, Shrivastava U: Obesity and dyslipidemia in South Asians. Nutrients 2013 5:2708-2733. https://www.ncbi.nlm.nih.gov/pubmed/23863826

81. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10;363(9403):157-63. doi: 10.1016/S0140-6736(03)15268-3. Erratum in: Lancet. 2004 Mar 13;363(9412):902. PMID: 14726171. https://pubmed.ncbi.nlm.nih.gov/14726171/

82. Banack HR, Wactawski-Wende J, Hovey KM, et al.: Is BMI a valid measure of obesity in postmenopausal women? Menopause 2017 https://www.ncbi.nlm.nih.gov/pubmed/29135897

83. Hsu WC, Araneta MR, Kanaya AM, et al.: BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care 2015 38:150-158. https://www.ncbi.nlm.nih.gov/pubmed/25538311

84. Calculator.net Army Fat Calculator https://www.calculator.net/army-body-fat-calculator.html (Accessed November 26, 2018).

85. Grundy SM, Stone NJ, Bailey AL, et al.: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018 https://www.ncbi.nlm.nih.gov/pubmed/30423393

86. Bays H: Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014 21:345-351. https://www.ncbi.nlm.nih.gov/pubmed/25106000

87. Carroll JF, Chiapa AL, Rodriquez M, et al.: Visceral fat, waist circumference, and BMI: impact of race/ethnicity. Obesity (Silver Spring) 2008 16:600-607. https://www.ncbi.nlm.nih.gov/pubmed/18239557

88. Xu F, Earp JE, Adami A, et al. The Sex and Race/Ethnicity-Specific Relationships of Abdominal Fat Distribution and Anthropometric Indices in US Adults. Int J Environ Res Public Health. 2022;19(23):15521. Published 2022 Nov 23. doi:10.3390/ijerph192315521

89. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012 Mar;13(3):275-86. doi: 10.1111/j.1467-789X.2011.00952.x.

90. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: A Joint Interim

Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644

91. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev. 2010 Dec;23(2):247-69. doi: 10.1017/S0954422410000144. Epub 2010 Sep 7. PMID: 20819243.

92. Wang Z, Ma J, Si D: Optimal cut-off values and population means of waist circumference in different populations. Nutr Res Rev 2010 23:191-199. https://www.ncbi.nlm.nih.gov/pubmed/20642876

93. ICD10Data.com. Overweight and Obesity. http://www.icd10data.com/ICD10CM/Codes/E00-E89/E65-E68/E66-/E66 (Accessed August 20, 2016).

94. Chen GC, Arthur R, Iyengar NM, et al.: Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J 2019 https://www.ncbi.nlm.nih.gov/pubmed/31256194

95. Seidell JC. Looking back: BMI as a measure of body fatness: age- and sex-specific prediction formulas. Thirty years later. Br J Nutr. 2022;127(8):1279-1280. doi:10.1017/S0007114522000150

96. Sun Q, van Dam RM, Spiegelman D, et al.: Comparison of dual-energy x-ray absorptiometric and anthropometric measures of adiposity in relation to adiposity-related biologic factors. Am J Epidemiol 2010 172:1442-1454. https://www.ncbi.nlm.nih.gov/pubmed/20952596

97. Heo M, Faith MS, Pietrobelli A, Heymsfield SB. Percentage of body fat cutoffs by sex, age, and race-ethnicity in the US adult population from NHANES 1999-2004 [published correction appears in Am J Clin Nutr. 2012 Aug;96(2):448]. Am J Clin Nutr. 2012;95(3):594-602. doi:10.3945/ajcn.111.025171

98. Imboden MT, Welch WA, Swartz AM, et al.: Reference standards for body fat measures using GE dual energy x-ray absorptiometry in Caucasian adults. PLoS One 2017 12:e0175110. https://www.ncbi.nlm.nih.gov/pubmed/28388669

99. Stults-Kolehmainen MA, Stanforth PR, Bartholomew JB, et al.: DXA estimates of fat in abdominal, trunk and hip regions varies by ethnicity in men. Nutr Diabetes 2013 3:e64. https://www.ncbi.nlm.nih.gov/pubmed/23507968

100. Grundy SM, Neeland IJ, Turer AT, et al.: Waist circumference as measure of abdominal fat compartments. J Obes 2013 2013:454285.

101. Xu F, Earp JE, Adami A, et al. The Sex and Race/Ethnicity-Specific Relationships of Abdominal Fat Distribution and Anthropometric Indices in US Adults. Int J Environ Res Public Health. 2022;19(23):15521. Published 2022 Nov 23. doi:10.3390/ijerph192315521

102. Burridge K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022 1:100007.

103. Ndumele CE, Neeland IJ, Tuttle KR, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001186

Fat Mass Disease:

104. Kushner RF, Blatner DJ: Risk assessment of the overweight and obese patient. J Am Diet Assoc 2005 105:S53-62. https://www.ncbi.nlm.nih.gov/pubmed/15867897

105. Kushner RF, Roth JL: Assessment of the obese patient. Endocrinol Metab Clin North Am 2003 32:915-933. https://www.ncbi.nlm.nih.gov/pubmed/14711068

106. Bays HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004 12:1197-1211. https://www.ncbi.nlm.nih.gov/pubmed/15340100

107. Dekkers IA, Jansen PR, Lamb HJ: Obesity, Brain Volume, and White Matter Microstructure at MRI: A Cross-sectional UK Biobank Study. Radiology 2019 292:270. https://www.ncbi.nlm.nih.gov/pubmed/31219759

108. Pearl RL, Wadden TA, Hopkins CM, et al.: Association between weight bias internalization and metabol-

ic syndrome among treatment-seeking individuals with obesity. Obesity (Silver Spring) 2017 25:317-322. https://www.ncbi.nlm.nih.gov/pubmed/28124502

109. Obesity Action Coalition. Weight Bias Guides. https://www.obesityaction.org/action-through-advocacy/weight-bias/weight-bias-guides/ (Accessed January 5, 2019).

110. Phelan SM, Burgess DJ, Yeazel MW, et al.: Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev 2015 16:319-326.

111. Yacoub M, Youssef I, Salifu MO, McFarlane SI. Cardiovascular Disease Risk in Obstructive Sleep apnea: An Update. J Sleep Disord Ther. 2017;7(1):283. doi: 10.4172/2167-0277.1000283. Epub 2018 Feb 12. PMID: 29644149; PMCID: PMC5891150.

112. Gileles-Hillel A, Kheirandish-Gozal L, Gozal D: Biological plausibility linking sleep apnoea and metabolic dysfunction. Nat Rev Endocrinol 2016 12:290-298. https://www.ncbi.nlm.nih.gov/pubmed/26939978

113. Nagappa M, Liao P, Wong J, et al.: Validation of the STOP-Bang Questionnaire as a Screening Tool for Obstructive Sleep Apnea among Different Populations: A Systematic Review and Meta-Analysis. PLoS One 2015 10:e0143697. https://www.ncbi.nlm.nih.gov/pubmed/26658438

114. Broussard JL, Van Cauter E: Disturbances of sleep and circadian rhythms: novel risk factors for obesity. Curr Opin Endocrinol Diabetes Obes 2016 23:353-359. https://www.ncbi.nlm.nih.gov/pubmed/27584008

115. Pennings N, Golden L, Yashi K, Tondt J, Bays HE. Sleep-disordered breathing, sleep apnea, and other obesity-related sleep disorders: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 4:100043.

116. Poggiogalle E, Jamshed H, Peterson CM: Circadian regulation of glucose, lipid, and energy metabolism in humans. Metabolism 2018 84:11-27. https://www.ncbi.nlm.nih.gov/pubmed/29195759

117. Tan X, Chapman CD, Cedernaes J, et al.: Association between long sleep duration and increased risk of obesity and type 2 diabetes: A review of possible mechanisms. Sleep Med Rev 2018 40:127-134. https://www.ncbi.nlm.nih.gov/pubmed/29233612

118. Nedeltcheva AV, Kilkus JM, Imperial J, et al.: Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med 2010 153:435-441. https://www.ncbi.nlm.nih.gov/pubmed/20921542

119. Weaver TE, Calik MW, Farabi SS, et al.: Innovative treatments for adults with obstructive sleep apnea. Nat Sci Sleep 2014 6:137-147. https://www.ncbi.nlm.nih.gov/pubmed/25429246

120. Awad M, Gouveia C, Zaghi S, et al.: Changing practice: Trends in skeletal surgery for obstructive sleep apnea. J Craniomaxillofac Surg 2019 47:1185-1189. https://www.ncbi.nlm.nih.gov/pubmed/31182256

121. Anderson MR, Shashaty MGS. Impact of Obesity in Critical Illness. Chest. 2021 Dec;160(6):2135-2145. doi: 10.1016/j.chest.2021.08.001. Epub 2021 Aug 5. PMID: 34364868; PMCID: PMC8340548.

Adiposopathy (Sick Fat Disease):

122. Bays HE, Jones PH, Jacobson TA, et al.: Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. J Clin Lipidol 2016 10:33-57. https://www.ncbi.nlm.nih.gov/pubmed/26892120

123. Kloting N, Bluher M: Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord 2014 15:277-287. https://www.ncbi.nlm.nih.gov/pubmed/25344447

124. Bluher M: Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013 27:163-177. https://www.ncbi.nlm.nih.gov/pubmed/23731879

125. Bays HE, Gonzalez-Campoy JM, Henry RR, et al.: Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract 2008 62:1474-1483. https://www.ncbi.nlm.nih.gov/pubmed/18681905

126. Bays HE, Gonzalez-Campoy JM, Bray GA, et al.: Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008 6:343-368.https://www.ncbi.nlm.nih.gov/pubmed/18327995

127. Russo L, Lumeng CN: Properties and functions of adipose tissue macrophages in obesity. Immunology 2018 155:407-417. https://www.ncbi.nlm.nih.gov/pubmed/30229891

128. Chylikova J, Dvorackova J, Tauber Z, et al.: M1/M2 macrophage polarization in human obese adipose tissue. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018 162:79-82. https://www.ncbi.nlm.nih.gov/pubmed/29765169

129. Pirola L, Ferraz JC: Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem 2017 8:120-128. https://www.ncbi.nlm.nih.gov/pubmed/28588755

130. Rangel-Huerta OD, Pastor-Villaescusa B, Gil A: Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics 2019 15:93. https://www.ncbi.nlm.nih.gov/pubmed/31197497

131. Hamer M, Batty GD: Association of body mass index and waist-to-hip ratio with brain structure: UK Biobank study. Neurology 2019 https://www.ncbi.nlm.nih.gov/pubmed/30626649

132. Bliddal H, Leeds AR, Christensen R: Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. Obes Rev 2014 15:578-586. https://www.ncbi.nlm.nih.gov/pubmed/24751192

133. Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab 2004 89:2583-2589. https://www.ncbi.nlm.nih.gov/pubmed/15181027

134. Fauser BC, Tarlatzis BC, Rebar RW, et al.: Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 97:28-38 e25. https://www.ncbi.nlm.nih.gov/pubmed/22153789

135. Lim SS, Norman RJ, Davies MJ, et al.: The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 2013 14:95-109. https://www.ncbi.nlm.nih.gov/pubmed/23114091

136. Bays HE, Gonzalez-Campoy JM, Schorr AB: What men should know about metabolic syndrome, adiposopathy and 'sick fat'. Int J Clin Pract 2010 64:1735-1739. https://www.ncbi.nlm.nih.gov/pubmed/21070523

137. Shin D, Song WO: Prepregnancy body mass index is an independent risk factor for gestational hypertension, gestational diabetes, preterm labor, and small- and large-for-gestational-age infants. J Matern Fetal Neonatal Med 2015 28:1679-1686. https://www.ncbi.nlm.nih.gov/pubmed/25211384

138. Rocha AL, Oliveira FR, Azevedo RC, et al.: Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res 2019 8:https://www.ncbi.nlm.nih.gov/pubmed/31069057

139. Bozdag G, Mumusoglu S, Zengin D, et al.: The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016 31:2841-2855. https://www.ncbi.nlm.nih.gov/pubmed/27664216

140. American College of Obstetricians and Gynecologists. Obesity and Pregnancy. Frequently asked Questions. https://www.acog.org/-/media/For-Patients/faq182.pdf (Accessed September 10, 2016).

141. American College of Obstetricians Gynecologists: ACOG Committee opinion no. 549: obesity in pregnancy. Obstet Gynecol 2013 121:213-217. https://www.ncbi.nlm.nih.gov/pubmed/23262963

142. Pasquali R, Patton L, Gambineri A: Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007 14:482-487. https://www.ncbi.nlm.nih.gov/pubmed/17982356

143. Yu Z, Han S, Zhu J, et al.: Pre-pregnancy body mass index in relation to infant birth weight and offspring overweight/obesity: a systematic review and meta-analysis. PLoS One 2013 8:e61627. https://www.ncbi.nlm.nih.gov/pubmed/23613888

144. Bednarska S, Siejka A: The pathogenesis and treatment of polycystic ovary syndrome: What's new? Adv Clin Exp Med 2017 26:359-367. https://www.ncbi.nlm.nih.gov/pubmed/28791858

145. Mehta J, Kamdar V, Dumesic D: Phenotypic expression of polycystic ovary syndrome in South Asian women. Obstet Gynecol Surv 2013 68:228-234. https://www.ncbi.nlm.nih.gov/pubmed/23945839

146. Rojas J, Chavez M, Olivar L, et al.: Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med 2014 2014:719050. https://www.ncbi.nlm.nih.gov/pubmed/25763405

147. Berrino F, Bellati C, Secreto G, et al.: Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. Cancer Epidemiol Biomarkers Prev 2001 10:25-33. https://www.ncbi.nlm.nih.gov/pubmed/11205485

148. Chetrite GS, Feve B: Preface to special issue on: Adiposopathy in Cancer and (Cardio)Metabolic Diseases:an Endocrine Approach - Part 4. Horm Mol Biol Clin Investig 2015 23:1-4. https://www.ncbi.nlm.nih.gov/pubmed/26353175

149. Booth A, Magnuson A, Fouts J, et al.: Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig 2015 21:57-74. https://www.ncbi.nlm.nih.gov/pubmed/25781552

150. Hursting SD, Dunlap SM: Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental)issue. Ann N Y Acad Sci 2012 1271:82-87. https://www.ncbi.nlm.nih.gov/pubmed/23050968

151. Whiteman DC, Wilson LF: The fractions of cancer attributable to modifiable factors: A global review. Cancer Epidemiol 2016 44:203-221. https://www.ncbi.nlm.nih.gov/pubmed/27460784

152. Lauby-Secretan B, Scoccianti C, Loomis D, et al.: Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med 2016 375:794-798. https://www.ncbi.nlm.nih.gov/pubmed/27557308

153. Steele CB, Thomas CC, Henley SJ, et al.: Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity - United States, 2005-2014. MMWR Morb Mortal Wkly Rep 2017 66:1052-1058. https://www.ncbi.nlm.nih.gov/pubmed/28981482

154. Subak LL, Richter HE, Hunskaar S: Obesity and urinary incontinence: epidemiology and clinical research update. J Urol 2009 182:S2-7. https://www.ncbi.nlm.nih.gov/pubmed/19846133

155. Kudish BI, Iglesia CB, Sokol RJ, et al.: Effect of weight change on natural history of pelvic organ prolapse. Obstet Gynecol 2009 113:81-88. https://www.ncbi.nlm.nih.gov/pubmed/19104363

156. Gugliucci A. Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases. Adv Nutr. 2017 Jan 17;8(1):54-62. doi: 10.3945/an.116.013912. PMID: 28096127; PMCID: PMC5227984.

Obesity and Elevated Blood Sugar:

157. Cefalu WT, Kaul S, Gerstein HC, et al.: Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2018 41:14-31. https://www.ncbi.nlm.nih.gov/pubmed/29263194

158. Schnell O, Ryden L, Standl E, et al.: Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2017 16:128. https://www.ncbi.nlm.nih.gov/pubmed/29020969

159. Andrikou E, Tsioufis C, Andrikou I, et al.: GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol 2018 https://www.ncbi.nlm.nih.gov/pubmed/30528435

160. O'Brien MJ, Karam SL, Wallia A, et al.: Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Netw Open 2018 1:e186125.

161. Bays H, Blonde L, Rosenson R: Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 2006 4:871-895. https://www.ncbi.nlm.nih.gov/pubmed/17173503

162. Bays H, Ballantyne C: Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol. 2006 1:389-420.

163. Hsu PF, Sung SH, Cheng HM, et al.: Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. J Clin Endocrinol Metab 2018 103:3611-3619. https://www.ncbi.nlm.nih.gov/pubmed/30113697

164. Verma S, Poulter NR, Bhatt DL, et al.: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation 2018 138:2884-2894. https://www.ncbi.nlm.nih.gov/pubmed/30566004

165. Gerstein HC, Colhoun HM, Dagenais GR, et al.: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 394:121-130. https://www.ncbi.nlm.nih.gov/pubmed/31189511

166. Marso SP, Bain SC, Consoli A, et al.: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016 375:1834-1844. https://www.ncbi.nlm.nih.gov/pubmed/27633186

167. Kistorp C, Bliddal H, Goetze JP, et al.: Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. BMC Obes 2014 1:24. https://www.ncbi.nlm.nih.gov/pubmed/26217511

168. Lim K, Burke SL, Head GA: Obesity-related hypertension and the role of insulin and leptin in high-fat-fed rabbits. Hypertension 2013 61:628-634. https://www.ncbi.nlm.nih.gov/pubmed/23339171

169. Trahair LG, Horowitz M, Jones KL: Postprandial hypotension: a systematic review. J Am Med Dir Assoc 2014 15:394-409. https://www.ncbi.nlm.nih.gov/pubmed/24630686

170. von Schnurbein J, Manzoor J, Brandt S, et al.: Leptin Is Not Essential for Obesity-Associated Hypertension. Obes Facts 2019 12:460-475. https://www.ncbi.nlm.nih.gov/pubmed/31357197

171. Rust P, Ekmekcioglu C: Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension. Adv Exp Med Biol 2017 956:61-84. https://www.ncbi.nlm.nih.gov/pubmed/27757935

172. DiNicolantonio JJ, Lucan SC: The wrong white crystals: not salt but sugar as aetiological in hyperten-

sion and cardiometabolic disease. Open Heart 2014 1:e000167.

173. Grillo A, Salvi L, Coruzzi P, et al.: Sodium Intake and Hypertension. Nutrients 2019 11:https://www.ncbi.nlm.nih.gov/pubmed/31438636

174. Farquhar WB, Edwards DG, Jurkovitz CT, et al.: Dietary sodium and health: more than just blood pressure. J Am Coll Cardiol 2015 65:1042-1050. https://www.ncbi.nlm.nih.gov/pubmed/25766952

175. Barton M, Baretella O, Meyer MR: Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. Br J Pharmacol 2012 165:591-602. https://www.ncbi.nlm.nih.gov/pubmed/21557734

176. Buckley LF, Canada JM, Del Buono MG, et al.: Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail 2018 5:372-378. https://www.ncbi.nlm.nih.gov/pubmed/29345112

177. Engin A: Endothelial Dysfunction in Obesity. Adv Exp Med Biol 2017 960:345-379. https://www.ncbi.nlm.nih.gov/pubmed/28585207

178. Khalid U, Wruck LM, Quibrera PM, et al.: BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol 2017 233:61-66. https://www.ncbi.nlm.nih.gov/pubmed/28185703

179. Dormandy, J. A., Charbonnel, B., Eckland, D. J., & Erdmann, E. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): A randomised controlled trial. The Lancet, 366(9493), 1279–1289. https://doi.org/10.1016/s0140-6736(05)67528-9

180. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28. PMID: 20427778; PMCID: PMC2928471.

181. Kernan, W. N., Viscoli, C. M., & Furie, K. L. (2016). Pioglitazone after ischemic stroke or transient ischemic attack. New England Journal of Medicine, 374(14), 1321–1331. https://doi.org/10.1056/nejmoa1506930

182. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019 Mar;16(2):133-143. doi: 10.1177/1479164118825376. Epub 2019 Feb 1. PMID: 30706731.

183. Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, Belfort-DeAguiar R, Positano V, Barb D, Kadiyala S, Harrison S, Cusi K. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int. 2021 Nov;41(11):2659-2670. doi: 10.1111/liv.15005. Epub 2021 Jul 21. PMID: 34219361; PMCID: PMC9290929

184. Sayyed Kassem L, Rajpal A, Barreiro MV, Ismail-Beigi F. Beta-cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced? Journal of Diabetes. 2023; 15(10): 817-837. doi:10.1111/1753-0407.13446

Obesity and Cardiovascular Disease:

185. Cavender MA, Norhammar A, Birkeland KI, et al.: SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol 2018 71:2497-2506. https://www.ncbi.nlm.nih.gov/pubmed/29852973

186. Kosiborod M, Lam CSP, Kohsaka S, et al.: Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol 2018 71:2628-2639. https://www.ncbi.nlm.nih.gov/pubmed/29540325

187. Home P: Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia 2019 https://www.ncbi.nlm.nih.gov/pubmed/30607467

188. Coulter AA, Rebello CJ, Greenway FL: Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs 2018 78:1113-1132. https://www.ncbi.nlm.nih.gov/pubmed/30014268

189. Gadde KM, Martin CK, Berthoud HR, et al.: Obesity: Pathophysiology and Management. J Am Coll Cardiol 2018 71:69-84. https://www.ncbi.nlm.nih.gov/pubmed/29301630

190. Ritchey ME, Harding A, Hunter S, et al.: Cardiovascular Safety During and After Use of Phentermine and Topiramate. J Clin Endocrinol Metab 2019 104:513-522. https://www.ncbi.nlm.nih.gov/pubmed/30247575

191. Margulies KB, McNulty SE, Cappola TP: Lack of Benefit for Liraglutide in Heart Failure-Reply. JAMA 2016 316:2429-2430. https://www.ncbi.nlm.nih.gov/pubmed/27959992

192. Vorsanger MH, Subramanyam P, Weintraub HS, et al.: Cardiovascular Effects of the New Weight Loss Agents. J Am Coll Cardiol 2016 68:849-859.

193. Bethel MA, Patel RA, Merrill P, et al.: Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018 6:105-113.

194. Sharma A, Cooper LB, Fiuzat M, et al.: Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. JACC Heart Fail 2018 6:813-822.

195. Saab J, Salvatore SP: Evaluating the cause of death in obese individuals: a ten-year medical autopsy study. J Obes 2015 2015:695374. https://www.ncbi.nlm.nih.gov/pubmed/25653872

196. Collaborators GBDO, Afshin A, Forouzanfar MH, et al.: Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017 377:13-27. https://www.ncbi.nlm.nih.gov/pubmed/28604169

197. Nagy E, Jermendy AL, Merkely B, et al.: Clinical importance of epicardial adipose tissue. Arch Med Sci 2017 13:864-874. https://www.ncbi.nlm.nih.gov/pubmed/28721155

198. Riaz H, Khan MS, Siddiqi TJ, et al.: Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. JAMA Netw Open 2018 1:e183788.

199. Vilahur G, Ben-Aicha S, Badimon L: New insights into the role of adipose tissue in thrombosis. Cardiovasc Res 2017 113:1046-1054. https://www.ncbi.nlm.nih.gov/pubmed/28472252

200. Karmazyn M, Rajapurohitam V: Leptin as a cardiac pro-hypertrophic factor and its potential role in the development of heart failure. Curr Pharm Des 2014 20:646-651. https://www.ncbi.nlm.nih.gov/pubmed/23688017

201. Neeland IJ, Poirier P, Despres JP: Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation 2018 137:1391-1406. https://www.ncbi.nlm.nih.gov/pubmed/29581366

202. Ei Ei Khaing N, Shyong TE, Lee J, et al.: Epicardial and visceral adipose tissue in relation to subclinical atherosclerosis in a Chinese population. PLoS One 2018 13:e0196328.

203. Abazid RM, Kattea MO, Sayed S, et al.: Visceral adipose tissue influences on coronary artery calcification at young and middle-age groups using computed tomography angiography. Avicenna J Med 2015 5:83-88.

204. Csige I, Ujvarosy D, Szabo Z, et al.: The Impact of Obesity on the Cardiovascular System. J Diabetes Res 2018 2018:3407306. https://www.ncbi.nlm.nih.gov/pubmed/30525052

205. Kaushik M, Reddy YM: Distinction of “fat around the heart”. J Am Coll Cardiol 2011 58:1640; author reply 1640-1641. https://www.ncbi.nlm.nih.gov/pubmed/21958896

206. Prenner SB, Mather PJ: Obesity and heart failure with preserved ejection fraction: A growing problem. Trends Cardiovasc Med 2018 28:322-327. https://www.ncbi.nlm.nih.gov/pubmed/29305040

207. Tsujimoto T, Kajio H: Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF. J Am Coll Cardiol 2017 70:2739-2749. https://www.ncbi.nlm.nih.gov/pubmed/29191321

208. Parikh KS, Sharma K, Fiuzat M, et al.: Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. JACC Heart Fail 2018 6:619-632. https://www.ncbi.nlm.nih.gov/pubmed/30071950

209. Savji N, Meijers WC, Bartz TM, et al.: The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC Heart Fail 2018 6:701-709. https://www.ncbi.nlm.nih.gov/pubmed/30007554

210. Obokata M, Reddy YNV, Pislaru SV, et al.: Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation 2017 136:6-19. https://www.ncbi.nlm.nih.gov/pubmed/28381470

211. Oikonomou EK, Marwan M, Desai MY, et al.: Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 2018 392:929-939. https://www.ncbi.nlm.nih.gov/pubmed/30170852

212. Goeller M, Achenbach S, Marwan M, et al.: Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects. J Cardiovasc Comput Tomogr 2018 12:67-73. https://www.ncbi.nlm.nih.gov/pubmed/29233634

213. Wu Y, Zhang A, Hamilton DJ, et al.: Epicardial Fat in the Maintenance of Cardiovascular Health. Method-

ist Debakey Cardiovasc J 2017 13:20-24. https://www.ncbi.nlm.nih.gov/pubmed/28413578

214. Pandey A, LaMonte M, Klein L, et al.: Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. J Am Coll Cardiol 2017 69:1129-1142.

215. Patel VB, Shah S, Verma S, et al.: Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev 2017 22:889-902. https://www.ncbi.nlm.nih.gov/pubmed/28762019

216. Packer M: Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol 2018 71:2360-2372. https://www.ncbi.nlm.nih.gov/pubmed/29773163

217. Fitzgibbons TP, Czech MP: Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc 2014 3:e000582. https://www.ncbi.nlm.nih.gov/pubmed/24595191

218. Javaheri S, Javaheri S, Javaheri A: Sleep apnea, heart failure, and pulmonary hypertension. Curr Heart Fail Rep 2013 10:315-320. https://www.ncbi.nlm.nih.gov/pubmed/24097114

219. Blokhin IO, Lentz SR: Mechanisms of thrombosis in obesity. Curr Opin Hematol 2013 20:437-444. https://www.ncbi.nlm.nih.gov/pubmed/23817170

220. Lefranc C, Friederich-Persson M, Palacios-Ramirez R, et al.: Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor. J Endocrinol 2018 238:R143-R159. https://www.ncbi.nlm.nih.gov/pubmed/29875164

221. Gruzdeva OV, Akbasheva OE, Dyleva YA, et al.: Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease. Bull Exp Biol Med 2017 163:608-611. https://www.ncbi.nlm.nih.gov/pubmed/28948552

222. Uchida Y, Uchida Y, Shimoyama E, et al.: Human pericoronary adipose tissue as storage and possible supply site for oxidized low-density lipoprotein and high-density lipoprotein in coronary artery. J Cardiol 2017 69:236-244. https://www.ncbi.nlm.nih.gov/pubmed/27209423

223. Subbotin VM: Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial vasa vasorum, but not from the arterial lumen: a hypothesis. Theor Biol Med Model 2012 9:11. https://www.ncbi.nlm.nih.gov/pubmed/22490844

224. Salazar J, Luzardo E, Mejias JC, et al.: Epicardial Fat: Physiological, Pathological, and Therapeutic Implications. Cardiol Res Pract 2016 2016:1291537. https://www.ncbi.nlm.nih.gov/pubmed/27213076

225. Zhu N, Jiang W, Wang Y, et al.: Plasma levels of free fatty acid differ in patients with left ventricular preserved, mid-range, and reduced ejection fraction. BMC Cardiovasc Disord 2018 18:104. https://www.ncbi.nlm.nih.gov/pubmed/29843618

226. Das SR, Everett BM, Birtcher KK, et al.: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018 72:3200-3223. https://www.ncbi.nlm.nih.gov/pubmed/30497881

227. Kramer CK, Ye C, Campbell S, et al.: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. JACC Heart Fail 2018 6:823-830. https://www.ncbi.nlm.nih.gov/pubmed/30196071

228. Sanches Machado d'Almeida K, Ronchi Spillere S, Zuchinali P, et al.: Mediterranean Diet and Other Dietary Patterns in Primary Prevention of Heart Failure and Changes in Cardiac Function Markers: A Systematic Review. Nutrients 2018 10: https://www.ncbi.nlm.nih.gov/pubmed/29320401

229. Jorsal A, Kistorp C, Holmager P, et al.: Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017 19:69-77. https://www.ncbi.nlm.nih.gov/pubmed/27790809

230. Retwinski A, Kosmalski M, Crespo-Leiro M, et al.: The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. Kardiol Pol 2018 76:1336-1343. https://www.ncbi.nlm.nih.gov/pubmed/29862487

231. Weir DL, Abrahamowicz M, Beauchamp ME, et al.: Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. Diabetes Obes Metab 2018 20:2653-2660. https://www.ncbi.nlm.nih.gov/pubmed/29934961

232. Margulies KB, Hernandez AF, Redfield MM, et al.: Effects of Liraglutide on Clinical Stability Among Pa-

tients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2016 316:500-508. https://www.ncbi.nlm.nih.gov/pubmed/27483064

233. Bays H, Abate N, Chandalia M: Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol 2005 1:39-59. https://www.ncbi.nlm.nih.gov/pubmed/19804060

234. Bays H: Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 2005 3:393-404. https://www.ncbi.nlm.nih.gov/pubmed/15889967

235. Yu JS, Cui W: Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development 2016 143:3050-3060. https://www.ncbi.nlm.nih.gov/pubmed/27578176

236. Makki K, Froguel P, Wolowczuk I: Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013 2013:139239. https://www.ncbi.nlm.nih.gov/pubmed/24455420

237. DeMarco VG, Aroor AR, Sowers JR: The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol 2014 10:364-376. https://www.ncbi.nlm.nih.gov/pubmed/24732974

238. Zoller V, Funcke JB, Keuper M, et al.: TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors. Cell Death Dis 2016 7:e2412.

239. Fronczyk A, Moleda P, Safranow K, et al.: Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control. Inflammation 2014 37:349-357. https://www.ncbi.nlm.nih.gov/pubmed/24197824

240. D'Souza A M, Neumann UH, Glavas MM, et al.: The glucoregulatory actions of leptin. Mol Metab 2017 6:1052-1065. https://www.ncbi.nlm.nih.gov/pubmed/28951828

241. Geer EB, Islam J, Buettner C: Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am 2014 43:75-102. https://www.ncbi.nlm.nih.gov/pubmed/24582093

242. Fisette A, Lapointe M, Cianflone K: Obesity-inducing diet promotes acylation stimulating protein resistance. Biochem Biophys Res Commun 2013 437:403-407. https://www.ncbi.nlm.nih.gov/pubmed/23831465

243. Thorp AA, Schlaich MP: Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. J Diabetes Res 2015 2015:341583. https://www.ncbi.nlm.nih.gov/pubmed/26064978

244. Stimson RH, Walker BR: The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Horm Mol Biol Clin Investig 2013 15:37-48.

245. Balland E, Chen W, Tiganis T, et al.: Persistent leptin signalling in the arcuate nucleus impairs hypothalamic insulin signalling and glucose homeostasis in obese mice. Neuroendocrinology 2019 https://www.ncbi.nlm.nih.gov/pubmed/30995667

246. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004 89:463-478. https://www.ncbi.nlm.nih.gov/pubmed/14764748

247. Veret J, Bellini L, Giussani P, et al.: Roles of Sphingolipid Metabolism in Pancreatic beta Cell Dysfunction Induced by Lipotoxicity. J Clin Med 2014 3:646-662. https://www.ncbi.nlm.nih.gov/pubmed/26237395

248. Larsen PJ, Tennagels N: On ceramides, other sphingolipids and impaired glucose homeostasis. Mol Metab 2014 3:252-260. https://www.ncbi.nlm.nih.gov/pubmed/24749054

249. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al.: Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for beta Cell Recovery. Cell Metab 2018 28:547-556 e543. https://www.ncbi.nlm.nih.gov/pubmed/30078554

250. Hernandez AF, Green JB, Janmohamed S, et al.: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018 392:1519-1529. https://www.ncbi.nlm.nih.gov/pubmed/30291013

251. Rosenstock J, Perkovic V, Johansen OE, et al.: Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2018 https://www.ncbi.nlm.nih.gov/pubmed/30418475

252. Wiviott SD, Raz I, Bonaca MP, et al.: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2018 https://www.ncbi.nlm.nih.gov/pubmed/30415602

253. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine.

Obesity and High Blood Pressure:

254. Landsberg L, Aronne LJ, Beilin LJ, et al.: Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 2013 21:8-24. https://www.ncbi.nlm.nih.gov/pubmed/23401272

255. Kim DH, Kim C, Ding EL, et al.: Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension 2013 62:27-32. https://www.ncbi.nlm.nih.gov/pubmed/23716587

256. Nguyen NQ, Debreceni TL, Burgstad CM, et al.: Effects of Posture and Meal Volume on Gastric Emptying, Intestinal Transit, Oral Glucose Tolerance, Blood Pressure and Gastrointestinal Symptoms After Roux-en-Y Gastric Bypass. Obes Surg 2015 25:1392-1400. https://www.ncbi.nlm.nih.gov/pubmed/25502436

257. Kawarazaki W, Fujita T: The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens 2016 29:415-423. https://www.ncbi.nlm.nih.gov/pubmed/26927805

258. Di Folco U, Vallecorsa N, Nardone MR, Pantano AL, Tubili C. Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. Acta Diabetol. 2022 Oct;59(10):1287-1294. doi: 10.1007/s00592-022-01936-6. Epub 2022 Jul 17. PMID: 35842847; PMCID: PMC9288662.v

259. Johnson RJ, Lanaspa MA, Sanchez-Lozada LG, Tolan D, Nakagawa T, Ishimoto T, Andres-Hernando A, Rodriguez-Iturbe B, Stenvinkel P. The fructose survival hypothesis for obesity. Philos Trans R Soc Lond B Biol Sci. 2023 Sep 11;378(1885):20220230. doi: 10.1098/rstb.2022.0230. Epub 2023 Jul 24. PMID: 37482773; PMCID: PMC10363705.

Obesity and Dislipidemia:

260. Dansinger M, Williams PT, Superko HR, et al.: Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women. J Clin Lipidol 2019 13:308-316. https://www.ncbi.nlm.nih.gov/pubmed/30665769

261. Bays H, Kothari SN, Azagury DE, et al.: Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surg Obes Relat Dis 2016 12:468-495. https://www.ncbi.nlm.nih.gov/pubmed/27050404

262. Aguilar D, Fernandez ML: Hypercholesterolemia induces adipose dysfunction in conditions of obesity and nonobesity. Adv Nutr 2014 5:497-502. https://www.ncbi.nlm.nih.gov/pubmed/25469381

263. Collins JM, Neville MJ, Pinnick KE, et al.: De novo lipogenesis in the differentiating human adipocyte can provide all fatty acids necessary for maturation. J Lipid Res 2011 52:1683-1692. https://www.ncbi.nlm.nih.gov/pubmed/21677304

264. Chung S, Parks JS: Dietary cholesterol effects on adipose tissue inflammation. Curr Opin Lipidol 2016 27:19-25. https://www.ncbi.nlm.nih.gov/pubmed/26655292

265. Christou GA, Kiortsis DN: Adiponectin and lipoprotein metabolism. Obes Rev 2013 14:939-949. https://www.ncbi.nlm.nih.gov/pubmed/23957239

266. Ebbert JO, Jensen MD: Fat depots, free fatty acids, and dyslipidemia. Nutrients 2013 5:498-508. https://www.ncbi.nlm.nih.gov/pubmed/23434905

267. Klop B, Elte JW, Cabezas MC: Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013 5:1218-1240. https://www.ncbi.nlm.nih.gov/pubmed/23584084

268. The fructose survival hypothesis for obesity - PMC (nih.gov) Johnson RJ, Lanaspa MA, Sanchez-Lozada LG, Tolan D, Nakagawa T, Ishimoto T, Andres-Hernando A, Rodriguez-Iturbe B, Stenvinkel P. The fructose survival hypothesis for obesity. Philos Trans R Soc Lond B Biol Sci. 2023 Sep 11;378(1885):20220230. doi: 10.1098/rstb.2022.0230. Epub 2023 Jul 24. PMID: 37482773; PMCID: PMC10363705.

269. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024;18(3):e320-e350. doi:10.1016/j.jacl.2024.04.001

270. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obes Pillars. 2024;10: 100108. doi:10.1016/j.obpill.2024.100108

Obesity and Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD):

271. Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., ... & Newsome, P. N. (2023). A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. Newsome, NNc, group.

272. Karjoo S, Auriemma A, Fraker T, Bays HE. Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 3:100027.

273. Barb D, Portillo-Sanchez P, Cusi K: Pharmacological management of nonalcoholic fatty liver disease. Metabolism 2016 65:1183-1195. https://www.ncbi.nlm.nih.gov/pubmed/27301803

274. Choo VL, Viguiliouk E, Blanco Mejia S, et al.: Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies. BMJ 2018 363:k4644. https://www.ncbi.nlm.nih.gov/pubmed/30463844

275. Jung UJ, Choi MS: Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014 15:6184-6223. https://www.ncbi.nlm.nih.gov/pubmed/24733068

276. Calzadilla Bertot L, Adams LA: The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016 17:

277. Kanda H, Tateya S, Tamori Y, et al.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006 116:1494-1505. https://www.ncbi.nlm.nih.gov/pubmed/16691291

278. Duwaerts CC, Maher JJ: Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Curr Hepatol Rep 2014 13:119-129. https://www.ncbi.nlm.nih.gov/pubmed/25045618

279. Saponaro C, Gaggini M, Carli F, et al.: The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients 2015 7:9453-9474. https://www.ncbi.nlm.nih.gov/pubmed/26580649

280. Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018 67:328-357. https://www.ncbi.nlm.nih.gov/pubmed/28714183

281. Lee DH: Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol 2017 23:290-301. https://www.ncbi.nlm.nih.gov/pubmed/28994271

282. Idilman IS, Keskin O, Celik A, et al.: A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol 2016 57:271-278. https://www.ncbi.nlm.nih.gov/pubmed/25855666

283. Leoni S, Tovoli F, Napoli L, et al.: Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018 24:3361-3373.

284. Pandyarajan V, Gish RG, Alkhouri N, et al.: Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. Gastroenterol Hepatol (N Y) 2019 15:357-365. https://www.ncbi.nlm.nih.gov/pubmed/31391806

285. de Alwis NM, Anstee QM, Day CP: How to Diagnose Nonalcoholic Fatty Liver Disease. Dig Dis 2016 34 Suppl 1:19-26. https://www.ncbi.nlm.nih.gov/pubmed/27547937

286. Kneeman JM, Misdraji J, Corey KE: Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2012 5:199-207. https://www.ncbi.nlm.nih.gov/pubmed/22570680

287. Vos MB, Abrams SH, Barlow SE, et al.: NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017 64:319-334 https://www.ncbi.nlm.nih.gov/pubmed/28107283

288. Harrison SA, Neuschwander-Tetri BA: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004 8:861-879, ix. https://www.ncbi.nlm.nih.gov/pubmed/15464659

289. Luukkonen PK, Sadevirta S, Zhou Y, et al.: Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. Diabetes Care 2018 41:1732-1739. https://www.ncbi.nlm.nih.gov/pubmed/29844096

290. van der Windt DJ, Sud V, Zhang H, et al.: The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr 2018 18:89-101.

291. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Wan ZH, Tang NSY, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2809-2817.e28. doi: 10.1016/j.cgh.2021.12.002. Epub 2021 Dec 7. PMID: 34890795.

292. Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J, Yong JN, Zeng RW, Chew NWS, Nah B, Kulkarni A, Siddiqui MS, Dan YY, Wong VW, Sanyal AJ, Noureddin M, Muthiah M, Ng CH. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16. PMID: 36400097.

293. Rinella, Mary E.1; Neuschwander-Tetri, Brent A.2; Siddiqui, Mohammad Shadab3; Abdelmalek, Manal F.4; Caldwell, Stephen5; Barb, Diana6; Kleiner, David E.7; Loomba, Rohit8. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):p 1797-1835, May 2023. | DOI: 10.1097/HEP.0000000000000323

294. https://www.rezdiffrahcp.com/

295. Kanwal, F., Neuschwander-Tetri, B. A., Loomba, R., & Rinella, M. E. (2024). Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology, 79(5), 1212-1219.

Obesity and Cancer:

296. Lazarus E, Bays HE. Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 3:100026.

297. Islami F, Goding Sauer A, Gapstur SM, et al.: Proportion of Cancer Cases Attributable to Excess Body Weight by US State, 2011-2015. JAMA Oncol 2018 https://www.ncbi.nlm.nih.gov/pubmed/30589925

298. Sung H, Siegel RL, Torre LA, et al.: Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 2018 https://www.ncbi.nlm.nih.gov/pubmed/30548482

299. Sung H, Siegel RL, Rosenberg PS, et al.: Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019 https://www.ncbi.nlm.nih.gov/pubmed/30733056

300. Spyrou N, Avgerinos KI, Mantzoros CS, et al.: Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies. Curr Obes Rep 2018 7:260-275. https://www.ncbi.nlm.nih.gov/pubmed/30145771

301. Golemis EA, Scheet P, Beck TN, et al.: Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 2018 32:868-902. https://www.ncbi.nlm.nih.gov/pubmed/29945886

302. Druso JE, Fischbach C: Biophysical Properties of Extracellular Matrix: Linking Obesity and Cancer. Trends Cancer 2018 4:271-273. https://www.ncbi.nlm.nih.gov/pubmed/29606310

303. Wlodarczyk M, Nowicka G: Obesity, DNA Damage, and Development of Obesity-Related Diseases. Int J Mol Sci 2019 20: https://www.ncbi.nlm.nih.gov/pubmed/30845725

304. Mackenzie H, Markar SR, Askari A, et al.: Obesity surgery and risk of cancer. Br J Surg 2018 105:1650-1657. https://www.ncbi.nlm.nih.gov/pubmed/30003539

305. Seiler A, Chen MA, Brown RL, et al.: Obesity, Dietary Factors, Nutrition, and Breast Cancer Risk. Curr Breast Cancer Rep 2018 10:14-27.

306. Pan K, Luo J, Aragaki AK, et al.: Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women. Oncotarget 2019 0:3088-3092. https://www.ncbi.nlm.nih.gov/pubmed/31139321

307. Diallo A, Deschasaux M, Latino-Martel P, et al.: Red and processed meat intake and cancer risk: Results from the prospective NutriNet-Santecohort study. Int J Cancer 2018 142:230-237. https://www.ncbi.nlm.nih.gov/pubmed/28913916

308. Liou GY, Storz P: Reactive oxygen species in cancer. Free Radic Res 2010 44:479-496.

309. Salehi B, Martorell M, Arbiser JL, et al.: Antioxidants: Positive or Negative Actors? Biomolecules 2018 8: https://www.ncbi.nlm.nih.gov/pubmed/30366441

310. Gorlach A, Dimova EY, Petry A, et al.: Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? Redox Biol 2015 6:372-385. https://www.ncbi.nlm.nih.gov/pubmed/26339717

311. Davidson KT, Zhu Z, Balabanov D, et al.: Beyond Conventional Medicine - a Look at Blueberry, a Cancer-Fighting Superfruit. Pathol Oncol Res 2018 24:733-738. 699.

312. Turati F, Rossi M, Pelucchi C, et al.: Fruit and vegetables and cancer risk: a review of southern European studies. Br J Nutr 2015 113 Suppl 2:S102-110.

313. Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. Cancers (Basel). 2023 Jan 12;15(2):485. doi: 10.3390/cancers15020485. PMID: 36672434; PMCID: PMC9857053.

314. Isaksen IM, Dankel SN. Ultra-processed food consumption and cancer risk: A systematic review and meta-analysis. Clin Nutr. 2023 Jun;42(6):919-928. doi: 10.1016/j.clnu.2023.03.018. Epub 2023 Mar 30. PMID: 37087831.

Obesity and Sleep:

315. Papatriantafyllou E, Efthymiou D, Zoumbaneas E, Popescu CA, Vassilopoulou E. Sleep Deprivation: Effects on Weight Loss and Weight Loss Maintenance. Nutrients. 2022;14(8):1549. Published 2022 Apr 8. doi:10.3390/nu14081549

316. Wang X, Sparks JR, Bowyer KP, Youngstedt SD. Influence of sleep restriction on weight loss outcomes associated with caloric restriction. Sleep. 2018;41(5):10.1093/sleep/zsy027. doi:10.1093/sleep/zsy027

317. Watson NF, Badr MS, Belenky G, et al. Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38(6):843-844. Published 2015 Jun 1. doi:10.5665/sleep.4716

318. Nedeltcheva AV, Kilkus JM, Imperial J, Kasza K, Schoeller DA, Penev PD. Sleep curtailment is accompanied by increased intake of calories from snacks. Am J Clin Nutr. 2009;89(1):126-133. doi:10.3945/ajcn.2008.26574

319. McHill AW, Phillips AJ, Czeisler CA, et al. Later circadian timing of food intake is associated with increased body fat. Am J Clin Nutr. 2017;106(5):1213-1219. doi:10.3945/ajcn.117.161588

320. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387-1394. doi:10.1378/chest.14-0970

321. Chernyshev OY. Sleep Deprivation and Its Consequences. Continuum (Minneap Minn). 2023;29(4):1234-1252. doi:10.1212/CON.0000000000001323

322. Craven MP, Fekete EM. Internalized Weight Stigma, Psychological Well-Being, and Sleep in Women. Int J Behav Med. 2022;29(2):199-208. doi:10.1007/s12529-021-10008-y

323. Christensen Pacella KA, Forbush KT. Weight bias internalization is positively associated with insomnia symptom severity in young women with disordered eating. Sleep Health. 2024;10(1):60-64. doi:10.1016/j.sleh.2023.10.014

324. Morgenthaler TI, Lee-Chiong T, Alessi C, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report [published correction appears in Sleep. 2008 Jul 1;31(7):table of contents]. Sleep. 2007;30(11):1445-1459. doi:10.1093/sleep/30.11.1445

325. McHill AW, Wright KP Jr. Role of sleep and circadian disruption on energy expenditure and in metabolic predisposition to human obesity and metabolic disease. Obes Rev. 2017;18 Suppl 1:15-24. doi:10.1111/obr.12503

326. Silber MH, Buchfuhrer MJ, Earley CJ, et al. The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clin Proc. 2021;96(7):1921-1937. doi:10.1016/j.mayocp.2020.12.026

327. Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and Management of Obesity Hypoventilation Syn-

drome. An Official American Thoracic Society Clinical Practice Guideline [published correction appears in Am J Respir Crit Care Med. 2019 Nov 15;200(10):1326. doi: 10.1164/rccm.v200erratum7]. Am J Respir Crit Care Med. 2019;200(3):e6-e24. doi:10.1164/rccm.201905-1071ST

328. Antoine MH, Sankari A, Bollu PC. Obesity-Hypoventilation Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 11, 2024.

329. Masa JF, Pépin JL, Borel JC, Mokhlesi B, Murphy PB, Sánchez-Quiroga MÁ. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28(151):180097. Published 2019 Mar 14. doi:10.1183/16000617.0097-2018

330. Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med. 2011;183(3):292-298. doi:10.1164/rccm.201008-1280CI

331. Troester MM, Quan SF, Berry RB, et al; for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Version 3. Dariel IL: American Academy of Sleep Medicine; 2023.

332. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. Published 2017 Mar 15. doi:10.5664/jcsm.6506

333. Caples SM, Anderson WM, Calero K, Howell M, Hashmi SD. Use of polysomnography and home sleep apnea tests for the longitudinal management of obstructive sleep apnea in adults: an American Academy of Sleep Medicine clinical guidance statement. J Clin Sleep Med. 2021;17(6):1287-1293. doi:10.5664/jcsm.9240

334. Silber MH, Buchfuhrer MJ, Earley CJ, et al. The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clin Proc. 2021;96(7):1921-1937. doi:10.1016/j.mayocp.2020.12.026

335. American Academy of Sleep Medicine. Healthy Sleep Habits. August 2020. Accessed August 2024. https://sleepeducation.org/healthy-sleep/healthy-sleep-habits/

Obesity and Stress:

336. Christensen SM, Varney C, Gupta V, Wenz L, Bays HE. Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 4:100041.

337. Harrell CS, Gillespie CF, Neigh GN: Energetic stress: The reciprocal relationship between energy availability and the stress response. Physiol Behav 2016 166:43-55. https://www.ncbi.nlm.nih.gov/pubmed/26454211

338. Yau YH, Potenza MN: Stress and eating behaviors. Minerva Endocrinol 2013 38:255-267. https://www.ncbi.nlm.nih.gov/pubmed/24126546

339. Thaler JP, Guyenet SJ, Dorfman MD, et al.: Hypothalamic inflammation: marker or mechanism of obesity pathogenesis? Diabetes 2013 62:2629-2634. https://www.ncbi.nlm.nih.gov/pubmed/23881189

340. Moore CJ, Cunningham SA: Social position, psychological stress, and obesity: a systematic review. J Acad Nutr Diet 2012 112:518-526. https://www.ncbi.nlm.nih.gov/pubmed/22709702

341. Ouakinin SRS, Barreira DP, Gois CJ: Depression and Obesity: Integrating the Role of Stress, Neuroendocrine Dysfunction and Inflammatory Pathways. Front Endocrinol (Lausanne) 2018 9:431. https://www.ncbi.nlm.nih.gov/pubmed/30108549

342. Stress, Stress Reduction and Obesity in Childhood and Adolescence Subject Area: Endocrinology , Women's and Children's Health Claudia Kappes; Robert Stein; Antje Körner; Andreas Merkenschlager; Wieland Kiess Horm Res Paediatr (2023) 96 (1): 88–96. https://doi.org/10.1159/000519284

343. The impact of acute and chronic stress on gastrointestinal physiology and function: a microbiota–gut–brain axis perspective Sarah-Jane Leigh, Friederike Uhlig, Lars Wilmes, Paula Sanchez-Diaz, Cassandra E. Gheorghe, Michael S. Goodson, Nancy Kelley-Loughnane, Niall P. Hyland, John F. Cryan, Gerard Clarke First published: 27 September 2023 https://doi.org/10.1113/JP281951

Obesity and Women:

344. Tauqeer, Z., Gomez, G., and Stanford, F. C. (2018). Obesity in Women: Insights for the Clinician. Journal of women's health (2002), 27(4), 444–457. https://doi.org/10.1089/jwh.2016.6196

345. Bae, J., Park, S., and Kwon, J. W. (2018). Factors associated with menstrual cycle irregularity and menopause. BMC women's health, 18(1), 36. https://doi.org/10.1186/s12905-018-0528-x

346. Rocha AL, Oliveira FR, Azevedo RC, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res. 2019;8:F1000 Faculty Rev-565. Published 2019 Apr 26. doi: 10.12688/f1000research.15318.1

347. Moran, C., Arriaga, M., Rodriquez, G., Moran, S. Obesity differentially affects phenotypes of polycystic ovary syndrome. Int J Endocrinol. 2012;2012:317241. doi: 10.1155/2012/317241

348. Dutton H, Borengasser SJ, Gaudet LM, Barbour LA, Keely EJ. Obesity in Pregnancy: Optimizing Outcomes for Mom and Baby. Med Clin North Am. 2018 Jan;102(1):87-106. doi: 10.1016/j.mcna.2017.08.008. PMID: 29156189; PMCID: PMC6016082.

349. Sauder, K. A., and Ritchie, N. D. (2021). Reducing intergenerational obesity and diabetes risk. Diabetologia, 64(3), 481–490. https://doi.org/10.1007/s00125-020-05341-y

350. LeBlanc, E. S., Smith, N. X., Vesco, K. K., Hillier, T. A., and Stevens, V. J. (2021). Weight Loss Prior to Pregnancy and Early Gestational Glycemia: Prepare, a Randomized Clinical Trial. The Journal of clinical endocrinology and metabolism, 106(12), e5001–e5010. https://doi.org/10.1210/clinem/dgab547

351. Tschiderer, L., Seekircher, L., Kunutsor, S. K., Peters, S., O'Keeffe, L. M., and Willeit, P. (2022). Breastfeeding Is Associated With a Reduced Maternal Cardiovascular Risk: Systematic Review and Meta-Analysis Involving Data From 8 Studies and 1 192 700 Parous Women. Journal of the American Heart Association, 11(2), e022746. https://doi.org/10.1161/JAHA.121.022746

352. Lyons S, Currie S, Smith DM. Learning from Women with a Body Mass Index (Bmi) ≥ 30 kg/m2 who have Breastfed and/or are Breastfeeding: a Qualitative Interview Study. Matern Child Health J. 2019 May;23(5):648-656. doi: 10.1007/s10995-018-2679-7. PMID: 30610528; PMCID: PMC6459079

353. Chang, Y. S., Glaria, A. A., Davie, P., Beake, S., and Bick, D. (2020). Breastfeeding experiences and support for women who are overweight or obese: A mixed-methods systematic review. Maternal and child nutrition, 16(1), e12865. https://doi.org/10.1111/mcn.12865

354. Chowdhury R, Sinha B, Sankar MJ, Taneja S, Bhandari N, Rollins N, Bahl R, Martines J. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. Acta Paediatr. 2015 Dec;104(467):96-113. doi: 10.1111/apa.13102. PMID: 26172878; PMCID: PMC4670483.

355. Neville CE, McKinley MC, Holmes VA, Spence D, Woodside JV. The relationship between breastfeeding and postpartum weight change--a systematic review and critical evaluation. Int J Obes (Lond). 2014 Apr;38(4):577-90. doi: 10.1038/ijo.2013.132. Epub 2013 Jul 29. PMID: 23892523.

356. He X, Zhu M, Hu C, Tao X, Li Y, Wang Q, Liu Y. Breast-feeding and postpartum weight retention: a systematic review and meta-analysis. Public Health Nutr. 2015 Dec;18(18):3308-16. doi: 10.1017/S1368980015000828. Epub 2015 Apr 21. PMID: 25895506.

357. Peacock, K. and Ketvertis, K. (2022). Menopause. In StatPearls (Internet). August 11, 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507826/

358. Varney, C. Management of peri and post-menopausal weight gain. Obesity Medicine Association Spring Conference 2022.

359. Takahashi, A., Anzai, Y., Tanji, N., Imaizumi, H., Fujita, M., Hayashi, M., Abe, K., and Ohira, H. (2021). Association of equol with obesity in postmenopausal women. Menopause (New York, N.Y.), 28(7), 807–810. https://doi.org/10.1097/GME.0000000000001761

360. Rolland, Y. M., Perry, H. M., 3rd, Patrick, P., Banks, W. A., and Morley, J. E. (2007). Loss of appendicular muscle mass and loss of muscle strength in young postmenopausal women. The journals of gerontology. Series A, Biological sciences and medical sciences, 62(3), 330–335. https://doi.org/10.1093/gerona/62.3.330

361. Knight MG, Anekwe C, Washington K, Akam EY, Wang E, Stanford FC. Weight regulation in menopause. Menopause. 2021 May 24;28(8):960-965. doi: 10.1097/GME.0000000000001792. PMID: 34033603; PMCID: PMC8373626.

362. Marlatt, K. L., Pitynski-Miller, D. R., Gavin, K. M., Moreau, K. L., Melanson, E. L., Santoro, N., and Kohrt, W. M. (2022). Body composition and cardiometabolic health across the menopause transition. Obesity (Silver Spring, Md.), 30(1), 14–27. https://doi.org/10.1002/oby.23289

363. Reavey, J. J., Walker, C., Murray, A. A., Brito-Mutunayagam, S., Sweeney, S., Nicol, M., Cambursano, A., Critchley, H., and Maybin, J. A. (2021). Obesity is associated with heavy menstruation that may be due to delayed endometrial repair. The Journal of endocrinology, 249(2), 71–82. https://doi.org/10.1530/JOE-20-0446

364. Lowe, D. A., Baltgalvis, K. A., and Greising, S. M. (2010). Mechanisms behind estrogen's beneficial effect on muscle strength in females. Exercise and sport sciences reviews, 38(2), 61–67. https://doi.org/10.1097/JES.0b013e3181d496bc

365. Tauqeer, Z., Gomez, G., and Stanford, F. C. (2018). Obesity in Women: Insights for the Clinician. Journal of women's health (2002), 27(4), 444–457. https://doi.org/10.1089/jwh.2016.6196

366. Batsis, J. A., and Villareal, D. T. (2018). Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature reviews. Endocrinology, 14(9), 513–537. https://doi.org/10.1038/s41574-018-0062-9

367. Marlatt, K. L., Pitynski-Miller, D. R., Gavin, K. M., Moreau, K. L., Melanson, E. L., Santoro, N., and Kohrt, W. M. (2022). Body composition and cardiometabolic health across the menopause transition. Obesity (Silver Spring, Md.), 30(1), 14–27. https://doi.org/10.1002/oby.23289

368. Launer, L. J., Harris, T., Rumpel, C., and Madans, J. (1994). Body mass index, weight change, and risk of mobility disability in middle-aged and older women. The epidemiologic follow-up study of NHANES I. JAMA, 271(14), 1093–1098.

369. Liu, C. J., and Latham, N. K. (2009). Progressive resistance strength training for improving physical function in older adults. The Cochrane database of systematic reviews, 2009(3), CD002759. https://doi.org/10.1002/14651858.CD002759.pub2

370. Ford C, Chang S, Vitolins MZ, Fenton JI, Howard BV, Rhee JJ, Stefanick M, Chen B, Snetselaar L, Urrutia R, Frazier-Wood AC. Evaluation of diet pattern and weight gain in postmenopausal women enrolled in the Women's Health Initiative Observational Study. Br J Nutr. 2017 Apr;117(8):1189-1197. doi: 10.1017/S0007114517000952. Epub 2017 May 16. PMID: 28509665; PMCID: PMC5728369.

371. Gynecological malignancies and obesity - ScienceDirect Heather J. Agnew, Sarah J. Kitson, Emma J. Crosbie, Gynecological malignancies and obesity, Best Practice & Research Clinical Obstetrics & Gynaecology, Volume 88, 2023, 102337, ISSN 1521-6934, https://doi.org/10.1016/j.bpobgyn.2023.102337. (https://www.sciencedirect.com/science/article/pii/S1521693423000378)

372. Di Lorenzo M, Cacciapuoti N, Lonardo MS, et al. Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review. Curr Nutr Rep. 2023;12(3):527-544. doi:10.1007/s13668-023-00479-8

373. Deshmukh H, Papageorgiou M, Wells L, et al. The Effect of a Very-Low-Calorie Diet (VLCD) vs. a Moderate Energy Deficit Diet in Obese Women with Polycystic Ovary Syndrome (PCOS)-A Randomised Controlled Trial. Nutrients. 2023;15(18):3872. Published 2023 Sep 6. doi:10.3390/nu15183872

Evalution and Treatment Overview:

374. Nesbitt S, Palomarez RE: Review: Increasing Awareness and Education on Health Disparities for Health Care Providers. Ethn Dis 2016 26:181-190. https://www.ncbi.nlm.nih.gov/pubmed/27103768

375. Rusin M, Arsand E, Hartvigsen G: Functionalities and input methods for recording food intake: a systematic review. Int J Med Inform 2013 82:653-664. https://www.ncbi.nlm.nih.gov/pubmed/23415822

376. Jaworowska A, Blackham T, Davies IG, et al.: Nutritional challenges and health implications of takeaway and fast food. Nutr Rev 2013 71:310-318. https://www.ncbi.nlm.nih.gov/pubmed/23590707

377. Holmes CJ, Racette SB. The Utility of Body Composition Assessment in Nutrition and Clinical Practice: An Overview of Current Methodology. Nutrients. 2021 Jul 22;13(8):2493. doi: 10.3390/nu13082493. PMID: 34444653; PMCID: PMC8399582

378. Horn DB, O'Neill JR, Pfeiffer KA, et al.: Predictors of physical activity in the transition after high school among young women. J Phys Act Health 2008 5:275-285. https://www.ncbi.nlm.nih.gov/pubmed/18382036

379. Vanhees L, De Sutter J, Gelada SN, et al.: Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol 2012 19:670-686. https://www.ncbi.nlm.nih.gov/pubmed/22637742

380. Vanhees L, Geladas N, Hansen D, et al.: Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012 19:1005-1033. https://www.ncbi.nlm.nih.gov/pubmed/22637741

381. Burridge K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022 1:100007.

382. Steelman GM, Westman EC: Obesity: Evaluation and Treatment Essentials. New York: Informa Healthcare 2010

383. Bays HE, Toth PP, Kris-Etherton PM, et al.: Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol 2013 7:304-383. https://www.ncbi.nlm.nih.gov/pubmed/23890517

384. O'Connor MY, Thoreson CK, Ramsey NL, et al.: The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature. Prog Cardiovasc Dis 2013 56:261-269. https://www.ncbi.nlm.nih.gov/pubmed/24267433

385. Kim JJ, Choi YM: Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci 2013 56:137-142. https://www.ncbi.nlm.nih.gov/pubmed/24327994

386. Corona G, Rastrelli G, Monami M, et al.: Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013 168:829-843. https://www.ncbi.nlm.nih.gov/pubmed/23482592

387. Hochberg I, Hochberg Z: Expanding the definition of hypothalamic obesity. Obes Rev 2010 11:709-721. https://www.ncbi.nlm.nih.gov/pubmed/20233310

388. Lim SP, Arasaratnam P, Chow BJ, et al.: Obesity and the challenges of noninvasive imaging for the detection of coronary artery disease. Can J Cardiol 2015 31:223-226. https://www.ncbi.nlm.nih.gov/pubmed/25661558

389. Jensen, J. C., Dardari, Z. A., Blaha, M. J., White, S., Shaw, L. J., Rumberger, J., ... & Miedema, M. D. (2020). Association of body mass index with coronary artery calcium and subsequent cardiovascular mortality: the coronary artery calcium consortium. Circulation: Cardiovascular Imaging, 13(7), e009495. https://doi.org/10.1161/CIRCIMAGING.119.009495

390. Ginde SR, Geliebter A, Rubiano F, et al.: Air displacement plethysmography: validation in overweight and obese subjects. Obes Res 2005 13:1232-1237. https://www.ncbi.nlm.nih.gov/pubmed/16076993

391. Beam JR, Szymanski DJ: Validity of 2 skinfold calipers in estimating percent body fat of college-aged men and women. J Strength Cond Res 2010 24:3448-3456. https://www.ncbi.nlm.nih.gov/pubmed/20040894

392. Muller MJ, Bosy-Westphal A, Lagerpusch M, et al.: Use of balance methods for assessment of short-term changes in body composition. Obesity (Silver Spring) 2012 20:701-707. https://www.ncbi.nlm.nih.gov/pubmed/21869755

393. Kendler DL, Borges JL, Fielding RA, et al.: The Official Positions of the International Society for Clinical Densitometry: Indications of Use and Reporting of DXA for Body Composition. J Clin Densitom 2013 16:496-507. https://www.ncbi.nlm.nih.gov/pubmed/24090645

394. Goni L, Cuervo M, Milagro FI, et al.: Future Perspectives of Personalized Weight Loss Interventions Based on Nutrigenetic, Epigenetic, and Metagenomic Data. J Nutr 2016 https://www.ncbi.nlm.nih.gov/pubmed/26962191

395. Allison KC, Grilo CM, Masheb RM, et al.: High self-reported rates of neglect and emotional abuse, by persons with binge eating disorder and night eating syndrome. Behav Res Ther 2007 45:2874-2883. https://www.ncbi.nlm.nih.gov/pubmed/17659255

396. St-Onge MP: The role of sleep duration in the regulation of energy balance: effects on energy intakes and expenditure. J Clin Sleep Med 2013 9:73-80. https://www.ncbi.nlm.nih.gov/pubmed/23319909

397. Pearce EN: Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 2012 19:408-413. https://www.ncbi.nlm.nih.gov/pubmed/22931855

398. Pearce EN: Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012 97:326-333. https://www.ncbi.nlm.nih.gov/pubmed/22205712

399. Taylor SA Jr. Clinical Evaluation of the Sleepy and Sleepless Patient. Continuum (Minneap Minn). 2023;29(4):1031-1044. doi:10.1212/CON.0000000000001281

400. Malhotra RK. Evaluating the Sleepy and Sleepless Patient. Continuum (Minneap Minn). 2020;26(4):871-889. doi:10.1212/CON.0000000000000880

401. Kolb H, Kempf K, Röhling M, Martin S. Insulin: too much of a good thing is bad. BMC Med. 2020 Aug 21;18(1):224. doi: 10.1186/s12916-020-01688-6. PMID: 32819363; PMCID: PMC7441661.

402. Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, Hannan MA, Uddin MJ, Pang MG. Role of Insulin in Health and Disease: An Update. Int J Mol Sci. 2021 Jun 15;22(12):6403. doi: 10.3390/ijms22126403. PMID: 34203830; PMCID: PMC8232639.

Body Composition:

403. Burridge K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022 1:100007.

404. Hoffmann J, Thiele J, Kwast S, Borger MA, Schröter T, Falz R, Busse M. Measurement of subcutaneous fat tissue: reliability and comparison of caliper and ultrasound via systematic body mapping. Sci Rep. 2022 Sep 22;12(1):15798. doi: 10.1038/s41598-022-19937-4. PMID: 36138057

405. Nuijten MAH, Eijsvogels TMS, Monpellier VM, et al. 2021 The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: A systematic review and meta-analysis. Obesity Reviews. 2022;23:e13370.

406. Dulloo AG, Jacquet J, Solinas G, et al.: Body composition phenotypes in pathways to obesity and the metabolic syndrome. Int J Obes (Lond) 2010 34 Suppl 2:S4-17. https://www.ncbi.nlm.nih.gov/pubmed/21151146

407. Heymsfield SB, Ebbeling CB, Zheng J, et al.: Multi-component molecular-level body composition reference methods: evolving concepts and future directions. Obes Rev 2015 16:282-294. https://www.ncbi.nlm.nih.gov/pubmed/25645009

408. Muller MJ, Braun W, Pourhassan M, et al.: Application of standards and models in body composition analysis. Proc Nutr Soc 2016 75:181-187. https://www.ncbi.nlm.nih.gov/pubmed/26541411

409. Choi YJ: Dual-Energy X-Ray Absorptiometry: Beyond Bone Mineral Density Determination. Endocrinol Metab (Seoul) 2016 31:25-30. https://www.ncbi.nlm.nih.gov/pubmed/26996419

410. Marra M, Sammarco R, De Lorenzo A, et al.: Assessment of Body Composition in Health and Disease Using Bioelectrical Impedance Analysis (BIA) and Dual Energy X-Ray Absorptiometry (DXA): A Critical Overview. Contrast Media Mol Imaging 2019 2019:3548284. https://www.ncbi.nlm.nih.gov/pubmed/31275083

411. Miazgowski T, Kucharski R, Soltysiak M, et al.: Visceral fat reference values derived from healthy European men and women aged 20-30 years using GE Healthcare dual-energy x-ray absorptiometry. PLoS One 2017 12:e0180614. https://www.ncbi.nlm.nih.gov/pubmed/28683146

412. Sasai H, Brychta RJ, Wood RP, et al.: Does Visceral Fat Estimated by Dual-Energy X-ray Absorptiometry Independently Predict Cardiometabolic Risks in Adults? J Diabetes Sci Technol 2015 9:917-924. https://www.ncbi.nlm.nih.gov/pubmed/25802470

413. Achamrah N, Colange G, Delay J, et al.: Comparison of body composition assessment by DXA and BIA according to the body mass index: A retrospective study on 3655 measures. PLoS One 2018 13:e0200465. https://www.ncbi.nlm.nih.gov/pubmed/30001381

414. Santos DA, Dawson JA, Matias CN, et al.: Reference values for body composition and anthropometric measurements in athletes. PLoS One 2014 9:e97846. https://www.ncbi.nlm.nih.gov/pubmed/24830292

415. Hunter GR, Plaisance EP, Fisher G: Weight loss and bone mineral density. Curr Opin Endocrinol Diabetes Obes 2014 21:358-362. https://www.ncbi.nlm.nih.gov/pubmed/25105997

416. Hinton PS, Nigh P, Thyfault J: Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial. Bone 2015 79:203-212. https://www.ncbi.nlm.nih.gov/pubmed/26092649

417. Fields DA, Hunter GR, Goran MI: Validation of the BOD POD with hydrostatic weighing: influence of body clothing. Int J Obes Relat Metab Disord 2000 24:200-205. https://www.ncbi.nlm.nih.gov/pubmed/10702771

418. Smith S, Madden AM: Body composition and functional assessment of nutritional status in adults: a narrative review of imaging, impedance, strength and functional techniques. J Hum Nutr Diet 2016 29:714-732. https://www.ncbi.nlm.nih.gov/pubmed/27137882

419. Rotella CM, Dicembrini I: Measurement of body composition as a surrogate evaluation of energy balance in obese patients. World J Methodol 2015 5:1-9. https://www.ncbi.nlm.nih.gov/pubmed/25825693

420. Bosy-Westphal A, Jensen B, Braun W, et al.: Quantification of whole-body and segmental skeletal mus-

cle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices. Eur J Clin Nutr 2017 71:1061-1067. https://www.ncbi.nlm.nih.gov/pubmed/28327564

421. Day K, Kwok A, Evans A, et al.: Comparison of a Bioelectrical Impedance Device against the Reference Method Dual Energy X-Ray Absorptiometry and Anthropometry for the Evaluation of Body Composition in Adults. Nutrients 2018 10: https://www.ncbi.nlm.nih.gov/pubmed/30308974

422. Lee K, Lee S, Kim YJ, et al.: Waist circumference, dual-energy X-ray absortiometrically measured abdominal adiposity, and computed tomographically derived intra-abdominal fat area on detecting metabolic risk factors in obese women. Nutrition 2008 24:625-631. https://www.ncbi.nlm.nih.gov/pubmed/18485667

423. Alvero-Cruz JR, Garcia-Romero JC, Carrillo de Albornoz-Gil M, et al.: Longitudinal validity of abdominal adiposity assessment by regional bioelectrical impedance. Eur J Clin Nutr 2018 72:1055-1057.

424. Long V, Short M, Smith S, et al.: Testing Bioimpedance to Estimate Body Fat Percentage across Different Hip and Waist Circumferences. J Sports Med (Hindawi Publ Corp) 2019 2019:7624253. https://www.ncbi.nlm.nih.gov/pubmed/31281848

425. Becroft L, Ooi G, Forsyth A, et al.: Validity of multi-frequency bioelectric impedance methods to measure body composition in obese patients: a systematic review. Int J Obes (Lond) 2019 43:1497-1507. https://www.ncbi.nlm.nih.gov/pubmed/30568268

426. Heymsfield SB, Adamek M, Gonzalez MC, et al.: Assessing skeletal muscle mass: historical overview and state of the art. J Cachexia Sarcopenia Muscle 2014 5:9-18. https://www.ncbi.nlm.nih.gov/pubmed/24532493

427. Seabolt LA, Welch EB, Silver HJ: Imaging methods for analyzing body composition in human obesity and cardiometabolic disease. Ann N Y Acad Sci 2015 1353:41-59. https://www.ncbi.nlm.nih.gov/pubmed/26250623

428. Fosbol MO, Zerahn B: Contemporary methods of body composition measurement. Clin Physiol Funct Imaging 2015 35:81-97. https://www.ncbi.nlm.nih.gov/pubmed/24735332

Energy Expenditure:

429. Burridge K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022 1:100007.

430. Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014;15(4):310-321. doi:10.1111/obr.12143

431. Ruggiero C, Ferrucci L: The endeavor of high maintenance homeostasis: resting metabolic rate and the legacy of longevity. J Gerontol A Biol Sci Med Sci 2006 61:466-471. https://www.ncbi.nlm.nih.gov/pubmed/16720742

432. Konarzewski M, Ksiazek A: Determinants of intra-specific variation in basal metabolic rate. J Comp Physiol B 2013 183:27-41. https://www.ncbi.nlm.nih.gov/pubmed/22847501

433. Anthanont P, Jensen MD: Does basal metabolic rate predict weight gain? Am J Clin Nutr 2016 104:959-963. https://www.ncbi.nlm.nih.gov/pubmed/27581474

434. Delsoglio M, Achamrah N, Berger MM, Pichard C. Indirect Calorimetry in Clinical Practice. Journal of Clinical Medicine. 2019; 8(9):1387. https://doi.org/10.3390/jcm8091387

435. Cancello R, Soranna D, Brunani A, et al. Analysis of Predictive Equations for Estimating Resting Energy Expenditure in a Large Cohort of Morbidly Obese Patients. Front Endocrinol. 2018; 9: 367. Published online 2018 Jul 25. doi: 10.3389/fendo.2018.00367

436. Achamrah N, Jésus P, Grigioni S, Rimbert A, Petit A, Déchelotte P, Folope V, Coëffier M. Validity of Predictive Equations for Resting Energy Expenditure Developed for Obese Patients: Impact of Body Composition Method. Nutrients. 2018 Jan 10;10(1):63. doi: 10.3390/nu10010063. PMID: 29320432; PMCID: PMC5793291.

437. Thomas, D. M., Gonzalez, M. C., Pereira, A. Z., Redman, L. M., and Heymsfield, S. B. (2014). Time to correctly predict the amount of weight loss with dieting. Journal of the Academy of Nutrition and Dietetics, 114(6), 857–861. https://doi.org/10.1016/j.jand.2014.02.003

438. Kraus WE, Janz KF, Powell KE, Campbell WW, Jakicic JM, Troiano RP, Sprow K, Torres A, Piercy KL; 2018

PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Daily Step Counts for Measuring Physical Activity Exposure and Its Relation to Health. Med Sci Sports Exerc. 2019 Jun;51(6):1206-1212. doi: 10.1249/MSS.0000000000001932. PMID: 31095077; PMCID: PMC6527133.

439. Johannsen DL, Marlatt KL, Conley KE, et al.: Metabolic adaptation is not observed after 8 weeks of overfeeding but energy expenditure variability is associated with weight recovery. Am J Clin Nutr 2019 https://www.ncbi.nlm.nih.gov/pubmed/31204775

440. Pettersen AK, Marshall DJ, White CR: Understanding variation in metabolic rate. J Exp Biol 2018 221: https://www.ncbi.nlm.nih.gov/pubmed/29326115

441. Pontzer H, Yamada Y, Sagayama H, et al. Daily energy expenditure through the human life course. Science. 2021;373(6556):808-812. doi:10.1126/science.abe5017

442. Calcagno M, Kahleova H, Alwarith J, et al. The Thermic Effect of Food: A Review. J Am Coll Nutr. 2019;38(6):547-551. doi:10.1080/07315724.2018.1552544

443. Chung N, Park MY, Kim J, et al.: Non-exercise activity thermogenesis (NEAT): a component of total daily energy expenditure. J Exerc Nutrition Biochem 2018 22:23-30.

444. Barclay CJ: The basis of differences in thermodynamic efficiency among skeletal muscles. Clin Exp Pharmacol Physiol 2017 44:1279-1286. https://www.ncbi.nlm.nih.gov/pubmed/28892557

445. Rosenbaum M, Heaner M, Goldsmith RL, et al.: Resistance Training Reduces Skeletal Muscle Work Efficiency in Weight-Reduced and Non-Weight-Reduced Subjects. Obesity (Silver Spring) 2018 26:1576-1583. https://www.ncbi.nlm.nih.gov/pubmed/30260099

446. Mavanji V, Pomonis B, Kotz CM. Orexin, serotonin, and energy balance. WIREs Mech Dis. 2022;14(1):e1536. doi:10.1002/wsbm.1536

447. Alessio N, Squillaro T, Monda V, et al.: Circulating factors present in the sera of naturally skinny people may influence cell commitment and adipocyte differentiation of mesenchymal stromal cells. World J Stem Cells 2019 11:180-195. https://www.ncbi.nlm.nih.gov/pubmed/30949296

448. Howell S, Kones R: "Calories in, calories out" and macronutrient intake: the hope, hype, and science of calories. Am J Physiol Endocrinol Metab 2017 313:E608-E612. https://www.ncbi.nlm.nih.gov/pubmed/28765272

449. Hall KD: What is the required energy deficit per unit weight loss? Int J Obes (Lond) 2008 32:573-576. https://www.ncbi.nlm.nih.gov/pubmed/17848938

450. Piercy KL, Troiano RP, Ballard RM, et al.: The Physical Activity Guidelines for Americans. Jama 2018 320:2020-2028.

451. Flatt JP: Differences in basal energy expenditure and obesity. Obesity (Silver Spring) 2007 15:2546-2548. https://www.ncbi.nlm.nih.gov/pubmed/18070743

452. Pourhassan M, Bosy-Westphal A, Schautz B, et al.: Impact of body composition during weight change on resting energy expenditure and homeostasis model assessment index in overweight nonsmoking adults. Am J Clin Nutr 2014 99:779-791.https://www.ncbi.nlm.nih.gov/pubmed/24500156

453. Gallagher D, Belmonte D, Deurenberg P, et al.: Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol 1998 275:E249-258. https://www.ncbi.nlm.nih.gov/pubmed/9688626

454. Wang Z, Ying Z, Bosy-Westphal A, et al.: Evaluation of specific metabolic rates of major organs and tissues: comparison between men and women. Am J Hum Biol 2011 23:333-338. https://www.ncbi.nlm.nih.gov/pubmed/21484913

455. Lam YY, Ravussin E. Indirect calorimetry: an indispensable tool to understand and predict obesity. Eur J Clin Nutr. 2017;71(3):318-322. doi:10.1038/ejcn.2016.220

456. Psota T, Chen KY: Measuring energy expenditure in clinical populations: rewards and challenges. Eur J Clin Nutr 2013 67:436-442. https://www.ncbi.nlm.nih.gov/pubmed/23443826

457. Sabounchi NS, Rahmandad H, Ammerman A: Best-fitting prediction equations for basal metabolic rate: informing obesity interventions in diverse populations. Int J Obes (Lond) 2013 37:1364-1370. https://www.ncbi.nlm.nih.gov/pubmed/23318720

458. Even PC, Nadkarni NA: Indirect calorimetry in laboratory mice and rats: principles, practical considerations, interpretation and perspectives. Am J Physiol Regul Integr Comp Physiol 2012 303:R459-476. https://www.ncbi.nlm.nih.gov/pubmed/22718809

459. Patel H, Kerndt CC, Bhardwaj A. Physiology, Respiratory Quotient. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 13, 2023.

460. Jette M, Sidney K, Blumchen G: Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. Clin Cardiol 1990 13:555-565. https://www.ncbi.nlm.nih.gov/pubmed/2204507

461. Park J, Kazuko IT, Kim E, et al.: Estimating free-living human energy expenditure: Practical aspects of the doubly labeled water method and its applications. Nutr Res Pract 2014 8:241-248. https://www.ncbi.nlm.nih.gov/pubmed/24944767

462. Byham-Gray L, Parrott JS, Ho WY, et al.: Development of a predictive energy equation for maintenance hemodialysis patients: a pilot study. J Ren Nutr 2014 24:32-41. https://www.ncbi.nlm.nih.gov/pubmed/24355819

463. Evenson KR, Goto MM, Furberg RD: Systematic review of the validity and reliability of consumer-wearable activity trackers. Int J Behav Nutr Phys Act 2015 12:159. https://www.ncbi.nlm.nih.gov/pubmed/26684758

464. Hall KD, Guo J: Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition. Gastroenterology 2017 152:1718-1727 e1713. https://www.ncbi.nlm.nih.gov/pubmed/28193517

465. Zheng J, Zheng S, Feng Q, et al.: Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications. Biosci Rep 2017 37: https://www.ncbi.nlm.nih.gov/pubmed/28424369

466. Demine S, Renard P, Arnould T: Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases. Cells 2019 8: https://www.ncbi.nlm.nih.gov/pubmed/31366145

467. Busiello RA, Savarese S, Lombardi A: Mitochondrial uncoupling proteins and energy metabolism. Front Physiol 2015 6:36. https://www.ncbi.nlm.nih.gov/pubmed/25713540

468. Flouris AD, Dinas PC, Valente A, et al.: Exercise-induced effects on UCP1 expression in classical brown adipose tissue: a systematic review. Horm Mol Biol Clin Investig 2017 31: https://www.ncbi.nlm.nih.gov/pubmed/28085671

469. Careau V, Halsey LG, Pontzer H, et al. Energy compensation and adiposity in humans. Curr Biol. 2021;31(20):4659-4666.e2. doi:10.1016/j.cub.2021.08.016

Nutrition:

470. Alexander L, Christensen SM, Richardson L, Ingersoll AB, Burridge K, Golden A, Karjoo S, Cortez D, Shelver M, Bays HE. Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022. Obesity Pillars. 2022. 1:100005.

471. Tarantino G, Citro V, Finelli C. Hype or reality: Should patients with metabolic syndrome-related NAFLD be on the hunter-gatherer (paleo) diet to decrease morbidity? J Gastrointestin Liver Dis. 2015;24:359-368. DOI: 10.15403/jgld.2014.1121.243.gta.

472. Kim KK, Kang JH, Kim EM. Updated Meta-Analysis of Studies from 2011 to 2021 Comparing the Effectiveness of Intermittent Energy Restriction and Continuous Energy Restriction. J Obes Metab Syndr. 2022 Sep 30;31(3):230-244. doi: 10.7570/jomes22050. PMID: 36177730; PMCID: PMC9579470.

473. Eslami O, Shidfar F, Dehnad A: Inverse association of long-term nut consumption with weight gain and risk of overweight/obesity: a systematic review. Nutr Res 2019 68:1-8. https://www.ncbi.nlm.nih.gov/pubmed/31151081

474. U.S. Department of Agriculture. https://fnic.nal.usda.gov/how-many-calories-are-one-gram-fat-carbohydrate-or-protein. Food and Nutrition Information Center (Accessed August 20, 2016).

475. Sacks FM, Lichtenstein AH, Wu JHY, et al.: Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation 2017 136:e1-e23. https://www.ncbi.nlm.nih.gov/pubmed/28620111

476. Gepner Y, Shelef I, Schwarzfuchs D, et al.: Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. Circulation 2018 137:1143-1157. https://www.ncbi.nlm.nih.gov/pubmed/29142011

477. Hyde PN, Sapper TN, Crabtree CD, et al.: Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight 2019 4: https://www.ncbi.nlm.nih.gov/pubmed/31217353

478. Hernandez-Alonso P, Camacho-Barcia L, Bullo M, et al.: Nuts and Dried Fruits: An Update of Their Beneficial Effects on Type 2 Diabetes. Nutrients 2017 9: https://www.ncbi.nlm.nih.gov/pubmed/28657613

479. Higgins KA, Mattes RD: A randomized controlled trial contrasting the effects of 4 low-calorie sweeten-

ers and sucrose on body weight in adults with overweight or obesity. Am J Clin Nutr 2019 109:1288-1301. https://www.ncbi.nlm.nih.gov/pubmed/30997499

480. Borradaile KE, Halpern SD, Wyatt HR, et al.: Relationship between treatment preference and weight loss in the context of a randomized controlled trial. Obesity (Silver Spring) 2012 20:1218-1222. https://www.ncbi.nlm.nih.gov/pubmed/21760633

481. Yancy WS, Jr., McVay MA, Voils CI: Effect of allowing choice of diet on weight loss--in response. Ann Intern Med 2015 163:805-806. https://www.ncbi.nlm.nih.gov/pubmed/26571246

482. Gonzalez-Campoy JM, St Jeor ST, Castorino K, et al.: Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. Endocr Pract 2013 19 Suppl 3:1-82. https://www.ncbi.nlm.nih.gov/pubmed/24129260

483. Clifton PM: Dietary treatment for obesity. Nat Clin Pract Gastroenterol Hepatol 2008 5:672-681. https://www.ncbi.nlm.nih.gov/pubmed/18852729

484. Brown T, Avenell A, Edmunds LD, et al.: Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults. Obes Rev 2009 10:627-638. https://www.ncbi.nlm.nih.gov/pubmed/19754634

485. Tsai AG, Wadden TA: Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 2005 142:56-66. https://www.ncbi.nlm.nih.gov/pubmed/15630109

486. Westman EC, Yancy WS, Jr., Mavropoulos JC, et al.: The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond) 2008 5:36. https://www.ncbi.nlm.nih.gov/pubmed/19099589

487. Westman EC, Feinman RD, Mavropoulos JC, et al.: Low-carbohydrate nutrition and metabolism. Am J Clin Nutr 2007 86:276-284. https://www.ncbi.nlm.nih.gov/pubmed/17684196

488. Volek JS, Phinney SD, Forsythe CE, et al.: Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids 2009 44:297-309. https://www.ncbi.nlm.nih.gov/pubmed/19082851

489. Foster GD, Wyatt HR, Hill JO, et al.: Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med 2010 153:147-157. https://www.ncbi.nlm.nih.gov/pubmed/20679559

490. Tirosh A, Golan R, Harman-Boehm I, et al.: Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care 2013 36:2225-2232. https://www.ncbi.nlm.nih.gov/pubmed/23690533

491. Lutas A, Yellen G: The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci 2013 36:32-40. https://www.ncbi.nlm.nih.gov/pubmed/23228828

492. Laviada-Molina H, Molina-Segui F, Pérez-Gaxiola G, Cuello-García C, Arjona-Villicaña R, Espinosa-Marrón A, Martinez-Portilla RJ. Effects of nonnutritive sweeteners on body weight and BMI in diverse clinical contexts: Systematic review and meta-analysis. Obes Rev. 2020 Jul;21(7):e13020. doi: 10.1111/obr.13020. Epub 2020 Mar 25. PMID: 32216045.

493. Rogers PJ, Hogenkamp PS, de Graaf C, Higgs S, Lluch A, Ness AR, Penfold C, Perry R, Putz P, Yeomans MR, Mela DJ. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Int J Obes (Lond). 2016 Mar;40(3):381-94. doi: 10.1038/ijo.2015.177. Epub 2015 Sep 14. PMID: 26365102; PMCID: PMC4786736.

494. Yunker AG, Alves JM, Luo S, Angelo B, DeFendis A, Pickering TA, Monterosso JR, Page KA. Obesity and Sex-Related Associations With Differential Effects of Sucralose vs Sucrose on Appetite and Reward Processing: A Randomized Crossover Trial. JAMA Netw Open. 2021 Sep 1;4(9):e2126313. doi: 10.1001/jamanetworkopen.2021.26313. PMID: 34581796; PMCID: PMC8479585.

495. Nichol AD, Salame C, Rother KI, Pepino MY. Effects of Sucralose Ingestion versus Sucralose Taste on Metabolic Responses to an Oral Glucose Tolerance Test in Participants with Normal Weight and Obesity: A Randomized Crossover Trial. Nutrients. 2019 Dec 20;12(1):29. doi: 10.3390/nu12010029. PMID: 31877631; PMCID: PMC7019725.

496. Viveros-Watty PE, López-Franco O, Zepeda RC, Aguirre G, Rodríguez-Alba JC, Gómez-Martínez MA, Castillo-Martínez L, Flores-Muñoz M. Effects on cardiometabolic risk factors after reduction of artificially sweetened beverage consumption in overweight subjects. A randomised controlled trial. Endocrinol Diabetes Nutr (Engl Ed). 2022 Mar;69(3):168-177. doi: 10.1016/j.endien.2022.02.015. PMID: 35396115.

497. Ahmad SY, Friel J, Mackay D. The Effects of Non-Nutritive Artificial Sweeteners, Aspartame and Sucralose, on the Gut Microbiome in Healthy Adults: Secondary Outcomes of a Randomized Double-Blinded Crossover Clinical Trial. Nutrients. 2020 Nov 6;12(11):3408. doi: 10.3390/nu12113408. PMID: 33171964; PMCID: PMC7694690.

498. Ahmad SY, Friel JK, MacKay DS. The effect of the artificial sweeteners on glucose metabolism in healthy adults: a randomized, double-blinded, crossover clinical trial. Appl Physiol Nutr Metab. 2020 Jun;45(6):606-612. doi: 10.1139/apnm-2019-0359. Epub 2019 Nov 7. PMID: 31697573.

499. Serrano J, Smith KR, Crouch AL, Sharma V, Yi F, Vargova V, LaMoia TE, Dupont LM, Serna V, Tang F, Gomes-Dias L, Blakeslee JJ, Hatzakis E, Peterson SN, Anderson M, Pratley RE, Kyriazis GA. High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice. Microbiome. 2021 Jan 12;9(1):11. doi: 10.1186/s40168-020-00976-w. PMID: 33431052; PMCID: PMC7802287.

500. Thomson P, Santibañez R, Aguirre C, Galgani JE, Garrido D. Short-term impact of sucralose consumption on the metabolic response and gut microbiome of healthy adults. Br J Nutr. 2019 Oct 28;122(8):856-862. doi: 10.1017/S0007114519001570. Epub 2019 Sep 13. PMID: 31258108.

501. Kim Y, Keogh JB, Clifton PM. Consumption of a Beverage Containing Aspartame and Acesulfame K for Two Weeks Does Not Adversely Influence Glucose Metabolism in Adult Males and Females: A Randomized Crossover Study. Int J Environ Res Public Health. 2020 Dec 4;17(23):9049. doi: 10.3390/ijerph17239049. PMID: 33291649; PMCID: PMC7731387.

502. Toews I, Lohner S, Küllenberg de Gaudry D, Sommer H, Meerpohl JJ. Association between intake of non-sugar sweeteners and health outcomes: systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies. BMJ. 2019 Jan 2;364:k4718. doi: 10.1136/bmj.k4718. Erratum in: BMJ. 2019 Jan 15;364:l156. PMID: 30602577; PMCID: PMC6313893.

503. Christofides EA. POINT: Artificial Sweeteners and Obesity-Not the Solution and Potentially a Problem. Endocr Pract. 2021 Oct;27(10):1052-1055. doi: 10.1016/j.eprac.2021.08.001. Epub 2021 Aug 11. PMID: 34389515.

504. Nadolsky KZ. COUNTERPOINT: Artificial Sweeteners for Obesity-Better than Sugary Alternatives; Potentially a Solution. Endocr Pract. 2021 Oct;27(10):1056-1061. doi: 10.1016/j.eprac.2021.06.013. Epub 2021 Sep 3. PMID: 34481971.

505. Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, Lallukka S, Pelloux V, Gaggini M, Jian C, Hakkarainen A, Lundbom N, Gylling H, Salonen A, Orešič M, Hyötyläinen T, Orho-Melander M, Rissanen A, Gastaldelli A, Clément K, Hodson L, Yki-Järvinen H. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. Diabetes Care. 2018 Aug;41(8):1732-1739. doi: 10.2337/dc18-0071. Epub 2018 May 29. PMID: 29844096; PMCID: PMC7082640.

506. Guo H, Wang L, Huang X, Shen F, Lu Y, Zhang P. Effects of low-carbohydrate vs low-fat diets on weight loss and metabolic risk factors in obese/overweight individuals with impaired glucose regulation: A randomized controlled trial. Asia Pac J Clin Nutr. 2022;31(3):512-519. doi: 10.6133/apjcn.202209_31(3).0018. PMID: 36173222.

507. Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, Johansson L, Ahlström H, Arner P, Dahlman I, Risérus U. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014 Jul;63(7):2356-68. doi: 10.2337/db13-1622. Epub 2014 Feb 18. PMID: 24550191.

508. Goss AM, Dowla S, Pendergrass M, Ashraf A, Bolding M, Morrison S, Amerson A, Soleymani T, Gower B. Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: A pilot, randomized trial. Pediatr Obes. 2020 Jul;15(7):e12630. doi: 10.1111/ijpo.12630. Epub 2020 Mar 4. PMID: 32128995.

509. Gepner Y, Shelef I, Schwarzfuchs D, Zelicha H, Tene L, Yaskolka Meir A, Tsaban G, Cohen N, Bril N, Rein M, Serfaty D, Kenigsbuch S, Komy O, Wolak A, Chassidim Y, Golan R, Avni-Hassid H, Bilitzky A, Sarusi B, Goshen E, Shemesh E, Henkin Y, Stumvoll M, Blüher M, Thiery J, Ceglarek U, Rudich A, Stampfer MJ, Shai I. Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. Circulation. 2018 Mar 13;137(11):1143-1157. doi: 10.1161/CIRCULATIONAHA.117.030501. Epub 2017 Nov 15. PMID: 29142011.

510. Ko GJ, Obi Y, Tortorici AR, Kalantar-Zadeh K. Dietary protein intake and chronic kidney disease. Curr Opin Clin Nutr Metab Care. 2017;20(1):77-85. doi:10.1097/MCO.0000000000000342

511. Devries MC, Sithamparapillai A, Brimble KS, Banfield L, Morton RW, Phillips SM. Changes in Kidney Function Do Not Differ between Healthy Adults Consuming Higher- Compared with Lower- or Normal-Protein

Diets: A Systematic Review and Meta-Analysis. J Nutr. 2018 Nov 1;148(11):1760-1775. doi: 10.1093/jn/nxy197. PMID: 30383278; PMCID: PMC6236074.

512. Yan B, Su X, Xu B, Qiao X, Wang L. Effect of diet protein restriction on progression of chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018 Nov 7;13(11):e0206134. doi: 10.1371/journal.pone.0206134. PMID: 30403710; PMCID: PMC6221301.

513. Rhee CM, Ahmadi SF, Kovesdy CP, Kalantar-Zadeh K. Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):235-245. doi: 10.1002/jcsm.12264. Epub 2017 Nov 2. PMID: 29094800; PMCID: PMC5879959.

514. Ebbeling CB, Feldman HA, Klein GL, et al.: Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. BMJ 2018 363:k4583. https://www.ncbi.nlm.nih.gov/pubmed/30429127

515. Schwingshackl L, Hoffmann G: Long-term effects of low-fat diets either low or high in protein on cardiovascular and metabolic risk factors: a systematic review and meta-analysis. Nutr J 2013 12:48. https://www.ncbi.nlm.nih.gov/pubmed/23587198

516. Ebbeling CB, Feldman HA, Klein GL, et al.: Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. BMJ 2018 363:k4583. https://www.ncbi.nlm.nih.gov/pubmed/30429127

517. Schwingshackl L, Hoffmann G: Long-term effects of low-fat diets either low or high in protein on cardiovascular and metabolic risk factors: a systematic review and meta-analysis. Nutr J 2013 12:48. https://www.ncbi.nlm.nih.gov/pubmed/23587198

518. Meckling KA, O'Sullivan C, Saari D: Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. J Clin Endocrinol Metab 2004 89:2717-2723. https://www.ncbi.nlm.nih.gov/pubmed/15181047

519. Mulholland Y, Nicokavoura E, Broom J, et al.: Very-low-energy diets and morbidity: a systematic review of longer-term evidence. Br J Nutr 2012 108:832-851. https://www.ncbi.nlm.nih.gov/pubmed/22800763

520. Johansson K, Sundstrom J, Marcus C, et al.: Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes (Lond) 2014 38:279-284. https://www.ncbi.nlm.nih.gov/pubmed/23736359

521. Noronha JC, Nishi SK, Braunstein CR, et al.: The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2019 42:767-776. https://www.ncbi.nlm.nih.gov/pubmed/30923163

522. Teegala SM, Willett WC, Mozaffarian D: Consumption and health effects of trans fatty acids: a review. J AOAC Int 2009 92:1250-1257. https://www.ncbi.nlm.nih.gov/pubmed/19916363

523. Nestel P: Trans fatty acids: are its cardiovascular risks fully appreciated? Clin Ther 2014 36:315-321. https://www.ncbi.nlm.nih.gov/pubmed/24636816

524. Shen W, McIntosh MK: Nutrient Regulation: Conjugated Linoleic Acid's Inflammatory and Browning Properties in Adipose Tissue. Annu Rev Nutr 2016 36:183-210. https://www.ncbi.nlm.nih.gov/pubmed/27431366

525. Dehghan M, Mente A, Rangarajan S, et al.: Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2018 392:2288-2297. https://www.ncbi.nlm.nih.gov/pubmed/30217460

526. Lambert EA, Phillips S, Belski R, et al.: Endothelial Function in Healthy Young Individuals Is Associated with Dietary Consumption of Saturated Fat. Front Physiol 2017 8:876. https://www.ncbi.nlm.nih.gov/pubmed/29170641

527. Dow CA, Stauffer BL, Greiner JJ, et al.: Influence of dietary saturated fat intake on endothelial fibrinolytic capacity in adults. Am J Cardiol 2014 114:783-788. https://www.ncbi.nlm.nih.gov/pubmed/25052545

528. Hall WL: Dietary saturated and unsaturated fats as determinants of blood pressure and vascular function. Nutr Res Rev 2009 22:18-38. https://www.ncbi.nlm.nih.gov/pubmed/19243668

529. Tapsell LC: Fermented dairy food and CVD risk. Br J Nutr 2015 113 Suppl 2:S131-135. https://www.ncbi.nlm.nih.gov/pubmed/26148916

530. Vieira SA, McClements DJ, Decker EA: Challenges of utilizing healthy fats in foods. Adv Nutr 2015 6:309S-317S. https://www.ncbi.nlm.nih.gov/pubmed/25979504

531. Key TJ, Appleby PN, Bradbury KE, et al.: Consumption of Meat, Fish, Dairy Products, and Eggs and Risk of Ischemic Heart Disease. Circulation 2019 139:2835-2845. https://www.ncbi.nlm.nih.gov/pubmed/31006335

532. Pollin TI, Quartuccio M: What We Know About Diet, Genes, and Dyslipidemia: Is There Potential for Translation? Curr Nutr Rep 2013 2:236-242. https://www.ncbi.nlm.nih.gov/pubmed/24524012

533. Jaarin K, Kamisah Y: Repeatedly Heated Vegetable Oils and Lipid Peroxidation https://www.intechopen.com/books/lipid-peroxidation/repeatedly-heated-vegetable-oils-and-lipid-peroxidation (Accessed January 6, 2019). Lipid Peroxidation Chapter 10 2012

534. Przybylski O, Aladedunye FA: Formation of trans fats during food preparation. Can J Diet Pract Res 2012 73:98-101. https://www.ncbi.nlm.nih.gov/pubmed/22668846

535. Wang DD, Li Y, Chiuve SE, et al.: Association of Specific Dietary Fats With Total and Cause-Specific Mortality. JAMA Intern Med 2016 176:1134-1145. https://www.ncbi.nlm.nih.gov/pubmed/27379574

536. Li Y, Hruby A, Bernstein AM, et al.: Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. J Am Coll Cardiol 2015 66:1538-1548. https://www.ncbi.nlm.nih.gov/pubmed/26429077

537. Beulen Y, Martinez-Gonzalez MA, van de Rest O, et al.: Quality of Dietary Fat Intake and Body Weight and
Obesity in a Mediterranean Population: Secondary Analyses within the PREDIMED Trial. Nutrients 2018 10:https://www.ncbi.nlm.nih.gov/pubmed/30572588

538. Reynolds A, Mann J, Cummings J, et al.: Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. The Lancet https://doi.org/10.1016/S0140-6736(18)31809-9

539. Clifton PM, Keogh JB: A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease. Nutr Metab Cardiovasc Dis 2017 27:1060-1080. https://www.ncbi.nlm.nih.gov/pubmed/29174025

540. Ferro-Luzzi A, Sette S: The Mediterranean Diet: an attempt to define its present and past composition. Eur J Clin Nutr 1989 43 Suppl 2:13-29. https://www.ncbi.nlm.nih.gov/pubmed/2689161

541. Fito M, Konstantinidou V: Nutritional Genomics and the Mediterranean Diet's Effects on Human Cardiovascular Health. Nutrients 2016 8:218. https://www.ncbi.nlm.nih.gov/pubmed/27089360

542. Estruch R, Ros E, Salas-Salvado J, et al.: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013 368:1279-1290. https://www.ncbi.nlm.nih.gov/pubmed/23432189

543. Kris-Etherton P, Eckel RH, Howard BV, et al.: AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation 2001 103:1823-1825. https://www.ncbi.nlm.nih.gov/pubmed/11282918

544. Rees K, Takeda A, Martin N, et al.: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2019 3:CD009825. https://www.ncbi.nlm.nih.gov/pubmed/30864165

545. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285:2486-2497. https://www.ncbi.nlm.nih.gov/pubmed/11368702

546. U.S. Department Of Health And Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Your guide to lowering your cholesterol with TLC. NIH Publication No. 06–5235. Bethesda, MD: National Heart, Lung, and Blood Institute; 2005.

547. Scrutinio D: The potential of lifestyle changes for improving the clinical outcome of patients with coronary heart disease: mechanisms of benefit and clinical results. Rev Recent Clin Trials 2010 5:1-13. https://www.ncbi.nlm.nih.gov/pubmed/20205683

548. Gibson AA, Seimon RV, Lee CM, et al.: Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. Obes Rev 2015 16:64-76. https://www.ncbi.nlm.nih.gov/pubmed/25402637

549. Bueno NB, de Melo IS, de Oliveira SL, et al.: Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr 2013 110:1178-1187. https://www.ncbi.nlm.nih.gov/pubmed/23651522

550. Mansoor N, Vinknes KJ, Veierod MB, et al.: Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr 2016

115:466-479. https://www.ncbi.nlm.nih.gov/pubmed/26768850

551. Murphy EA, Jenkins TJ: A ketogenic diet for reducing obesity and maintaining capacity for physical activity: hype or hope? Curr Opin Clin Nutr Metab Care 2019 22:314-319. https://www.ncbi.nlm.nih.gov/pubmed/31166223

552. Fuehrlein BS, Rutenberg MS, Silver JN, et al.: Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets. J Clin Endocrinol Metab 2004 89:1641-1645. https://www.ncbi.nlm.nih.gov/pubmed/15070924

553. Sansone M, Sansone A, Borrione P, et al.: Effects of Ketone Bodies on Endurance Exercise. Curr Sports Med Rep 2018 17:444-453. https://www.ncbi.nlm.nih.gov/pubmed/30531462

554. Rosenbaum M, Hall KD, Guo J, et al.: Glucose and Lipid Homeostasis and Inflammation in Humans Following an Isocaloric Ketogenic Diet. Obesity (Silver Spring) 2019 27:971-981. https://www.ncbi.nlm.nih.gov/pubmed/31067015

555. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al.: Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab 2019 https://www.ncbi.nlm.nih.gov/pubmed/31399389

556. Ornish D, Brown SE, Scherwitz LW, et al.: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990 336:129-133. https://www.ncbi.nlm.nih.gov/pubmed/1973470

557. Gardner CD, Kiazand A, Alhassan S, et al.: Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 2007 297:969-977. https://www.ncbi.nlm.nih.gov/pubmed/17341711

558. Ornish D, Scherwitz LW, Billings JH, et al.: Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998 280:2001-2007. https://www.ncbi.nlm.nih.gov/pubmed/9863851

559. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Your guide to lowering your blood pressure with DASH. NIH Publication No. 06-4082. Bethesda,
MD: National Heart, Lung, and Blood Institute; 2006.

560. Appel LJ, Sacks FM, Carey VJ, et al.: Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005 294:2455-2464. https://www.ncbi.nlm.nih.gov/pubmed/16287956

561. Manheimer EW, van Zuuren EJ, Fedorowicz Z, et al.: Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis. Am J Clin Nutr 2015 102:922-932. https://www.ncbi.nlm.nih.gov/pubmed/26269362

562. Jonsson T, Granfeldt Y, Lindeberg S, et al.: Subjective satiety and other experiences of a Paleolithic diet compared to a diabetes diet in patients with type 2 diabetes. Nutr J 2013 12:105. https://www.ncbi.nlm.nih.gov/pubmed/23890471

563. Jonsson T, Granfeldt Y, Ahren B, et al.: Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovasc Diabetol 2009 8:35. https://www.ncbi.nlm.nih.gov/pubmed/19604407

564. Craig WJ: Health effects of vegan diets. Am J Clin Nutr 2009 89:1627S-1633S. https://www.ncbi.nlm.nih.gov/pubmed/19279075

565. Dinu M, Abbate R, Gensini GF, et al.: Vegetarian, vegan diets and multiple health outcomes: a systematic review with meta-analysis of observational studies. Crit Rev Food Sci Nutr 2016 0. https://www.ncbi.nlm.nih.gov/pubmed/26853923

566. Satija A, Bhupathiraju SN, Spiegelman D, et al.: Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J Am Coll Cardiol 2017 70:411-422. https://www.ncbi.nlm.nih.gov/pubmed/28728684

567. Key TJ, Fraser GE, Thorogood M, et al.: Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. Am J Clin Nutr 1999 70:516s-524s.

568. Kim H, Caulfield LE, Rebholz CM: Healthy Plant-Based Diets Are Associated with Lower Risk of All-Cause Mortality in US Adults. J Nutr 2018 148:624-631.

569. Tharrey M, Mariotti F, Mashchak A, et al.: Patterns of plant and animal protein intake are strongly associated with cardiovascular mortality: the Adventist Health Study-2 cohort. Int J Epidemiol 2018 47:1603-1612.

570. Kahleova H, Levin S, Barnard N: Cardio-Metabolic Benefits of Plant-Based Diets. Nutrients 2017 9(8):

848. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579641/

571. Huang RY, Huang CC, Hu FB, et al.: Vegetarian Diets and Weight Reduction: a Meta-Analysis of Randomized Controlled Trials. J Gen Intern Med 2016 31:109-116.

572. Borude S: Which Is a Good Diet-Veg or Non-veg? Faith-Based Vegetarianism for Protection From Obesity - a Myth or Actuality? Obes Surg 2019

573. Lara KM, Levitan EB, Gutierrez OM, et al.: Dietary Patterns and Incident Heart Failure in U.S. Adults Without Known Coronary Disease. J Am Coll Cardiol 2019 73:2036-2045. https://www.ncbi.nlm.nih.gov/pubmed/31023426

574. Gabel K, Hoddy KK, Haggerty N, et al.: Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: A pilot study. Nutr Healthy Aging 2018 4:345-353. https://www.ncbi.nlm.nih.gov/pubmed/29951594

575. Antoni R, Johnston KL, Collins AL, et al.: Effects of intermittent fasting on glucose and lipid metabolism. Proc Nutr Soc 2017 76:361-368. https://www.ncbi.nlm.nih.gov/pubmed/28091348

576. Hutchison AT, Liu B, Wood RE, et al.: Effects of Intermittent Versus Continuous Energy Intakes on Insulin Sensitivity and Metabolic Risk in Women with Overweight. Obesity (Silver Spring) 2019 27:50-58. https://www.ncbi.nlm.nih.gov/pubmed/30569640

577. Stice E, Davis K, Miller NP, et al.: Fasting increases risk for onset of binge eating and bulimic pathology: a 5-year prospective study. J Abnorm Psychol 2008 117:941-946. https://www.ncbi.nlm.nih.gov/pubmed/19025239

578. Kerndt PR, Naughton JL, Driscoll CE, et al.: Fasting: the history, pathophysiology and complications. West J Med 1982 137:379-399. https://www.ncbi.nlm.nih.gov/pubmed/6758355

579. Harris L, Hamilton S, Azevedo LB, et al.: Intermittent fasting interventions for treatment of overweight and obesity in adults: a systematic review and meta-analysis. JBI Database System Rev Implement Rep 2018 16:507-547. https://www.ncbi.nlm.nih.gov/pubmed/29419624

580. Lessan N, Ali T: Energy Metabolism and Intermittent Fasting: The Ramadan Perspective. Nutrients 2019 11: https://www.ncbi.nlm.nih.gov/pubmed/31137899

581. Gabel K, Kroeger CM, Trepanowski JF, et al.: Differential Effects of Alternate-Day Fasting Versus Daily Calorie Restriction on Insulin Resistance. Obesity (Silver Spring) 2019 27:1443-1450. https://www.ncbi.nlm.nih.gov/pubmed/31328895

582. Golbidi S, Daiber A, Korac B, et al.: Health Benefits of Fasting and Caloric Restriction. Curr Diab Rep 2017 17:123. https://www.ncbi.nlm.nih.gov/pubmed/29063418

583. Yildiran H, Mercanligil SM: Does increasing meal frequency improve weight loss and some biochemical parameters in overweight/obese females? Nutr Hosp 2019 36:66-72. https://www.ncbi.nlm.nih.gov/pubmed/30836763

584. Malinowski B, Zalewska K, Wesierska A, et al.: Intermittent Fasting in Cardiovascular Disorders-An Overview. Nutrients 2019 11: https://www.ncbi.nlm.nih.gov/pubmed/30897855

585. Trumbo P, Schlicker S, Yates AA, Poos M; Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids [published correction appears in J Am Diet Assoc. 2003 May;103(5):563]. J Am Diet Assoc. 2002;102(11):1621-1630. doi:10.1016/s0002-8223(02)90346-9

586. Conz A, Salmona M, Diomede L. Effect of Non-Nutritive Sweeteners on the Gut Microbiota. Nutrients. 2023 Apr 13;15(8):1869. doi: 10.3390/nu15081869. PMID: 37111090; PMCID: PMC10144565.

587. Academy of Nutrition and Dietetics. Anti-obesity medication and the role of lifestyle interventions delivered by RDNs. June 20, 2024. Accessed August 2024. https://www.eatrightpro.org/aom

588. Almandoz JP, Wadden TA, Tewksbury C, et al. Nutritional considerations with antiobesity medications. Obesity (Silver Spring). 2024;32(9):1613-1631. doi:10.1002/oby.24067

589. Murphy E, Finucane FM. Structured lifestyle modification as an adjunct to obesity pharmacotherapy: There is much to learn. Int J Obes. 2024; doi: 10.1038/s41366-024-01499-2

590. Raynor HA, Morgan-Bathke M, Baxter SD, et al. Position of the Academy of Nutrition and Dietetics: Medical Nutrition Therapy Behavioral Interventions Provided by Dietitians for Adults With Overweight or Obesity, 2024. J Acad Nutr Diet. 2024;124(3):408-415. doi:10.1016/j.jand.2023.11.013

591. Wadden TA, Chao AM, Moore M, et al. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep. 2023;12(4):453-473. doi:10.1007/s13679-023-00534-z

Physical Activity:

592. Alexander L, Christensen SM, Richardson L, Ingersoll AB, Burridge K, Golden A, Karjoo S, Cortez D, Shelver M, Bays HE. Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022. Obesity Pillars. 2022. 1:100005.

593. Hajna S, Ross NA, Dasgupta K: Steps, moderate-to-vigorous physical activity, and cardiometabolic profiles. Prev Med 2017 https://www.ncbi.nlm.nih.gov/pubmed/29126915

594. Warburton DE, Nicol CW, Bredin SS: Health benefits of physical activity: the evidence. CMAJ 2006 174:801-809. https://www.ncbi.nlm.nih.gov/pubmed/16534088

595. Stanford KI, Middelbeek RJ, Goodyear LJ: Exercise Effects on White Adipose Tissue: Beiging and Metabolic Adaptations. Diabetes 2015 64:2361-2368. https://www.ncbi.nlm.nih.gov/pubmed/26050668

596. Jeremic N, Chaturvedi P, Tyagi SC: Browning of White Fat: Novel Insight Into Factors, Mechanisms, and Therapeutics. J Cell Physiol 2017 232:61-68. https://www.ncbi.nlm.nih.gov/pubmed/27279601

597. Jakicic JM, Davis KK: Obesity and physical activity. Psychiatr Clin North Am 2011 34:829-840. https://www.ncbi.nlm.nih.gov/pubmed/22098807

598. Gomez-Pinilla F, Hillman C: The influence of exercise on cognitive abilities. Compr Physiol 2013 3:403-428. https://www.ncbi.nlm.nih.gov/pubmed/23720292

599. Fletcher GF, Landolfo C, Niebauer J, et al.: Promoting Physical Activity and Exercise: JACC Health Promotion Series. J Am Coll Cardiol 2018 72:1622-1639.

600. Luan X, Tian X, Zhang H, et al.: Exercise as a prescription for patients with various diseases. J Sport Health Sci 2019 8:422-441. https://www.ncbi.nlm.nih.gov/pubmed/31534817

601. Meriwether RA, Lee JA, Lafleur AS, et al.: Physical activity counseling. Am Fam Physician 2008 77:1129-1136. https://www.ncbi.nlm.nih.gov/pubmed/18481560

602. Vincent HK, Raiser SN, Vincent KR: The aging musculoskeletal system and obesity-related considerations with exercise. Ageing Res Rev 2012 11:361-373. https://www.ncbi.nlm.nih.gov/pubmed/22440321

603. Parr EB, Coffey VG, Hawley JA: 'Sarcobesity': a metabolic conundrum. Maturitas 2013 74:109-113. https://www.ncbi.nlm.nih.gov/pubmed/23201324

604. Strasser B: Physical activity in obesity and metabolic syndrome. Ann N Y Acad Sci 2013 1281:141-159. https://www.ncbi.nlm.nih.gov/pubmed/23167451

605. Carlson SA, Fulton JE, Schoenborn CA, et al.: Trend and prevalence estimates based on the 2008 Physical Activity Guidelines for Americans. Am J Prev Med 2010 39:305-313. https://www.ncbi.nlm.nih.gov/pubmed/20837280

606. Garland T, Jr., Schutz H, Chappell MA, et al.: The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. J Exp Biol 2011 214:206-229. https://www.ncbi.nlm.nih.gov/pubmed/21177942

607. Ng SW, Popkin BM: Time use and physical activity: a shift away from movement across the globe. Obes Rev 2012 13:659-680. https://www.ncbi.nlm.nih.gov/pubmed/22694051

608. Bushman BA: Determining the I (Intensity) for a FITT-VP Aerobic Exercise Prescription. ACSM's Health and Fitness Journal 2014 18:4-7. http://journals.lww.com/acsm-healthfitness/Fulltext/2014/05000/Determining_the_I__Intensity__for_a_FITT_VP.4.aspx

609. Zaleski AL, Taylor BA, Panza GA, et al.: Coming of Age: Considerations in the Prescription of Exercise for Older Adults. Methodist Debakey Cardiovasc J 2016 12:98-104.

610. Lakoski SG, Barlow CE, Farrell SW, et al.: Impact of body mass index, physical activity, and other clinical factors on cardiorespiratory fitness (from the Cooper Center longitudinal study). Am J Cardiol 2011 108:34-39. https://www.ncbi.nlm.nih.gov/pubmed/21529738

611. Van Camp CM, Hayes LB: Assessing and increasing physical activity. J Appl Behav Anal 2012 45:871-875. https://www.ncbi.nlm.nih.gov/pubmed/23322945

612. Butte NF, Ekelund U, Westerterp KR: Assessing physical activity using wearable monitors: measures of physical activity. Med Sci Sports Exerc 2012 44:S5-12. https://www.ncbi.nlm.nih.gov/pubmed/22157774

613. Mercer K, Li M, Giangregorio L, et al.: Behavior Change Techniques Present in Wearable Activity Trackers: A Critical Analysis. JMIR Mhealth Uhealth 2016 4:e40. https://www.ncbi.nlm.nih.gov/pubmed/27122452

614. Allen LN, Christie GP: The Emergence of Personalized Health Technology. J Med Internet Res 2016 18:e99. https://www.ncbi.nlm.nih.gov/pubmed/27165944

615. Cardoso CG Jr, Gomides RS, Queiroz AC, Pinto LG, da Silveira Lobo F, Tinucci T, Mion D Jr, de Moraes Forjaz CL. Acute and chronic effects of aerobic and resistance exercise on ambulatory blood pressure. Clinics (Sao Paulo). 2010 Mar;65(3):317-25. doi: 10.1590/S1807-59322010000300013. PMID: 20360924; PMCID: PMC2845774.

616. Warburton, D.E.R., Jamnik, V., Bredin, S.S.D., Shephard, R.J. and Gledhill, N. 2018. The 2018 Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) and electronic Physical Activity Readiness Medical Examination (ePARmed-X+): 2018 PAR-Q+. The Health and Fitness Journal of Canada. 11, 1 (Jan. 2018), 31–34. DOI:https://doi.org/10.14288/hfjc.v11i1.260.

617. Islam MM, Poly TN, Walther BA, Jack Li YC. Use of Mobile Phone App Interventions to Promote Weight Loss: Meta-Analysis. JMIR Mhealth Uhealth. 2020 Jul 22;8(7):e17039. doi: 10.2196/17039. PMID: 32706724; PMCID: PMC7407260.

618. Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009;41(2):459-471. doi:10.1249/MSS.0b013e3181949333

Behavioral Therapy:

619. Dobkin BH: Wearable motion sensors to continuously measure real-world physical activities. Curr Opin Neurol 2013 26:602-608. https://www.ncbi.nlm.nih.gov/pubmed/24136126

620. Chou WY, Prestin A, Kunath S: Obesity in social media: a mixed methods analysis. Transl Behav Med 2014 4:314-323. https://www.ncbi.nlm.nih.gov/pubmed/25264470

621. Freshwater M, Christensen S, Oshman L, Bays HE. Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022 2:100014.

622. Ries AV, Blackman LT, Page RA, et al.: Goal setting for health behavior change: evidence from an obesity intervention for rural low-income women. Rural Remote Health 2014 14:2682. https://www.ncbi.nlm.nih.gov/pubmed/24785265

623. Giannisi F, Pervanidou P, Michalaki E, et al.: Parental readiness to implement life-style behaviour changes in relation to children's excess weight. J Paediatr Child Health 2014 50:476-481. https://www.ncbi.nlm.nih.gov/pubmed/24612057

624. Tyler DO, Horner SD: Family-centered collaborative negotiation: a model for facilitating behavior change in primary care. J Am Acad Nurse Pract 2008 20:194-203. https://www.ncbi.nlm.nih.gov/pubmed/18387016

625. Miller WR, Rose GS: Toward a theory of motivational interviewing. Am Psychol 2009 64:527-537. https://www.ncbi.nlm.nih.gov/pubmed/19739882

626. Teixeira PJ, Silva MN, Mata J, et al.: Motivation, self-determination, and long-term weight control. Int J Behav Nutr Phys Act 2012 9:22. https://www.ncbi.nlm.nih.gov/pubmed/22385818

627. Miller NH: Motivational interviewing as a prelude to coaching in healthcare settings. J Cardiovasc Nurs 2010 25:247-251. https://www.ncbi.nlm.nih.gov/pubmed/20386250

628. Vallis M, Piccinini-Vallis H, Sharma AM, et al.: Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. Can Fam Physician 2013 59:27-31. https://www.ncbi.nlm.nih.gov/pubmed/23341653

629. Alexander SC, Cox ME, Boling Turer CL, et al.: Do the five A's work when physicians counsel about weight loss? Fam Med 2011 43:179-184. https://www.ncbi.nlm.nih.gov/pubmed/21380950

630. Searight R: Realistic approaches to counseling in the office setting. Am Fam Physician 2009 79:277-284. https://www.ncbi.nlm.nih.gov/pubmed/19235494

631. Foote J, DeLuca A, Magura S, et al.: A group motivational treatment for chemical dependency. J Subst Abuse Treat 1999 17:181-192. https://www.ncbi.nlm.nih.gov/pubmed/10531624

632. Pollak KI, Alexander SC, Tulsky JA, et al.: Physician empathy and listening: associations with patient satisfaction and autonomy. J Am Board Fam Med 2011 24:665-672. https://www.ncbi.nlm.nih.gov/pubmed/22086809

633. Williams DM, Rhodes RE: The confounded self-efficacy construct: conceptual analysis and recommendations for future research. Health Psychol Rev 2016 10:113-128. https://www.ncbi.nlm.nih.gov/pubmed/25117692

634. Westra HA, Aviram A: Core skills in motivational interviewing. Psychotherapy (Chic) 2013 50:273-278. https://www.ncbi.nlm.nih.gov/pubmed/24000834

635. Pollak KI, Coffman CJ, Alexander SC, et al.: Weight's up? Predictors of weight-related communication during primary care visits with overweight adolescents. Patient Educ Couns 2014 96:327-332. https://www.ncbi.nlm.nih.gov/pubmed/25130793

636. Pantalon MV, Sledge WH, Bauer SF, et al.: Important medical decisions: Using brief motivational interviewing to enhance patients' autonomous decision-making. J Psychiatr Pract 2013 19:98-108. https://www.ncbi.nlm.nih.gov/pubmed/23507811

637. Codern-Bove N, Pujol-Ribera E, Pla M, et al.: Motivational interviewing interactions and the primary health care challenges presented by smokers with low motivation to stop smoking: a conversation analysis. BMC Public Health 2014 14:1225. https://www.ncbi.nlm.nih.gov/pubmed/25427643

638. Williams AA, Wright KS: Engaging families through motivational interviewing. Pediatr Clin North Am 2014 61:907-921. https://www.ncbi.nlm.nih.gov/pubmed/25242705

639. Resnicow K, McMaster F: Motivational Interviewing: moving from why to how with autonomy support. Int J Behav Nutr Phys Act 2012 9:19. https://www.ncbi.nlm.nih.gov/pubmed/22385702

640. Miller ST, Oates VJ, Brooks MA, et al.: Preliminary efficacy of group medical nutrition therapy and motivational interviewing among obese African American women with type 2 diabetes: a pilot study. J Obes 2014 2014:345941. https://www.ncbi.nlm.nih.gov/pubmed/25243082

641. Elwyn G, Dehlendorf C, Epstein RM, et al.: Shared decision making and motivational interviewing: achieving patient-centered care across the spectrum of health care problems. Ann Fam Med 2014 12:270-275. https://www.ncbi.nlm.nih.gov/pubmed/24821899

642. Carcone AI, Naar-King S, Brogan KE, et al.: Provider communication behaviors that predict motivation to change in black adolescents with obesity. J Dev Behav Pediatr 2013 34:599-608. https://www.ncbi.nlm.nih.gov/pubmed/24131883

643. Windham ME, Hastings ES, Anding R, et al.: "Teens Talk Healthy Weight": the impact of a motivational digital video disc on parental knowledge of obesity-related diseases in an adolescent clinic. J Acad Nutr Diet 2014 114:1611-1618. https://www.ncbi.nlm.nih.gov/pubmed/24882205

644. Saelens BE, Lozano P, Scholz K: A randomized clinical trial comparing delivery of behavioral pediatric obesity treatment using standard and enhanced motivational approaches. J Pediatr Psychol 2013 38:954-964. https://www.ncbi.nlm.nih.gov/pubmed/23902797

645. Kushner RF, Ryan DH: Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. JAMA 2014 312:943-952. https://www.ncbi.nlm.nih.gov/pubmed/25182103

646. Kisely S, Ligate L, Roy MA, et al.: Applying Motivational Interviewing to the initiation of long-acting injectable atypical antipsychotics. Australas Psychiatry 2012 20:138-142. https://www.ncbi.nlm.nih.gov/pubmed/22467557

647. Goldberg JH, Kiernan M: Innovative techniques to address retention in a behavioral weight-loss trial. Health Educ Res 2005 20:439-447. https://www.ncbi.nlm.nih.gov/pubmed/15598664

648. Freshwater M, Christensen S, Oshman L, Bays HE. Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022 2:100014.

649. Guerdjikova AI, Mori N, Casuto LS, McElroy SL. Update on Binge Eating Disorder. Med Clin North Am. 2019 Jul;103(4):669-680. doi: 10.1016/j.mcna.2019.02.003. PMID: 31078199.

650. Udo T, Grilo CM. Prevalence and Correlates of DSM-5-Defined Eating Disorders in a Nationally Representative Sample of U.S. Adults. Biol Psychiatry. 2018 Sep 1;84(5):345-354. doi: 10.1016/j.bio-

psych.2018.03.014. Epub 2018 Apr 17. PMID: 29859631; PMCID: PMC6097933.

651. Erskine HE, Whiteford HA. Epidemiology of binge eating disorder. Curr Opin Psychiatry. 2018 Nov;31(6):462-470. doi: 10.1097/YCO.0000000000000449. PMID: 30113324.

652. Schneeberger M, Gomis R, Claret M: Hypothalamic and brainstem neuronal circuits controlling homeostatic energy balance. J Endocrinol 2014 220:T25-46. https://www.ncbi.nlm.nih.gov/pubmed/24222039

653. Cruwys T, Bevelander KE, Hermans RC: Social modeling of eating: a review of when and why social influence affects food intake and choice. Appetite 2015 86:3-18. https://www.ncbi.nlm.nih.gov/pubmed/25174571

654. Neymotin F, Nemzer LR: Locus of control and obesity. Front Endocrinol (Lausanne) 2014 5:159. https://www.ncbi.nlm.nih.gov/pubmed/25339940

655. Kemps E, Tiggemann M: Approach bias for food cues in obese individuals. Psychol Health 2015 30:370-380. https://www.ncbi.nlm.nih.gov/pubmed/25307785

656. Johnson PM, Kenny PJ: Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010 13:635-641. https://www.ncbi.nlm.nih.gov/pubmed/20348917

657. Adam TC, Epel ES: Stress, eating and the reward system. Physiol Behav 2007 91:449-458. https://www.ncbi.nlm.nih.gov/pubmed/17543357

658. Monteleone P, Piscitelli F, Scognamiglio P, et al.: Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab 2012 97:E917-924. https://www.ncbi.nlm.nih.gov/pubmed/22442280

659. Miller AC, Polgreen LA, Segre EM, et al.: Variations in Marginal Taste Perception by Body Mass Index Classification: A Randomized Controlled Trial. J Acad Nutr Diet 2019 https://www.ncbi.nlm.nih.gov/pubmed/31375462

660. Batra P, Das SK, Salinardi T, et al.: Eating behaviors as predictors of weight loss in a 6 month weight loss intervention. Obesity (Silver Spring) 2013 21:2256-2263. https://www.ncbi.nlm.nih.gov/pubmed/23512619

661. Amianto F, Ottone L, Abbate Daga G, et al.: Binge-eating disorder diagnosis and treatment: a recap in front of DSM-5. BMC Psychiatry 2015 15:70. https://www.ncbi.nlm.nih.gov/pubmed/25885566

662. Rikani AA, Choudhry Z, Choudhry AM, et al.: A critique of the literature on etiology of eating disorders. Ann Neurosci 2013 20:157-161. https://www.ncbi.nlm.nih.gov/pubmed/25206042

663. Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord. 2020 Feb;53(2):266-277. doi: 10.1002/eat.23192. Epub 2019 Nov 13. PMID: 31721257.

664. McElroy SL. Pharmacologic Treatments for Binge-Eating Disorder. J Clin Psychiatry. 2017;78 Suppl 1:14-19. doi: 10.4088/JCP.sh16003su1c.03. PMID: 28125174.

665. Hansen TT, Andersen SV, Astrup A, et al.: Is reducing appetite beneficial for body weight management in the context of overweight and obesity? A systematic review and meta-analysis from clinical trials assessing body weight management after exposure to satiety enhancing and/or hunger reducing products. Obes Rev 2019 20:983-997.https://www.ncbi.nlm.nih.gov/pubmed/30945414

666. Rutledge T, Groesz LM, Linke SE, et al.: Behavioural weight management for the primary careprovider. Obes Rev 2011 12:e290-297. https://www.ncbi.nlm.nih.gov/pubmed/21348915

667. Harvey J, Krukowski R, Priest J, et al.: Log Often, Lose More: Electronic Dietary Self-Monitoring for Weight Loss. Obesity 2019 27:380-384. https://doi.org/10.1002/oby.22382

668. Jeffery RW, Bjornson-Benson WM, Rosenthal BS, et al.: Behavioral treatment of obesity with monetary contracting: two-year follow-up. Addict Behav 1984 9:311-313. https://www.ncbi.nlm.nih.gov/pubmed/6496209

669. Brambila-Macias J, Shankar B, Capacci S, et al.: Policy interventions to promote healthy eating: a review of what works, what does not, and what is promising. Food Nutr Bull 2011 32:365-375.

https://www.ncbi.nlm.nih.gov/pubmed/22590970

670. Lynch E, Emery-Tiburcio E, Dugan S, et al.: Results of ALIVE: A Faith-Based Pilot Intervention to Improve Diet Among African American Church Members. Prog Community Health Partnersh 2019 13:19-30. https://www.ncbi.nlm.nih.gov/pubmed/30956244

671. Karasu SR: Psychotherapy-lite: obesity and the role of the mental health practitioner. Am J Psychother 2013 67:3-22. https://www.ncbi.nlm.nih.gov/pubmed/23682511

672. Gupta H: Barriers to and Facilitators of Long Term Weight Loss Maintenance in Adult UK People: A Thematic Analysis. Int J Prev Med 2014 5:1512-1520. https://www.ncbi.nlm.nih.gov/pubmed/25709786

673. Peterson JA: Get moving! Physical activity counseling in primary care. J Am Acad Nurse Pract 2007 19:349-357. https://www.ncbi.nlm.nih.gov/pubmed/17680900

674. Cornier MA: Is your brain to blame for weight regain? Physiol Behav 2011 104:608-612. https://www.ncbi.nlm.nih.gov/pubmed/21496461

675. Sainsbury A, Zhang L: Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit. Obes Rev 2012 13:234-257. https://www.ncbi.nlm.nih.gov/pubmed/22070225

676. Rosenbaum M, Leibel RL: Adaptive thermogenesis in humans. Int J Obes (Lond) 2010 34 Suppl 1:S47-55. https://www.ncbi.nlm.nih.gov/pubmed/20935667

677. Maclean PS, Bergouignan A, Cornier MA, et al.: Biology's response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol 2011 301:R581-600. https://www.ncbi.nlm.nih.gov/pubmed/21677272

678. Yoo S: Dynamic Energy Balance and Obesity Prevention. J Obes Metab Syndr 2018 27:203-212. https://www.ncbi.nlm.nih.gov/pubmed/31089565

679. Howlett N, Trivedi D, Troop NA, et al.: Are physical activity interventions for healthy inactive adults effective in promoting behavior change and maintenance, and which behavior change techniques are effective? A systematic review and meta-analysis. Transl Behav Med 2019 9:147-157. https://www.ncbi.nlm.nih.gov/pubmed/29506209

680. Lemstra M, Bird Y, Nwankwo C, et al.: Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer Adherence 2016 10:1547-1559. https://www.ncbi.nlm.nih.gov/pubmed/27574404

681. Richardson LA: Bariatric society is here to help. J Fam Pract 2010 59:488. https://www.ncbi.nlm.nih.gov/pubmed/20824223

682. Jacob JJ, Isaac R: Behavioral therapy for management of obesity. Indian J Endocrinol Metab 2012 16:28-32. https://www.ncbi.nlm.nih.gov/pubmed/22276250

683. Van Dorsten B, Lindley EM: Cognitive and behavioral approaches in the treatment of obesity. Med Clin North Am 2011 95:971-988. https://www.ncbi.nlm.nih.gov/pubmed/21855703

684. Rollnick, S., Miller, W. R., & Butler, C. C. (2023). Motivational interviewing in health care: Helping patients change behavior (2nd ed.). The Guilford Press.

685. Krebs P, Norcross JC, Nicholson JM, Prochaska JO. Stages of change and psychotherapy outcomes: A review and meta-analysis. J Clin Psychol. 2018;74(11):1964-1979. doi:10.1002/jclp.22683

686. Benowitz NL, Prochaska JJ. Smoking cessation after acute myocardial infarction. J Am Coll Cardiol. 2013;61(5):533-535. doi:10.1016/j.jacc.2012.11.017

687. Lindgren E, Gray K, Miller G, Tyler R, Wiers CE, Volkow ND, Wang GJ. Food addiction: A common neurobiological mechanism with drug abuse. Front Biosci (Landmark Ed). 2018 Jan 1;23(5):811-836. doi: 10.2741/4618. PMID: 28930574.

688. Xu R, Bannor R, Cardel MI, Foster GD, Pagoto S. How much food tracking during a digital weight-management program is enough to produce clinically significant weight loss?. Obesity (Silver Spring). 2023;31(7):1779-1786. doi:10.1002/oby.23795

689. Patel ML, Wakayama LN, Bennett GG. Self-Monitoring via Digital Health in Weight Loss Interventions: A Systematic Review Among Adults with Overweight or Obesity. Obesity (Silver Spring). 2021;29(3):478-499. doi:10.1002/oby.23088

690. Tarricone R, Petracca F, Svae L, Cucciniello M, Ciani O. Which behaviour change techniques work best for diabetes self-management mobile apps? Results from a systematic review and meta-analysis of randomised controlled trials. EBioMedicine. 2024;103:105091. doi:10.1016/j.ebiom.2024.105091

Obesity and Psychiatric Disease:

691. Brauhardt A, de Zwaan M, Hilbert A: The therapeutic process in psychological treatments for eating disorders: a systematic review. Int J Eat Disord 2014 47:565-584. https://www.ncbi.nlm.nih.gov/pubmed/24796817

692. Reas DL, Grilo CM: Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs 2014 19:99-142. https://www.ncbi.nlm.nih.gov/pubmed/24460483

693. Aigner M, Treasure J, Kaye W, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 2011 12:400-443. https://www.ncbi.nlm.nih.gov/pubmed/21961502

694. Flament MF, Bissada H, Spettigue W: Evidence-based pharmacotherapy of eating disorders. Int J Neuropsychopharmacol 2012 15:189-207. https://www.ncbi.nlm.nih.gov/pubmed/21414249

695. Smith KE, Ellison JM, Crosby RD, et al.: The validity of DSM-5 severity specifiers for anorexia nervosa, bulimia nervosa, and binge-eating disorder. Int J Eat Disord 2017 50:1109-1113. https://www.ncbi.nlm.nih.gov/pubmed/28623853

696. Lisdexamfetamine dimesylate (VYVANSE) Prescribing Information http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf (Accessed August 20, 2016).

697. Allison KC, Lundgren JD, O'Reardon JP, et al.: Proposed diagnostic criteria for night eating syndrome. Int J Eat Disord 2010 43:241-247. https://www.ncbi.nlm.nih.gov/pubmed/19378289

698. Gallant AR, Lundgren J, Drapeau V: The night-eating syndrome and obesity. Obes Rev 2012 13:528-536. https://www.ncbi.nlm.nih.gov/pubmed/22222118

699. Milano W, De Rosa M, Milano L, et al.: Night eating syndrome: an overview. J Pharm Pharmacol 2012 64:2-10. https://www.ncbi.nlm.nih.gov/pubmed/22150667

700. Stunkard AJ, Allison KC, Geliebter A, et al.: Development of criteria for a diagnosis: lessons from the night eating syndrome. Compr Psychiatry 2009 50:391-399. https://www.ncbi.nlm.nih.gov/pubmed/19683608

701. Christensen SM, Varney C, Gupta V, Wenz L, Bays HE. Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 4:100041.

702. Wurtman J, Wurtman R: The Trajectory from Mood to Obesity. Curr Obes Rep 2018 7:1-5. https://www.ncbi.nlm.nih.gov/pubmed/29218451

703. Jantaratnotai N, Mosikanon K, Lee Y, et al.: The interface of depression and obesity. Obes Res Clin Pract 2017 11:1-10. https://www.ncbi.nlm.nih.gov/pubmed/27498907

704. Rajan TM, Menon V: Psychiatric disorders and obesity: A review of association studies. J Postgrad Med 2017 63:182-190. https://www.ncbi.nlm.nih.gov/pubmed/28695871

705. Kohn JN, Cabrera Y, Dimitrov S, et al.: Sex-specific roles of cellular inflammation and cardiometabolism in obesity-associated depressive symptomatology. Int J Obes (Lond) 2019 https://www.ncbi.nlm.nih.gov/pubmed/31089263

706. Kurhe Y, Mahesh R: Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention. Asian J Psychiatr 2015 17:3-9. https://www.ncbi.nlm.nih.gov/pubmed/26243683

707. Kvam S, Kleppe CL, Nordhus IH, et al.: Exercise as a treatment for depression: A meta-analysis. J Affect Disord 2016 202:67-86. https://www.ncbi.nlm.nih.gov/pubmed/27253219

708. Krogh J, Hjorthoj C, Speyer H, et al.: Exercise for patients with major depression: a systematic review

with meta-analysis and trial sequential analysis. BMJ Open 2017 7:e014820. https://www.ncbi.nlm.nih.gov/pubmed/28928174

709. Crow SJ: Pharmacologic Treatment of Eating Disorders. Psychiatr Clin North Am 2019 42:253-262. https://www.ncbi.nlm.nih.gov/pubmed/31046927

710. Bello NT, Yeomans BL: Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Drug Saf 2018 17:17-23. https://www.ncbi.nlm.nih.gov/pubmed/29053927

711. Arnone D: Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 2005 4:5. https://www.ncbi.nlm.nih.gov/pubmed/15845141

712. Brownley KA, Berkman ND, Peat CM, et al.: Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med 2016 165:409-420. https://www.ncbi.nlm.nih.gov/pubmed/27367316

713. Dayabandara M, Hanwella R, Ratnatunga S, et al.: Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017 13:2231-2241. https://www.ncbi.nlm.nih.gov/pubmed/28883731

714. Solmi M, Murru A, Pacchiarotti I, et al.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017 13:757-777. https://www.ncbi.nlm.nih.gov/pubmed/28721057

715. Zhuo C, Xu Y, Liu S, et al.: Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis. Front Pharmacol 2018 9:1393. https://www.ncbi.nlm.nih.gov/pubmed/30546312

716. Mora F, Molina JD, Zubillaga E, et al.: CYP450 and Its Implications in the Clinical Use of Antipsychotic Drugs. doi:10.4172/2161-1459.1000176. https://www.longdom.org/open-access/cyp450-ahttps://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf. Clin Exp Pharmacol Physiol 2015 5:1-10.

717. Urichuk L, Prior TI, Dursun S, et al.: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008 9:410-418. https://www.ncbi.nlm.nih.gov/pubmed/18537577

718. Serralde-Zuñiga AE, González-Garay AG, Rodríguez-Carmona Y, Meléndez-Mier G. Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review. Obes Facts. 2022;15(4):473-486. doi: 10.1159/000524995. Epub 2022 Jun 2. PMID: 35654016; PMCID: PMC9421708.

719. Amiri S, Behnezhad S. Obesity and anxiety symptoms: a systematic review and meta-analysis. Neuropsychiatr. 2019 Jun;33(2):72-89. English. doi: 10.1007/s40211-019-0302-9. Epub 2019 Feb 18. PMID: 30778841.

720. Aylward L, Lilly C, Tabone L, Szoka N, Abunnaja S, Cox S. Anxiety predicts reduced weight loss 30 months after bariatric surgery. Surg Obes Relat Dis. 2022 Jul;18(7):919-927. doi: 10.1016/j.soard.2022.04.007. Epub 2022 Apr 20. PMID: 35660269; PMCID: PMC9233105.

721. Booth AO, Wang X, Turner AI, Nowson CA, Torres SJ. Diet-Induced Weight Loss Has No Effect on Psychological Stress in Overweight and Obese Adults: A Meta-Analysis of Randomized Controlled Trials. Nutrients. 2018 May 14;10(5):613. doi: 10.3390/nu10050613. PMID: 29757978; PMCID: PMC5986493.

Concomitant Medications:

722. Tondt J, Bays HE. Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 2:100017.

723. Pillinger T, McCutcheon RA, Vano L, et al.: Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020 7:64-77. https://www.ncbi.nlm.nih.gov/pubmed/31860457

724. Uguz F, Sahingoz M, Gungor B, et al.: Weight gain and associated factors in patients using newer

antidepressant drugs. Gen Hosp Psychiatry 2015 37:46-48. https://www.ncbi.nlm.nih.gov/pubmed/25467076

725. Rachdi C, Damak R, Fekih Romdhane F, et al.: Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients. Prim Care Diabetes 2019 13:57-62. https://www.ncbi.nlm.nih.gov/pubmed/30287230

726. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al.: Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res 2008 99:13-22. https://www.ncbi.nlm.nih.gov/pubmed/18053689

727. Alonso-Pedrero L, Bes-Rastrollo M, Marti A: Effects of antidepressant and antipsychotic use on weight gain: A systematic review. Obes Rev 2019 https://www.ncbi.nlm.nih.gov/pubmed/31524318

728. McIntyre, R. S., Kwan, A. T., Rosenblat, J. D., Teopiz, K.M., & Mansur, R. B. (2024). Psychotropic drug–related weight gain and its treatment. American Journal of Psychiatry, 181(1), 26-38.

729. Tek C, Kucukgoncu S, Guloksuz S, et al.: Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry 2016 10:193-202. https://www.ncbi.nlm.nih.gov/pubmed/25962699

730. Leucht S, Cipriani A, Spineli L, et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013 382:951-962. https://www.ncbi.nlm.nih.gov/pubmed/23810019

731. Apovian CM, Aronne LJ, Bessesen DH, et al.: Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 100:342-362. https://www.ncbi.nlm.nih.gov/pubmed/25590212

732. Bays H: From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009 25:671-681. https://www.ncbi.nlm.nih.gov/pubmed/19232040

733. Domecq JP, Prutsky G, Leppin A, et al.: Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015 100:363-370. https://www.ncbi.nlm.nih.gov/pubmed/25590213

734. DiNicolantonio JJ, Fares H, Niazi AK, et al.: beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart 2015 2:e000230. https://www.ncbi.nlm.nih.gov/pubmed/25821584

735. DeFronzo RA, Buse JB, Kim T, et al.: Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 2016 59:1645-1654. https://www.ncbi.nlm.nih.gov/pubmed/27216492

736. Mahmood K, Naeem M, Rahimnajjad NA: Metformin: the hidden chronicles of a magic drug. Eur J Intern Med 2013 24:20-26. https://www.ncbi.nlm.nih.gov/pubmed/23177353

737. Johnson NP: Metformin use in women with polycystic ovary syndrome. Ann Transl Med 2014 2:56. https://www.ncbi.nlm.nih.gov/pubmed/25333031

738. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):27-31. doi: 10.1055/s-0032-1327734. Epub 2012 Nov 12. PMID: 23147210.

739. Scinta W, Bayes H, Smith N: Insulin Resistance and Hunger in Childhood Obesity: A Patient and Physician's Perspective. Adv Ther 2017 34:2386-2391. https://www.ncbi.nlm.nih.gov/pubmed/2888444

740. Apolzan JW, Venditti EM, Edelstein SL, et al.: Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med 2019 170:682-690. https://www.ncbi.nlm.nih.gov/pubmed/3100993

741. Astrup A, Caterson I, Zelissen P, et al.: Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004 12:1658-1669. https://www.ncbi.nlm.nih.gov/pubmed/15536230

742. Ikeda H, Yonemochi N, Ardianto C, et al.: Pregabalin increases food intake through dopaminergic sys-

tems in the hypothalamus. Brain Res 2018 1701:219-226. https://www.ncbi.nlm.nih.gov/pubmed/30244110

743. Bostwick JM: A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc 2010 85:538-550. https://www.ncbi.nlm.nih.gov/pubmed/20431115

744. Hasnain M, Vieweg WV: Weight considerations in psychotropic drug prescribing and switching. Postgrad Med 2013 125:117-129. https://www.ncbi.nlm.nih.gov/pubmed/24113670

745. Hasnain M, Vieweg WV, Hollett B: Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012 124:154-167. https://www.ncbi.nlm.nih.gov/pubmed/22913904

746. Baldwin DS, Chrones L, Florea I, et al.: The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016 30:242-252. https://www.ncbi.nlm.nih.gov/pubmed/26864543

747. Newcomer JW, Eriksson H, Zhang P, et al.: Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin 2018 34:2197-2205. https://www.ncbi.nlm.nih.gov/pubmed/29985680

748. Parikh NB, Robinson DM, Clayton AH: Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag 2017 13:299-306. https://www.ncbi.nlm.nih.gov/pubmed/28331332

749. Cutler AJ, Durgam S, Wang Y, et al.: Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr 2018 23:39-50. https://www.ncbi.nlm.nih.gov/pubmed/28478771

750. McKnight RF, Adida M, Budge K, et al.: Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012 379:721-728. https://www.ncbi.nlm.nih.gov/pubmed/22265699

751. Bak M, Fransen A, Janssen J, et al.: Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014 9:e94112. https://www.ncbi.nlm.nih.gov/pubmed/24763306

752. Smith ME, Lee JS, Bonham A, et al.: Effect of new persistent opioid use on physiologic and psychologic outcomes following bariatric surgery. Surg Endosc 2018

753. Christinat A, Di Lascio S, Pagani O: Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis 2013 5 Suppl 1:S36-46. https://www.ncbi.nlm.nih.gov/pubmed/23819026

754. Lake JE, Currier JS: Switching antiretroviral therapy to minimize metabolic complications. HIV Ther 2010 4:693-711. https://www.ncbi.nlm.nih.gov/pubmed/22171239

755. Ighani A, Georgakopoulos JR, Zhou LL, et al.: Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. J Cutan Med Surg 2018 22:290-296. https://www.ncbi.nlm.nih.gov/pubmed/29373924

756. Valle-Cabrera R, Mendoza-Rodriguez Y, Robaina-Garcia M, et al.: Efficacy of Sertraline in Patients With Major Depressive Disorder Naive to Selective Serotonin Reuptake Inhibitors: A 10-Week Randomized, Multicenter, Placebo-Controlled, Double-Blind, Academic Clinical Trial. J Clin Psychopharmacol 2018 38:454-459. https://www.ncbi.nlm.nih.gov/pubmed/30106883

757. Wharton, S., Raiber, L., Serodio, K. J., Lee, J., & Christensen, R. A. (2018). Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, metabolic syndrome and obesity: targets and therapy, 427-438.

758. Haber R, Zarzour F, Ghezzawi M, Saadeh N, Bacha DS, Al Jebbawi L, Chakhtoura M, Mantzoros CS. The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024 May;26(5):1850-1867. doi: 10.1111/dom.15501. Epub 2024 Mar 11. PMID: 38468148.

Anti-Obesity Medications:

759. Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 2:100018.

760. Food and Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market.

761. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market?utm_campaign=FDA%20MedWatch%20-%20Belviq%2C%20Belviq%20XR%20%28lorcaserin%29%3A%20DSC%20-%20FDA%20Requests%20Withdrawal%20of%20Weight-Loss%20Drugandutm_medium=emailandutm_source=Eloqua (Accessed February 15, 2020).

762. Bray GA: Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring) 2013 21:893-899. https://www.ncbi.nlm.nih.gov/pubmed/23520198

763. Bays HE, Jones PH, Orringer CE, et al.: National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol 2016 10:S1-43. https://www.ncbi.nlm.nih.gov/pubmed/26891998

764. Piscitelli SC, Gallicano KD: Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001 344:984-996. https://www.ncbi.nlm.nih.gov/pubmed/11274626

765. Zhang X, Lerman LO: Obesity and renovascular disease. Am J Physiol Renal Physiol 2015 309:F273-279. https://www.ncbi.nlm.nih.gov/pubmed/26041447

766. Gupta D, Bhatia D, Dave V, et al.: Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations. Molecules 2018 23: https://www.ncbi.nlm.nih.gov/pubmed/30011904

767. Bays HE, Gadde KM: Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Drugs Today (Barc) 2011 47:903-914. https://www.ncbi.nlm.nih.gov/pubmed/22348915

768. Bays H: Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther 2010 8:1777-1801. https://www.ncbi.nlm.nih.gov/pubmed/20707765

769. Naltrexone HCL/Bupropion HCL Extended Release Prescribing Information (CONTRAVE). http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPIandcacheRandomizer=c5f9d506-7c0a-4c03-b357 2a926ba14990 (Accessed August 21, 2016).

770. LOMAIRA™ (phentermine hydrochloride USP) tablets, CIV) https://www.lomaira.com/Prescribing_Information.pdf (Accessed December 16, 2018).

771. Hanley MJ, Abernethy DR, Greenblatt DJ: Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010 49:71-87. https://www.ncbi.nlm.nih.gov/pubmed/20067334

772. Cheymol G: Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000 39:215-231. https://www.ncbi.nlm.nih.gov/pubmed/11020136

773. Jesudason DR, Clifton P: Interpreting different measures of glomerular filtration rate in obesity and weight loss: pitfalls for the clinician. Int J Obes (Lond) 2012 36:1421-1427. https://www.ncbi.nlm.nih.gov/pubmed/22184061

774. Bays HE: Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther 2011 9:265-277. https://www.ncbi.nlm.nih.gov/pubmed/21438803

775. Food and Drug Administration. Pregnancy and Lactation Labeling (Drugs) Final Rule. December 3, 2014. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm (Accessed August 21, 2016).

776. Hendricks EJ, Greenway FL, Westman EC, et al.: Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 2011

19:2351-2360. https://www.ncbi.nlm.nih.gov/pubmed/21527891

777. Fujioka K: Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab 2015 17:1021-1032. https://www.ncbi.nlm.nih.gov/pubmed/26040215

778. Kose M, Emet S, Akpinar TS, et al.: An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis. Case Rep Gastroenterol 2015 9:152-155. https://www.ncbi.nlm.nih.gov/pubmed/26078734

779. Lim S, Rogers LK, Tessler O, et al.: Phentermine: A Systematic Review for Plastic and Reconstructive Surgeons. Ann Plast Surg 2018 81:503-507. https://www.ncbi.nlm.nih.gov/pubmed/30204622

780. Liraglutide Prescribing Information for Treatment of Obesity (SAXENDA) https://www.novo-pi.com/saxenda.pdf (Accessed March 3, 2019).

781. Liraglutide Prescribing Information for Treatment of Type 2 Diabetes Mellitus (VICTOZA) https://www.novo-pi.com/victoza.pdf (Accessed March 3, 2019).

782. Phentermine HCL/Topiramate Extended Release Prescribing Information (QSYMIA) http://www.vivus.com/docs/QsymiaPI.pdf (Accessed August 21, 2016).

783. Garvey WT, Mechanick JI, Brett EM, et al.: American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract 2016 22 Suppl 3:1-203. https://www.ncbi.nlm.nih.gov/pubmed/27219496

784. Bays H, Rodbard HW, Schorr AB, et al.: Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med 2007 9:259-271. https://www.ncbi.nlm.nih.gov/pubmed/17761111

785. Cercato C, Roizenblatt VA, Leanca CC, et al.: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond) 2009 33:857-865. https://www.ncbi.nlm.nih.gov/pubmed/19564877

786. Le Riche WH, Van Belle G: Study of phendimetrazine bitartrate as an appetite suppressant in relation to dosage, weight loss and side effects. Can Med Assoc J 1962 87:29-31. https://www.ncbi.nlm.nih.gov/pubmed/14463177

787. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.

788. Hendricks EJ: Off-label drugs for weight management. Diabetes Metab Syndr Obes 2017 10:223-234. https://www.ncbi.nlm.nih.gov/pubmed/28652791

789. Lewis KH, Fischer H, Ard J, et al.: Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. Obesity (Silver Spring) 2019 27:591-602. https://www.ncbi.nlm.nih.gov/pubmed/30900410

790. Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., Davitkov, P., and AGA Clinical Guidelines Committee (2022). AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology, 163(5), 1198–1225. https://doi.org/10.1053/j.gastro.2022.08.045

791. XENICAL® (orlistat) Capsules https://www.xenical.com/pdf/PI_Xenical-brand_FINAL.PDF (Accessed December 16, 2018).

792. Kumar RB, Aronne LJ: Efficacy comparison of medications approved for chronic weight management. Obesity (Silver Spring) 2015 23 Suppl 1:S4-7. https://www.ncbi.nlm.nih.gov/pubmed/25900871

793. Saunders KH, Umashanker D, Igel LI, et al.: Obesity Pharmacotherapy. Med Clin North Am 2018 102:135-148. https://www.ncbi.nlm.nih.gov/pubmed/29156182

794. Bays HE, Cobble M: Individualizing Treatment with Statin Therapy. J Fam Pract 2018 67:S43-S48. https://www.ncbi.nlm.nih.gov/pubmed/30137053

795. Metreleptin (MYALEPT®) Prescribing Information

http://www.myaleptpro.com/sites/default/files/myalept_pi_sept2015_final.pdf (Accessed November 26, 2018).

796. He YL, Haynes W, Meyers CD, et al.: The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab 2019 21:1311-1321. https://www.ncbi.nlm.nih.gov/pubmed/30724002

797. Bays HE, Weinstein R, Law G, et al.: Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014 22:1042-1049. https://www.ncbi.nlm.nih.gov/pubmed/24227660

798. Yabe D, Iwasaki M, Kuwata H, et al.: Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab 2017 19:739- 743. https://www.ncbi.nlm.nih.gov/pubmed/27990776

799. Hollander P, Bays HE, Rosenstock J, et al.: Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care 2017 40:632-639. https://www.ncbi.nlm.nih.gov/pubmed/28289041

800. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014 Jun;32(6):1178-88. doi: 10.1097/HJH.0000000000000145. PMID: 24621808; PMCID: PMC4011567.

801. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.

Investigational Anti-Obesity Pharmacotherapy:

802. Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 2:100018.

803. Talukdar S, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016;23:427–440.

804. Bray G: Battle of the Bulge. Dorrance Publishing 2007 59.

805. James WP, Caterson ID, Coutinho W, et al.: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010 363:905-917. https://www.ncbi.nlm.nih.gov/pubmed/20818901

806. Saxena A, Sachin K: A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets. Curr Genomics 2018 19:630-666.

807. Srivastava G, Apovian C: Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. Curr Obes Rep 2018 7:147-161. https://www.ncbi.nlm.nih.gov/pubmed/29504049

808. Xiong Y, Walker K, Min X, et al.: Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys. Sci Transl Med 2017 9:https://www.ncbi.nlm.nih.gov/pubmed/29046435

809. Gerber JG, Freed CR, Nies AS: Antihypertensive pharmacology. West J Med 1980 132:430-439. https://www.ncbi.nlm.nih.gov/pubmed/6992462

810. 804. Bays HE, Ballantyne C: What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009 20:467-476. https://www.ncbi.nlm.nih.gov/pubmed/19779335

811. Maki KC, Bays HE, Dicklin MR: Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol 2012 6:413-426.

https://www.ncbi.nlm.nih.gov/pubmed/23009777

812. Bays HE, Goldberg RB: The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther 2007 14:567-580. https://www.ncbi.nlm.nih.gov/pubmed/18090882

813. Muppidi A, Zou H, Yang PY, et al.: Design of Potent and Proteolytically Stable Oxyntomodulin Analogs. ACS Chem Biol 2016 11:324-328. https://www.ncbi.nlm.nih.gov/pubmed/26727558

814. Khatib MN, Gaidhane S, Gaidhane AM, et al.: Ghrelin O Acyl Transferase (GOAT) as a Novel Metabolic Regulatory Enzyme. J Clin Diagn Res 2015 9:Le01-05.

815. Zhang SR, Fan XM: Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2015 21:3214-3222. https://www.ncbi.nlm.nih.gov/pubmed/25805927

816. Pratley RE, Kang J, Trautmann ME, et al.: Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes Obes Metab 2019 https://www.ncbi.nlm.nih.gov/pubmed/31264757

817. Chen J, Zhao H, Ma X, et al.: GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis. Cell Physiol Biochem 2017 42:1165-1176. https://www.ncbi.nlm.nih.gov/pubmed/28668964

818. Liu R, Li N, Lin Y, et al.: Glucagon Like Peptide-1 Promotes Adipocyte Differentiation via the Wnt4 Mediated Sequestering of Beta-Catenin. PLoS One 2016 11:e0160212. https://www.ncbi.nlm.nih.gov/pubmed/27504979

819. Guo C, Huang T, Chen A, et al.: Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. Braz J Med Biol Res 2016 49:e5826. https://www.ncbi.nlm.nih.gov/pubmed/27878229

820. Wang A, Li T, An P, et al.: Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway. PLoS One 2017 12:e0169469. https://www.ncbi.nlm.nih.gov/pubmed/28122026

821. Sanchez-Garrido MA, Brandt SJ, Clemmensen C, et al.: GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 2017 60:1851-1861. https://www.ncbi.nlm.nih.gov/pubmed/28733905

822. Gantz I, Erondu N, Mallick M, et al.: Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007 92:1754-1757. https://www.ncbi.nlm.nih.gov/pubmed/17341568

823. Scott R, Minnion J, Tan T, et al.: Oxyntomodulin analogue increases energy expenditure via the glucagon receptor. Peptides 2018 104:70-77. https://www.ncbi.nlm.nih.gov/pubmed/29680267

824. Persaud SJ, Bewick GA: Peptide YY: more than just an appetite regulator. Diabetologia 2014 57:1762-1769. https://www.ncbi.nlm.nih.gov/pubmed/24917132

825. Camilleri M, Acosta A: Combination Therapies for Obesity. Metab Syndr Relat Disord 2018 16:390-394. https://www.ncbi.nlm.nih.gov/pubmed/29993319

826. Frias JP, Nauck MA, Van J, et al.: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018 392:2180-2193. https://www.ncbi.nlm.nih.gov/pubmed/30293770

827. Coskun T, Sloop KW, Loghin C, et al.: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018 18:3-14. https://www.ncbi.nlm.nih.gov/pubmed/30473097

828. Alexiadou K, Anyiam O, Tan T: Cracking the combination: Gut hormones for the treatment of obesity and diabetes. J Neuroendocrinol 2018 e12664. https://www.ncbi.nlm.nih.gov/pubmed/30466162

829. Bessesen DH, Van Gaal LF: Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol 2018 6:237-248.

830. Yashiro H, Hamagami K, Hiyoshi H, et al.: SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice. Diabetes Obes Metab 2019 https://www.ncbi.nlm.nih.gov/pubmed/31144422

831. Bergmann NC, Lund A, Gasbjerg LS, et al.: Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia 2019 62:665-675. https://www.ncbi.nlm.nih.gov/pubmed/30683945

832. Jorsal T, Rungby J, Knop FK, et al.: GLP-1 and Amylin in the Treatment of Obesity. Curr Diab Rep 2016 16:1. https://www.ncbi.nlm.nih.gov/pubmed/26699764

833. Morton NM, Seckl JR: 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008 36:146-164. https://www.ncbi.nlm.nih.gov/pubmed/18230901

834. Duerrschmid C, He Y, Wang C, et al.: Asprosin is a centrally acting orexigenic hormone. Nat Med 2017 23:1444-1453. https://www.ncbi.nlm.nih.gov/pubmed/29106398

835. Tassi E, Garman KA, Schmidt MO, et al.: Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Sci Rep 2018 8:15973. https://www.ncbi.nlm.nih.gov/pubmed/30374109

836. Sonoda J, Chen MZ, Baruch A: FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig 2017 30:https://www.ncbi.nlm.nih.gov/pubmed/28525362

837. Achari AE, Jain SK: Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci 2017 18: https://www.ncbi.nlm.nih.gov/pubmed/28635626

838. Kim SH, Plutzky J: Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders. Diabetes Metab J 2016 40:12-21. https://www.ncbi.nlm.nih.gov/pubmed/26912151

839. Mullican SE, Lin-Schmidt X, Chin CN, et al.: GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 2017 23:1150-1157. https://www.ncbi.nlm.nih.gov/pubmed/28846097

840. Mullican SE, Rangwala SM: Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond. Trends Endocrinol Metab 2018 29:560-570. https://www.ncbi.nlm.nih.gov/pubmed/29866502

841. Sramkova V, Koc M, Krauzova E, et al.: Expression of lipogenic markers is decreased in subcutaneous adipose tissue and adipocytes of older women and is negatively linked to GDF15 expression. J Physiol Biochem 2019 75:253-262. https://www.ncbi.nlm.nih.gov/pubmed/30912009

842. Dludla PV, Nkambule BB, Jack B, et al.: Inflammation and Oxidative Stress in an Obese State and the Protective Effects of Gallic Acid. Nutrients 2018 11: https://www.ncbi.nlm.nih.gov/pubmed/30577684

843. Scott RV, Bloom SR: Problem or solution: The strange story of glucagon. Peptides 2018 100:36-41. https://www.ncbi.nlm.nih.gov/pubmed/29412829

844. Muo IM, MacDonald SD, Madan R, et al.: Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study. Diabetes Metab Syndr Obes 2019 12:743-759. https://www.ncbi.nlm.nih.gov/pubmed/31213865

845. Monteiro MP: Obesity vaccines. Hum Vaccin Immunother 2014 10:887-895. https://www.ncbi.nlm.nih.gov/pubmed/24365968

846. Pathak V, Flatt PR, Irwin N: Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. Peptides 2018 100:229-235. https://www.ncbi.nlm.nih.gov/pubmed/29412823

847. Malloy J, Zhuang D, Kim T, et al.: Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab 2018 20:1878-1884. https://www.ncbi.nlm.nih.gov/pubmed/29577550

848. Tam CS, Lecoultre V, Ravussin E: Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 2011 11:1677-1685. https://www.ncbi.nlm.nih.gov/pubmed/21910668

849. Behary P, Tharakan G, Alexiadou K, et al.: Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. Diabetes Care 2019 42:1446-1453. https://www.ncbi.nlm.nih.gov/pubmed/31177183

850. Mosli MM, Elyas M: Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction? Saudi J Gastroenterol 2017 23:117-122. https://www.ncbi.nlm.nih.gov/pubmed/28361843

851. Erondu N, Gantz I, Musser B, et al.: Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006 4:275-282. https://www.ncbi.nlm.nih.gov/pubmed/17011500

852. Erondu N, Wadden T, Gantz I, et al.: Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring) 2007 15:895-905. https://www.ncbi.nlm.nih.gov/pubmed/17426325

853. Tronieri JS, Wadden TA, Walsh OA, et al.: Effects of liraglutide plus phentermine in adults with obesity following 1year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial. Metabolism 2019 96:83-91. https://www.ncbi.nlm.nih.gov/pubmed/30902750

854. Rossini AA: Why control blood glucose levels? Arch Surg 1976 111:229-233. https://www.ncbi.nlm.nih.gov/pubmed/816331

855. Ryan C: New controversies in hypertension: questions answered, answers questioned. Compr Ther 1992 18:20-24. https://www.ncbi.nlm.nih.gov/pubmed/1547598

856. Thompson WG: Cholesterol: myth or reality? South Med J 1990 83:435-440. https://www.ncbi.nlm.nih.gov/pubmed/2181692

857. Pocai A: Action and therapeutic potential of oxyntomodulin. Mol Metab 2014 3:241-251. https://www.ncbi.nlm.nih.gov/pubmed/24749050

858. Tobert JA: The cholesterol controversy. BMJ 1992 304:713. https://www.ncbi.nlm.nih.gov/pubmed/1571657

859. Bierman EL: The oral antidiabetic agents. Am Fam Physician 1976 13:98-104. https://www.ncbi.nlm.nih.gov/pubmed/1251792

860. Rys P, Wojciechowski P, Rogoz-Sitek A, et al.: Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 2015 52:649-662. https://www.ncbi.nlm.nih.gov/pubmed/25585592

861. Mannucci E, Monami M, Masotti G, et al.: All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004 20:44-47. https://www.ncbi.nlm.nih.gov/pubmed/14737744

862. Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., ... & Titchenell, P. M. (2024). Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular Metabolism, 80, 101880.

Functional Foods, Supplements, and Over-the-Counter Therapies:

863. Tondt J, Bays HE. Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 2:100017.

864. Wharton S, Bonder R, Jeffery A, et al.: The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. Crit Rev Food Sci Nutr 2019 1-17. https://www.ncbi.nlm.nih.gov/pubmed/30896252

865. Barrea L, Altieri B, Polese B, et al.: Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. Int J Obes Suppl 2019 9:32-49. https://www.ncbi.nlm.nih.gov/pubmed/31391923

866. Zarin DA, Tse T, Sheehan J: The proposed rule for U.S. clinical trial registration and results submission. N Engl J Med 2015 372:174- 180. https://www.ncbi.nlm.nih.gov/pubmed/25539444

867. Dubben HH, Beck-Bornholdt HP: Systematic review of publication bias in studies on publication bias. BMJ 2005 331:433-434. https://www.ncbi.nlm.nih.gov/pubmed/15937056

868. Heyman ML, Williams RL: Ensuring global access to quality medicines: role of the US Pharmacopeia. J Pharm Sci 2011 100:1280-1287.

869. Navarro VJ, Khan I, Bjornsson E, et al.: Liver injury from herbal and dietary supplements. Hepatology 2017 65:363-373. https://www.ncbi.nlm.nih.gov/pubmed/27677775

870. Pol K, Christensen R, Bartels EM, et al.: Whole grain and body weight changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr 2013 98:872-884. https://www.ncbi.nlm.nih.gov/pubmed/23945718

871. Seganfredo FB, Blume CA, Moehlecke M, et al.: Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. Obes Rev 2017 18:832-851. https://www.ncbi.nlm.nih.gov/pubmed/28524627

872. He M, Shi B: Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci 2017 7:54. https://www.ncbi.nlm.nih.gov/pubmed/29090088

873. Gibson GR, Hutkins R, Sanders ME, et al.: Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017 14:491-502. https://www.ncbi.nlm.nih.gov/pubmed/28611480

874. Harpaz E, Tamir S, Weinstein A, et al.: The effect of caffeine on energy balance. J Basic Clin Physiol Pharmacol 2017 28:1-10. https://www.ncbi.nlm.nih.gov/pubmed/27824614

875. Zalewski BM, Szajewska H: No Effect of Glucomannan on Body Weight Reduction in Children and Adolescents with Overweight and Obesity: A Randomized Controlled Trial. J Pediatr 2019 211:85-91 e81. https://www.ncbi.nlm.nih.gov/pubmed/31036412

876. Yen M, Ewald MB: Toxicity of weight loss agents. J Med Toxicol 2012 8:145-152. https://www.ncbi.nlm.nih.gov/pubmed/22351299

877. Tucker J, Fischer T, Upjohn L, et al.: Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings. JAMA Netw Open 2018 1:e183337. https://www.ncbi.nlm.nih.gov/pubmed/30646238

878. U.S. Food and Drug Administration. HCG Diet Products are Illegal. www.fda.gov/forconsumers/consumerupdates/ucm281333.htm Accessed December 4, 2017.

879. Lijesen GK, Theeuwen I, Assendelft WJ, et al.: The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Br J Clin Pharmacol 1995 40:237-243. https://www.ncbi.nlm.nih.gov/pubmed/8527285

880. Obesity Medicine Association. Obesity Medicine Association Applauds American Medical Association's Decision to Adopt New Anti HCG Policy. https://obesitymedicine.org/use-of-hcg-for-weight-loss-inappropriate Accessed December 4, 2017.

881. Examine.com. https://examine.com Accessed December 4, 2017.

882. Janssens PL, Hursel R, Westerterp-Plantenga MS: Nutraceuticals for body-weight management: The role of green tea catechins. Physiol Behav 2016 162:83-87. https://www.ncbi.nlm.nih.gov/pubmed/26836279

883. Onakpoya I, Terry R, Ernst E: The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract 2011 2011: https://www.ncbi.nlm.nih.gov/pubmed/20871849

884. Onakpoya IJ, Posadzki PP, Watson LK, et al.: The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials. Eur J Nutr 2012 51:127-134. https://www.ncbi.nlm.nih.gov/pubmed/21990002

885. Cederroth CR, Nef S: Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol 2009 304:30-42. https://www.ncbi.nlm.nih.gov/pubmed/19433245

886. Cope MB, Erdman JW, Jr., Allison DB: The potential role of soyfoods in weight and adiposity reduction: an evidence-based review. Obes Rev 2008 9:219-235. https://www.ncbi.nlm.nih.gov/pubmed/18419671

887. Benjamin S, Prakasan P, Sreedharan S, et al.: Pros and cons of CLA consumption: an insight from clinical evidences. Nutr Metab (Lond) 2015 12:4. https://www.ncbi.nlm.nih.gov/pubmed/25972911

888. Patisaul HB, Jefferson W: The pros and cons of phytoestrogens. Front Neuroendocrinol 2010 31:400-419. https://www.ncbi.nlm.nih.gov/pubmed/20347861

889. Crespillo A, Alonso M, Vida M, et al.: Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. Br J Pharmacol 2011 164:1899-1915. https://www.ncbi.nlm.nih.gov/pubmed/21557739

890. Koba K, Yanagita T: Health benefits of conjugated linoleic acid (CLA). Obes Res Clin Pract 2014 8:e525-532. https://www.ncbi.nlm.nih.gov/pubmed/25434907

891. Onakpoya I, Davies L, Posadzki P, et al.: The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials. J Diet Suppl 2013 10:29-38. https://www.ncbi.nlm.nih.gov/pubmed/23419021

892. Onakpoya I, Posadzki P, Ernst E: The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr 2014 33:70-78. https://www.ncbi.nlm.nih.gov/pubmed/24533610

893. Marquez F, Babio N, Bullo M, et al.: Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Crit Rev Food Sci Nutr 2012 52:585-594. https://www.ncbi.nlm.nih.gov/pubmed/22530711

894. Lunsford KE, Bodzin AS, Reino DC, et al.: Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. World J Gastroenterol 2016 22:10071-10076. https://www.ncbi.nlm.nih.gov/pubmed/28018115

895. Loftus HL, Astell KJ, Mathai ML, et al.: Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial. Nutrients 2015 7:9508-9522. https://www.ncbi.nlm.nih.gov/pubmed/26593941

896. Smith C, Krygsman A: Hoodia gordonii: to eat, or not to eat. J Ethnopharmacol 2014 155:987-991. https://www.ncbi.nlm.nih.gov/pubmed/24955559

897. Roza O, Lovasz N, Zupko I, et al.: Sympathomimetic activity of a Hoodia gordonii product: a possible mechanism of cardiovascular side effects. Biomed Res Int 2013 2013:171059. https://www.ncbi.nlm.nih.gov/pubmed/24307991

898. Ju J, Li J, Lin Q, et al.: Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine 2018 50:25-34. https://www.ncbi.nlm.nih.gov/pubmed/30466986

899. Konstantinidi M, Koutelidakis AE. Functional Foods and Bioactive Compounds: A Review of Its Possible Role on Weight Management and Obesity's Metabolic Consequences. Medicines (Basel). 2019 Sep 9;6(3):94. doi: 10.3390/medicines6030094. PMID: 31505825; PMCID: PMC6789755.

900. Ganesan K, Xu B. Anti-Obesity Effects of Medicinal and Edible Mushrooms. Molecules. 2018 Nov 5;23(11):2880. doi: 10.3390/molecules23112880. PMID: 30400600; PMCID: PMC6278646.

901. Neff GW et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol. 2004;41(6):1062.

902. Skoulidis F et al. Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol. 2005 May;17(5):581-4.

Bariatric Surgery:

903. Shetye B, Hamilton FR, Bays HE. Bariatric surgery, gastrointestinal hormones, and the microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 2: 100015.

904. Neff KJ, Olbers T, le Roux CW: Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. BMC Med 2013 11:8. https://www.ncbi.nlm.nih.gov/pubmed/23302153

905. Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD. Clinical practice guidelines for the perioperative nutrition, metabolic, nonsurgical support of patients undergoing baritric procedures—2019 update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association and American Society of Anesthesiologists. Endocr Pract. 2019;25(12):1-75.

906. American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS). Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program https://www.facs.org/quality-programs/mbsaqip (Accessed August 21, 2016).

907. Appachi S, Kashyap SR: 'Adiposopathy' and cardiovascular disease: the benefits of bariatric surgery. Curr Opin Cardiol 2013 28:540-546. https://www.ncbi.nlm.nih.gov/pubmed/23928918

908. Abbatini F, Capoccia D, Casella G, et al.: Long-term remission of type 2 diabetes in morbidly obese patients after sleeve gastrectomy. Surg Obes Relat Dis 2013 9:498-502. https://www.ncbi.nlm.nih.gov/pubmed/23290187

909. Choi J, Digiorgi M, Milone L, et al.: Outcomes of laparoscopic adjustable gastric banding in patients with low body mass index. Surg Obes Relat Dis 2010 6:367-371. https://www.ncbi.nlm.nih.gov/pubmed/20185374

910. Gianos M, Abdemur A, Fendrich I, et al.: Outcomes of bariatric surgery in patients with body mass index <35 kg/m2. Surg Obes Relat Dis 2012 8:25-30. https://www.ncbi.nlm.nih.gov/pubmed/22019140

911. Scopinaro N, Adami GF, Papadia FS, et al.: Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg 2011 253:699-703. https://www.ncbi.nlm.nih.gov/pubmed/21475009

912. Scinta W: Measuring Success: A Comparison of Weight Loss Calculations. Bariatric Times 2012 9:18-20.

913. Albaugh VL, Flynn CR, Tamboli RA, et al.: Recent advances in metabolic and bariatric surgery. F1000Res 2016 5: https://www.ncbi.nlm.nih.gov/pubmed/27239296

914. Zepeda Mejia IA, Rogula T: Laparoscopic single-incision gastric bypass: initial experience, technique and short-term outcomes. Ann Surg Innov Res 2015 9:7. https://www.ncbi.nlm.nih.gov/pubmed/26473005

915. Palermo M, Acquafresca PA, Rogula T, et al.: Late surgical complications after gastric by-pass: a literature review. Arq Bras Cir Dig 2015 28:139-143. https://www.ncbi.nlm.nih.gov/pubmed/26176254

916. Weng TC, Chang CH, Dong YH, et al.: Anaemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. BMJ Open 2015 5:e006964. https://www.ncbi.nlm.nih.gov/pubmed/26185175

917. Lim R, Beekley A, Johnson DC, et al.: Early and late complications of bariatric operation. Trauma Surg Acute Care Open 2018 3:e000219. https://www.ncbi.nlm.nih.gov/pubmed/30402562

918. Stefater MA, Wilson-Perez HE, Chambers AP, et al.: All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev 2012 33:595-622. https://www.ncbi.nlm.nih.gov/pubmed/22550271

919. Kodner C, Hartman DR: Complications of adjustable gastric banding surgery for obesity. Am Fam Physician 2014 89:813-818. https://www.ncbi.nlm.nih.gov/pubmed/24866217

920. Dixon JB, Straznicky NE, Lambert EA, et al.: Laparoscopic adjustable gastric banding and other devices for the management of obesity. Circulation 2012 126:774-785. https://www.ncbi.nlm.nih.gov/pubmed/22869859

921. Anderson B, Gill RS, de Gara CJ, et al.: Biliopancreatic diversion: the effectiveness of duodenal switch and its limitations. Gastroenterol Res Pract 2013 2013:974762. https://www.ncbi.nlm.nih.gov/pubmed/24639868

922. Billeter AT, Fischer L, Wekerle AL, et al.: Malabsorption as a Therapeutic Approach in Bariatric Surgery. Viszeralmedizin 2014 30:198-204. https://www.ncbi.nlm.nih.gov/pubmed/26288594

923. Sullivan S, Stein R, Jonnalagadda S, et al.: Aspiration therapy leads to weight loss in obese sub-

jects: a pilot study. Gastroenterology 2013 145:1245-1252 e1241-1245. https://www.ncbi.nlm.nih.gov/pubmed/24012983

924. Sarr MG, Billington CJ, Brancatisano R, et al.: The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity. Obes Surg 2012 22:1771-1782. https://www.ncbi.nlm.nih.gov/pubmed/22956251

925. Kumar N, Sullivan S, Thompson CC: The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes Metab Syndr Obes 2017 10:311-316. https://www.ncbi.nlm.nih.gov/pubmed/28740414

926. Jain D, Bhandari BS, Arora A, et al.: Endoscopic Sleeve Gastroplasty - A New Tool to Manage Obesity. Clin Endosc 2017 https://www.ncbi.nlm.nih.gov/pubmed/28607328

927. Hill C, Khashab MA, Kalloo AN, et al.: Endoluminal weight loss and metabolic therapies: current and future techniques. Ann N Y Acad Sci 2017 https://www.ncbi.nlm.nih.gov/pubmed/28884820

928. Celio AC, Pories WJ: A History of Bariatric Surgery: The Maturation of a Medical Discipline. Surg Clin North Am 2016 96:655-667. https://www.ncbi.nlm.nih.gov/pubmed/27473793

929. Kim SH, Chun HJ, Choi HS, et al.: Current status of intragastric balloon for obesity treatment. World J Gastroenterol 2016 22:5495-5504. https://www.ncbi.nlm.nih.gov/pubmed/27350727

930. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al.: Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg 2008 18:841-846. https://www.ncbi.nlm.nih.gov/pubmed/18459025

931. Frattini F, Rausei S, Boni L, et al.: Gastric plication: how to decrease the size of the stomach without transection. Surg Technol Int 2013 23:84-87. https://www.ncbi.nlm.nih.gov/pubmed/24081847

932. Herron D, Roohipour R: Complications of Roux-en-Y gastric bypass and sleeve gastrectomy. Abdom Imaging 2012 37:712-718. https://www.ncbi.nlm.nih.gov/pubmed/22388668

933. Rogalski P, Daniluk J, Baniukiewicz A, et al.: Endoscopic management of gastrointestinal perforations, leaks and fistulas. World J Gastroenterol 2015 21:10542-10552. https://www.ncbi.nlm.nih.gov/pubmed/26457014

934. Chivot C, Robert B, Lafaye N, et al.: Laparoscopic sleeve gastrectomy: imaging of normal anatomic features and postoperative gastrointestinal complications. Diagn Interv Imaging 2013 94:823-834. https://www.ncbi.nlm.nih.gov/pubmed/23707144

935. Davidson JP, Connelly TM, Libove E, et al.: Gastropericardial fistula: radiologic findings and literature review. J Surg Res 2016 203:174-182. https://www.ncbi.nlm.nih.gov/pubmed/27338548

936. Pauli EM, Beshir H, Mathew A: Gastrogastric fistulae following gastric bypass surgery-clinical recognition and treatment. Curr Gastroenterol Rep 2014 16:405. https://www.ncbi.nlm.nih.gov/pubmed/25113040

937. Spivak H, Favretti F: Avoiding postoperative complications with the LAP-BAND system. Am J Surg 2002 184:31S-37S. https://www.ncbi.nlm.nih.gov/pubmed/12527348

938. Rausa E, Bonavina L, Asti E, et al.: Rate of Death and Complications in Laparoscopic and Open Roux-en-Y Gastric Bypass. A Meta-analysis and Meta-regression Analysis on 69,494 Patients. Obes Surg 2016 26:1956-1963. https://www.ncbi.nlm.nih.gov/pubmed/27189352

939. Karcz WK, Blazejczyk K, Wellner UF, et al.: [Internal hernias after bariatric surgery]. Chirurg 2015 86:855-860. https://www.ncbi.nlm.nih.gov/pubmed/26319178

940. Azagury D, Liu RC, Morgan A, et al.: Small bowel obstruction: A practical step-by-step evidence-based approach to evaluation, decision making, and management. J Trauma Acute Care Surg 2015 79:661-668. https://www.ncbi.nlm.nih.gov/pubmed/26402543

941. Levine MS, Carucci LR: Imaging of bariatric surgery: normal anatomy and postoperative complications. Radiology 2014 270:327-341. https://www.ncbi.nlm.nih.gov/pubmed/24471382

942. Lewis KD, Takenaka KY, Luber SD: Acute Abdominal Pain in the Bariatric Surgery Patient. Emerg Med Clin North Am 2016 34:387-407. https://www.ncbi.nlm.nih.gov/pubmed/27133251

943. Merkle EM, Hallowell PT, Crouse C, et al.: Roux-en-Y gastric bypass for clinically severe obesity: normal appearance and spectrum of complications at imaging. Radiology 2005 234:674-683. https://www.ncbi.nlm.nih.gov/pubmed/15650038

944. Mancini MC: Bariatric surgery--an update for the endocrinologist. Arq Bras Endocrinol Metabol 2014 58:875-888. https://www.ncbi.nlm.nih.gov/pubmed/25627042

945. Ritz P, Hanaire H: Post-bypass hypoglycaemia: a review of current findings. Diabetes Metab 2011 37:274-281. https://www.ncbi.nlm.nih.gov/pubmed/21676638

946. Monkhouse SJ, Morgan JD, Norton SA: Complications of bariatric surgery: presentation and emergency management--a review. Ann R Coll Surg Engl 2009 91:280-286. https://www.ncbi.nlm.nih.gov/pubmed/19344551

947. Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, De Luca M, Faria SL, Goodpaster KPS, Haddad A, Himpens JM, Kow L, Kurian M, Loi K, Mahawar K, Nimeri A, O'Kane M, Papasavas PK, Ponce J, Pratt JSA, Rogers AM, Steele KE, Suter M, Kothari SN. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022 Dec;18(12):1345-1356. doi: 10.1016/j.soard.2022.08.013. Epub 2022 Oct 21. PMID: 36280539.

948. Lei Y, Zheng MH, Huang W, et al.: Wet beriberi with multiple organ failure remarkably reversed by thiamine administration: A case report and literature review. Medicine (Baltimore) 2018 97:e0010. https://www.ncbi.nlm.nih.gov/pubmed/29489643

949. Gregorio VD, Lucchese R, Vera I, et al.: The Alcohol Consumption Is Amended after Bariatric Surgery? An Integrative Review. Arq Bras Cir Dig 2018 31:e1378. https://www.ncbi.nlm.nih.gov/pubmed/29972406

950. Jans G, Matthys C, Bogaerts A, et al.: Maternal micronutrient deficiencies and related adverse neonatal outcomes after bariatric surgery: a systematic review. Adv Nutr 2015 6:420-429. https://www.ncbi.nlm.nih.gov/pubmed/26178026

951. Balaji M, Ganjayi MS, Hanuma Kumar GE, et al.: A review on possible therapeutic targets to contain obesity: The role of phytochemicals. Obes Res Clin Pract 2016 10:363-380. https://www.ncbi.nlm.nih.gov/pubmed/26740473

952. Cilla A, Alegria A, Attanzio A, et al.: Dietary phytochemicals in the protection against oxysterol-induced damage. Chem Phys Lipids 2017 207:192-205. https://www.ncbi.nlm.nih.gov/pubmed/28267434

953. Liu RH: Health-promoting components of fruits and vegetables in the diet. Adv Nutr 2013 4:384S-392S. https://www.ncbi.nlm.nih.gov/pubmed/23674808

954. Berger MM, Pantet O, Schneider A, et al.: Micronutrient Deficiencies in Medical and Surgical Inpatients. J Clin Med 2019 8: https://www.ncbi.nlm.nih.gov/pubmed/31261695

955. Mechanick JI, Apovian C, Brethauer S, et al.: Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Endocr Pract 2019 https://www.ncbi.nlm.nih.gov/pubmed/31682518

956. Parrott J, Frank L, Rabena R, et al.: American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis 2017 13:727-741. https://www.ncbi.nlm.nih.gov/pubmed/28392254

957. Sinha S, Kataria A, Kolla BP, et al.: Wernicke Encephalopathy-Clinical Pearls. Mayo Clin Proc 2019 94:1065-1072. https://www.ncbi.nlm.nih.gov/pubmed/31171116

958. Nishimoto A, Usery J, Winton JC, et al.: High-dose Parenteral Thiamine in Treatment of Wernicke's Encephalopathy: Case Series and Review of the Literature. In Vivo 2017 31:121-124. https://www.ncbi.nlm.nih.gov/pubmed/28064230

959. Bensky MJ, Ayalon-Dangur I, Ayalon-Dangur R, et al.: Comparison of sublingual vs. intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency. Drug Deliv Transl Res 2019 9:625-630. https://www.ncbi.nlm.nih.gov/pubmed/30632091

960. Ushakumari, D. S., & Sladen, R. N. (2023). ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists. Anesthesiology. https://doi.org/10.1097/aln.0000000000004776

961. Pfeifer, K. J., Selzer, A., & Whinney, C. M. (2021). Preoperative management of gastrointestinal and pulmonary medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement. Mayo Clinic Proceedings, 96(12), 3158–3177. https://doi.org/10.1016/j.mayocp.2021.08.008

962. Preiser, J.-C., Provenzano, B., & Mongkolpun, W. (2020). Perioperative management of oral glucose-lowering drugs in the patient with type 2 diabetes. Anesthesiology, 133(2), 430–438. https://doi.org/10.1097/aln.0000000000003237

963. Tripkovic L, Wilson LR, Hart K, et al.: Daily supplementation with 15 mug vitamin D2 compared with vitamin D3 to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial. Am J Clin Nutr 2017 106:481-490. https://www.ncbi.nlm.nih.gov/pubmed/28679555

964. Alayed Albarri EM, Sameer Alnuaimi A, Abdelghani D. Effectiveness of vitamin D2 compared with vitamin D3 replacement therapy in a primary healthcare setting: a retrospective cohort study. Qatar Med J. 2022;2022(3):29. Published 2022 Aug 4. doi:10.5339/qmj.2022.35

965. Mingrone G, Bornstein S, Le Roux CW: Optimisation of follow-up after metabolic surgery. Lancet Diabetes Endocrinol 2018 6:487-499.

966. El-Mallah CA, Beyh YS, Obeid OA. Iron Fortification and Supplementation: Fighting Anemia of Chronic Diseases or Fueling Obesity?. Curr Dev Nutr. 2021;5(4):nzab032. Published 2021 Apr 7. doi:10.1093/cdn/nzab032

967. JI M: Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update. In Press 2019

968. Muscogiuri G, Cantone E, Cassarano S, et al.: Gut microbiota: a new path to treat obesity. Int J Obes Suppl 2019 9:10-19. https://www.ncbi.nlm.nih.gov/pubmed/31391921

969. Dimitriadis GK, Randeva MS, Miras AD: Potential Hormone Mechanisms of Bariatric Surgery. Curr Obes Rep 2017 6:253-265. https://www.ncbi.nlm.nih.gov/pubmed/28780756

970. Wolosowicz M, Prokopiuk S, Kaminski TW. Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?. Medicina (Kaunas). 2022;58(4):472. Published 2022 Mar 25. doi:10.3390/medicina58040472

971. Batterham RL, Cummings DE: Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. Diabetes Care 2016 39:893-901. https://www.ncbi.nlm.nih.gov/pubmed/27222547

972. Meek CL, Lewis HB, Reimann F, et al.: The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016 77:28-37. https://www.ncbi.nlm.nih.gov/pubmed/26344355

973. Pérez-Pevida B, Escalada J, Miras AD, Frühbeck G. Mechanisms Underlying Type 2 Diabetes Remission After Metabolic Surgery. Front Endocrinol (Lausanne). 2019;10:641. Published 2019 Sep 19. doi:10.3389/fendo.2019.00641

974. https://doi.org/10.1053/j.gastro.2021.03.003

975. Reja D, Zhang C, Sarkar A. Endoscopic bariatrics: current therapies and future directions. Transl Gastroenterol Hepatol. 2022 Apr 25;7:21. doi: 10.21037/tgh.2020.03.09. PMID: 35548475; PMCID: PMC9081914.

976. Hanscom, Mark, and Sara Ghoneim. “Clinical Applications of Endoscopic Bariatric Therapies: Potential and Pitfalls.” Gastroenterology vol. 165,4 (2023): 807-812. doi:10.1053/j.gastro.2023.07.022

977. Crossan K, Sheer AJ. Intragastric Balloon. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 30, 2023.

978. Telese A, Sehgal V, Magee CG, et al. Bariatric and Metabolic Endoscopy: A New Paradigm. Clin Transl Gastroenterol. 2021;12(6):e00364. Published 2021 Jun 18. doi:10.14309/ctg.0000000000000364

979. Ryan DH, Parkin CG, Longley W, Dixon J, Apovian C, Bode B. Efficacy and safety of an oral device to reduce food intake and promote weight loss. Obes Sci Pract. 2017;4(1):52-61. Published 2017 Dec 11. doi:10.1002/osp4.139

980. Thompson CC, Chand B, Chen YK, et al. Endoscopic suturing for transoral outlet reduction increases weight loss after Roux-en-Y gastric bypass surgery. Gastroenterology. 2013;145(1):129-137.e3. doi:10.1053/j.gastro.2013.04.002

981. Maselli DB, Alqahtani AR, Abu Dayyeh BK, et al. Revisional endoscopic sleeve gastroplasty of laparoscopic sleeve gastrectomy: an international, multicenter study. Gastrointest Endosc. 2021;93(1):122-130. doi:10.1016/j.gie.2020.05.028

982. Morton JM, Shah SN, Wolfe BM, Apovian CM, Miller CJ, Tweden KS, Billington CJ, Shikora SA. Effect of

vagal nerve blockade on moderate obesity with an obesity-related comorbid condition: the ReCharge study. Obesity surgery. 2016 May;26:983-9.

983. Obes Pillars. 2023 Sep 7:8:100087. doi: 10.1016/j.obpill.2023.100087. eCollection 2023 Dec. Obesity and malnutrition in children and adults: A clinical review

984. Morgan Bradley 1 , Julian Melchor 1, Rachel Carr 1, Sara Karjoo 1 2 3 Affiliations expand PMID: 38125660 PMCID: PMC10728708 DOI: 10.1016/j.obpill.2023.100087

985. Baumann, Alexandra J et al. “Endoscopic Dilation of Bariatric RNY Anastomotic Strictures: a Systematic Review and Meta-analysis.” Obesity surgery vol. 28,12 (2018): 4053-4063. doi:10.1007/s11695-018-3491-6

986. Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018 Apr;6(8):148. doi: 10.21037/atm.2018.03.16. PMID: 29862237; PMCID: PMC5952017.

987. Gala K, Ghusn W, Abu Dayyeh BK. Gut motility and hormone changes after bariatric procedures. Curr Opin Endocrinol Diabetes Obes. 2024 Jun 1;31(3):131-137. doi: 10.1097/MED.0000000000000860. Epub 2024 Mar 27. PMID: 38533785.

988. Baumann, Alexandra J et al. “Endoscopic Dilation of Bariatric RNY Anastomotic Strictures: a Systematic Review and Meta-analysis.” Obesity surgery vol. 28,12 (2018): 4053-4063. doi:10.1007/s11695-018-3491-6

989. Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018 Apr;6(8):148. doi: 10.21037/atm.2018.03.16. PMID: 29862237; PMCID: PMC5952017.

990. Lee CJ, Florea L, Sears CL, Maruthur N, Potter JJ, Schweitzer M, Magnuson T, Clark JM. Changes in Gut Microbiome after Bariatric Surgery Versus Medical Weight Loss in a Pilot Randomized Trial. Obes Surg. 2019 Oct;29(10):3239-3245. doi: 10.1007/s11695-019-03976-4. PMID: 31256356.

991. 2. Murphy R, Tsai P, Jüllig M, Liu A, Plank L, Booth M. Differential Changes in Gut Microbiota After Gastric Bypass and Sleeve Gastrectomy Bariatric Surgery Vary According to Diabetes Remission. Obes Surg. 2017 Apr;27(4):917-925. doi: 10.1007/s11695-016-2399-2. PMID: 27738970.

992. 3. Tremaroli V, Karlsson F, Werling M, Ståhlman M, Kovatcheva-Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F. Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metab. 2015 Aug 4;22(2):228-38. doi: 10.1016/j.cmet.2015.07.009. PMID: 26244932; PMCID: PMC4537510.

993. Hills RD Jr, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11: 1613. pmid:31315227

994. Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, Tarkowska A, et al. A new genomic blueprint of the human gut microbiota. Nature. 2019;568: 499–504. pmid:30745586

995. Bouillon, R., Manousaki, D., Rosen, C. et al. The health effects of vitamin D supplementation: evidence from human studies. Nat Rev Endocrinol 18, 96–110 (2022). https://doi.org/10.1038/s41574-021-00593-

996. Pereira-Santos, M., Costa, P. R. D. F., Assis, A. M. O. D., Santos, C. A. D. S. T. & Santos, D. B. D. Obesity and vitamin D deficiency: A systematic review and meta-analysis. Obes. Rev. 16, 341–349. https://doi.org/10.1111/obr.12239 (2015).

997. Bouillon, R., Manousaki, D., Rosen, C. et al. The health effects of vitamin D supplementation: evidence from human studies. Nat Rev Endocrinol 18, 96–110 (2022). https://doi.org/10.1038/s41574-021-00593-

998. Pereira-Santos, M., Costa, P. R. D. F., Assis, A. M. O. D., Santos, C. A. D. S. T. & Santos, D. B. D. Obesity and vitamin D deficiency: A systematic review and meta-analysis. Obes. Rev. 16, 341–349. https://doi.org/10.1111/obr.12239 (2015).

Obesity Paradox:

999. Smith KB, Smith MS: Obesity Statistics. Prim Care 2016 43:121-135, ix.

https://www.ncbi.nlm.nih.gov/pubmed/26896205

1000. Akin I, Nienaber CA: “Obesity paradox” in coronary artery disease. World J Cardiol 2015 7:603-608. https://www.ncbi.nlm.nih.gov/pubmed/26516414

1001. Yu E, Ley SH, Manson JE, et al.: Weight History and All-Cause and Cause-Specific Mortality in Three Prospective Cohort Studies. Ann Intern Med 2017 166:613-620.

1002. Caleyachetty R, Thomas GN, Toulis KA, et al.: Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol 2017 70:1429-1437. https://www.ncbi.nlm.nih.gov/pubmed/28911506

1003. Tutor AW, Lavie CJ, Kachur S, Milani RV, Ventura HO. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2023 May-Jun;78:2-10. doi: 10.1016/j.pcad.2022.11.013. Epub 2022 Dec 5. PMID: 36481212.

1004. Bhaskaran K, Dos-Santos-Silva I, Leon DA, et al.: Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol 2018 6:944-953. https://www.ncbi.nlm.nih.gov/pubmed/30389323

1005. Zhi G, Xin W, Ying W, et al.: “Obesity Paradox” in Acute Respiratory Distress Syndrome: Asystematic Review and Meta-Analysis. PLoS One 2016 11:e0163677. https://www.ncbi.nlm.nih.gov/pubmed/27684705

1006. Alzayer H, Roshanravan B. Dissecting the Obesity Paradox in Patients With Obesity and CKD. Kidney Int Rep. 2023;8(7):1281-1282. Published 2023 May 7. doi:10.1016/j.ekir.2023.05.003

1007. Panwar B, Hanks LJ, Tanner RM, et al.: Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int 2015 87:1216-1222. https://www.ncbi.nlm.nih.gov/pubmed/25517912

1008. Stenvinkel P, Gillespie IA, Tunks J, et al.: Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. J Am Soc Nephrol 2016 27:1479-1486. https://www.ncbi.nlm.nih.gov/pubmed/26567245

1009. Niederdeppe J, Roh S, Shapiro MA: Acknowledging individual responsibility while emphasizing social determinants in narratives to promote obesity-reducing public policy: a randomized experiment. PLoS One 2015 10:e0117565. https://www.ncbi.nlm.nih.gov/pubmed/25706743

1010. Yu SS, Castillo DC, Courville AB, Sumner AE. The triglyceride paradox in people of African descent. Metab Syndr Relat Disord. 2012 Apr;10(2):77-82. doi: 10.1089/met.2011.0108. Epub 2012 Jan 6. PMID: 22224930; PMCID: PMC3311911.

1011. Khan SS, Ning H, Wilkins JT, et al.: Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol 2018 3:280-287. https://www.ncbi.nlm.nih.gov/pubmed/29490333

1012. Wade KH, Carslake D, Sattar N, et al.: BMI and Mortality in UK Biobank: Revised Estimates Using Mendelian Randomization. Obesity (Silver Spring) 2018 26:1796-1806. https://www.ncbi.nlm.nih.gov/pubmed/30358150

1013. Iliodromiti S, Celis-Morales CA, Lyall DM, et al.: The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent. Eur Heart J 2018 39:1514-1520.

1014. Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, et al.: Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016 388:776-786. https://www.ncbi.nlm.nih.gov/pubmed/27423262

1015. Visaria A, Setoguchi S. Body mass index and all-cause mortality in a 21st century U.S. population: A National Health Interview Survey analysis. PLoS One. 2023;18(7):e0287218. Published 2023 Jul 5. doi:10.1371/journal.pone.0287218

1016. Soto ME, Pérez-Torres I, Rubio-Ruiz ME, Manzano-Pech L, Guarner-Lans V. Interconnection between Cardiac Cachexia and Heart Failure-Protective Role of Cardiac Obesity. Cells. 2022;11(6):1039. Published 2022 Mar 18. doi:10.3390/cells11061039

1017. Lavie CJ, De Schutter A, Parto P, et al.: Obesity and Prevalence of Cardiovascular Diseases and

Prognosis-The Obesity Paradox Updated. Prog Cardiovasc Dis 2016 58:537-547. https://www.ncbi.nlm.nih.gov/pubmed/26826295

1018. Nouws J, Fitch M, Mata M, et al.: Altered In Vivo Lipid Fluxes and Cell Dynamics in Subcutaneous Adipose Tissues Are Associated With the Unfavorable Pattern of Fat Distribution in Obese Adolescent Girls. Diabetes 2019 68:1168-1177. https://www.ncbi.nlm.nih.gov/pubmed/30936147

1019. Jung CH, Lee WJ, Song KH: Metabolically healthy obesity: a friend or foe? Korean J Intern Med 2017 32:611-621. https://www.ncbi.nlm.nih.gov/pubmed/28602062

1020. Mongraw-Chaffin M, Foster MC, Kalyani RR, et al.: Obesity Severity and Duration Are Associated With Incident Metabolic Syndrome: Evidence Against Metabolically Healthy Obesity From the Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab 2016 101:4117-4124. https://www.ncbi.nlm.nih.gov/pubmed/2755254412

1021. Lavie CJ, Laddu D, Arena R, et al.: Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol 2018 72:1506-1531. https://www.ncbi.nlm.nih.gov/pubmed/30236314

1022. Guo F, Garvey WT: Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring) 2016 24:516-525. https://www.ncbi.nlm.nih.gov/pubmed/26719125

1023. Kuk JL, Rotondi M, Sui X, et al.: Individuals with obesity but no other metabolic risk factors are not at significantly elevated all-cause mortality risk in men and women. Clin Obes 2018 8:305-312. https://www.ncbi.nlm.nih.gov/pubmed/29998631

1024. Schulze MB: Metabolic health in normal-weight and obese individuals. Diabetologia 2018 https://www.ncbi.nlm.nih.gov/pubmed/30569272

1025. Yu XY, Song P, Zou MH: Obesity Paradox and Smoking Gun: A Mystery of Statistical Confounding? Circ Res 2018 122:1642-1644. https://www.ncbi.nlm.nih.gov/pubmed/29880498

1026. Steele L, Lloyd A, Fotheringham J, et al.: A retrospective cross-sectional study on the association between tobacco smoking and incidence of ST-segment elevation myocardial infarction and cardiovascular risk factors. Postgrad Med J 2015 91:492-496. https://www.ncbi.nlm.nih.gov/pubmed/26265789

1027. Rallidis LS, Triantafyllis AS, Tsirebolos G, et al.: Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins. Atherosclerosis 2016 249:17-21. https://www.ncbi.nlm.nih.gov/pubmed/27062405

1028. Lavie CJ, Milani RV, Ventura HO: Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009 53:1925-1932. https://www.ncbi.nlm.nih.gov/pubmed/19460605

1029. Oesch L, Tatlisumak T, Arnold M, et al.: Obesity paradox in stroke - Myth or reality? A systematic review. PLoS One 2017 12:e0171334. https://www.ncbi.nlm.nih.gov/pubmed/28291782

1030. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi:10.1161/CIR.0000000000000973

Obesity Myths:

1031. Bays HE, Golden A, Tondt J. Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022. 3:100034.

1032. Rico-Campa A, Martinez-Gonzalez MA, Alvarez-Alvarez I, et al.: Association between consumption of ultra-processed foods and all cause mortality: SUN prospective cohort study. BMJ 2019 365:l1949. https://www.ncbi.nlm.nih.gov/pubmed/31142450

1033. Hall KD, Ayuketah A, Brychta R, et al.: Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab 2019 30:226.

https://www.ncbi.nlm.nih.gov/pubmed/31269427

1034. Herrmann SD, Willis EA, Ainsworth BE, et al. 2024 Adult Compendium of Physical Activities: A third update of the energy costs of human activities. J Sport Health Sci. 2024;13(1):6-12. doi:10.1016/j.jshs.2023.10.010

1035. Sperandei S, Vieira MC, Reis AC: Adherence to physical activity in an unsupervised setting: Explanatory variables for high attrition rates among fitness center members. J Sci Med Sport 2016 19:916-920. https://www.ncbi.nlm.nih.gov/pubmed/26874647

1036. Yen HY, Chiu HL: The effectiveness of wearable technologies as physical activity interventions in weight control: A systematic review and meta-analysis of randomized controlled trials. Obes Rev 2019 20:1485-1493. https://www.ncbi.nlm.nih.gov/pubmed/31342646

1037. Varkevisser RDM, van Stralen MM, Kroeze W, et al.: Determinants of weight loss maintenance: a systematic review. Obes Rev 2019 20:171-211. https://www.ncbi.nlm.nih.gov/pubmed/30324651

1038. Kim JY. Optimal Diet Strategies for Weight Loss and Weight Loss Maintenance. J Obes Metab Syndr. 2021;30(1):20-31. doi:10.7570/jomes20065

1039. Wang Z, Ying Z, Bosy-Westphal A, et al.: Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. Am J Clin Nutr 2010 92:1369-1377. https://www.ncbi.nlm.nih.gov/pubmed/20962155

1040. Bays HE, Gonzalez-Campoy JM: Adiposopathy. New Opathies: An Emerging Molecular Reclassification of Human Disease 2012 105-168.

1041. Pontzer H, Durazo-Arvizu R, Dugas LR, et al.: Constrained Total Energy Expenditure and Metabolic Adaptation to Physical Activity in Adult Humans. Curr Biol 2016 26:410-417. https://www.ncbi.nlm.nih.gov/pubmed/26832439

1042. Leech RM, Worsley A, Timperio A, McNaughton SA. Understanding meal patterns: definitions, methodology and impact on nutrient intake and diet quality. Nutr Res Rev. 2015 Jun;28(1):1-21. doi: 10.1017/S0954422414000262. Epub 2015 Mar 19. PMID: 25790334; PMCID: PMC4501369.

1043. Ruddick-Collins LC, Morgan PJ, Fyfe CL, Filipe JAN, Horgan GW, Westerterp KR, Johnston JD, Johnstone AM. Timing of daily calorie loading affects appetite and hunger responses without changes in energy metabolism in healthy subjects with obesity. Cell Metab. 2022 Oct 4;34(10):1472-1485.e6. doi: 10.1016/j.cmet.2022.08.001. Epub 2022 Sep 9. PMID: 36087576; PMCID: PMC9605877.

1044. Jakubowicz D, Barnea M, Wainstein J, Froy O. High caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity (Silver Spring). 2013 Dec;21(12):2504-12. doi: 10.1002/oby.20460. Epub 2013 Jul 2. PMID: 23512957.

1045. Richter J, Herzog N, Janka S, Baumann T, Kistenmacher A, Oltmanns KM. Twice as High Diet-Induced Thermogenesis After Breakfast vs Dinner On High-Calorie as Well as Low-Calorie Meals. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz311. doi: 10.1210/clinem/dgz311. PMID: 32073608.

1046. Ainsworth BE. Compendium of physical activities. Med Sci Sports Exerc 2011;43: 1575. 2011.

1047. U.S. Department of Agriculture. FoodData Central Search Results. https://fdc.nal.usda.gov/fdc-app.html#/food-details/170370/nutrients (Accessed January 17, 2023).

1048. U.S. Department of Agriculture. FoodData Central Search Results. https://fdc.nal.usda.gov/fdc-app.html#/food-details/173285/nutrients (Accessed January 17, 2023).

1049. Wang Z, Ying Z, Bosy-Westphal A, Zhang J, Schautz B, Later W, et al. Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. Am J Clin Nutr 2010;92: 1369–77.

1050. Sperandei S, Vieira MC, Reis AC. Adherence to physical activity in an unsupervised setting: explanatory variables for high attrition rates among fitness center members. J Sci Med Sport 2016;19:916–20.

1051. Drenowatz C, Grieve GL, DeMello MM: Change in energy expenditure and physical activity in response to aerobic and resistance exercise programs. Springerplus 2015 4:798. https://www.ncbi.nlm.nih.gov/pubmed/26702387

1052. Srour B, Fezeu LK, Kesse-Guyot E, et al.: Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Sante). BMJ 2019 365:l1451. https://www.ncbi.nlm.nih.gov/pubmed/31142457

1053. Vandevijvere S, Jaacks LM, Monteiro CA, et al.: Global trends in ultraprocessed food and drink product sales and their association with adult body mass index trajectories. Obes Rev 2019 https://www.ncbi.nlm.nih.gov/pubmed/31099480

1054. Ludwig DS, Astrup A, Bazzano LA, et al.: Ultra-Processed Food and Obesity: The Pitfalls of Extrapolation from Short Studies. Cell Metab 2019 30:3-4. https://www.ncbi.nlm.nih.gov/pubmed/31230987

1055. Monteiro CA, Cannon G, Moubarac JC, et al.: The UN Decade of Nutrition, the NOVA food classification and the trouble with ultra-processing. Public Health Nutr 2018 21:5-17. https://www.ncbi.nlm.nih.gov/pubmed/28322183

1056. Monteiro CA, Cannon G, Levy RB, et al.: Ultra-processed foods: what they are and how to identify them. Public Health Nutr 2019 22:936-941. https://www.ncbi.nlm.nih.gov/pubmed/30744710

1057. Rong S, Snetselaar LG, Xu G, et al.: Association of Skipping Breakfast With Cardiovascular and All-Cause Mortality. J Am Coll Cardiol 2019 73:2025-2032. https://www.ncbi.nlm.nih.gov/pubmed/31023424

1058. Ballon A, Neuenschwander M, Schlesinger S: Breakfast Skipping Is Associated with Increased Risk of Type 2 Diabetes among Adults: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. J Nutr 2019 149:106-113. https://www.ncbi.nlm.nih.gov/pubmed/30418612

1059. Sievert K, Hussain SM, Page MJ, et al.: Effect of breakfast on weight and energy intake: systematic review and meta-analysis of randomised controlled trials. BMJ 2019 364:l42. https://www.ncbi.nlm.nih.gov/pubmed/30700403

1060. Chowdhury EA, Richardson JD, Gonzalez JT, et al.: Six Weeks of Morning Fasting Causes Little Adaptation of Metabolic or Appetite Responses to Feeding in Adults with Obesity. Obesity (Silver Spring) 2019 27:813-821. https://www.ncbi.nlm.nih.gov/pubmed/30925197

1061. Betts JA, Chowdhury EA, Gonzalez JT, et al.: Is breakfast the most important meal of the day? Proc Nutr Soc 2016 75:464-474. https://www.ncbi.nlm.nih.gov/pubmed/27292940

1062. Casazza K, Fontaine KR, Astrup A, et al.: Myths, presumptions, and facts about obesity. N Engl J Med 2013 368:446-454. https://www.ncbi.nlm.nih.gov/pubmed/23363498

1063. Bjerregaard LG, Pedersen DC, Mortensen EL, et al.: Breastfeeding duration in infancy and adult risks of type 2 diabetes in a high-income country. Matern Child Nutr 2019 e12869. https://www.ncbi.nlm.nih.gov/pubmed/31267694

1064. Woo JG, Martin LJ: Does Breastfeeding Protect Against Childhood Obesity? Moving Beyond Observational Evidence. Curr Obes Rep 2015 4:207-216. https://www.ncbi.nlm.nih.gov/pubmed/26627216

1065. Ventura AK: Does Breastfeeding Shape Food Preferences? Links to Obesity. Ann Nutr Metab 2017 70 Suppl 3:8-15. https://www.ncbi.nlm.nih.gov/pubmed/28903109

1066. Verduci E, Banderali G, Barberi S, et al.: Epigenetic effects of human breast milk. Nutrients 2014 6:1711-1724. https://www.ncbi.nlm.nih.gov/pubmed/24763114

1067. Allegretti JR, Kassam Z, Mullish BH, et al.: Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol 2019 https://www.ncbi.nlm.nih.gov/pubmed/31301451

1068. Hunter GR, Singh H, Carter SJ, et al.: Sarcopenia and Its Implications for Metabolic Health. J Obes 2019 2019:8031705. https://www.ncbi.nlm.nih.gov/pubmed/30956817

1069. Rossi AP, Rubele S, Calugi S, et al.: Weight Cycling as a Risk Factor for Low Muscle Mass and Strength in a Population of Males and Females with Obesity. Obesity (Silver Spring) 2019 27:1068-1075. https://www.ncbi.nlm.nih.gov/pubmed/31231958